<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title-group><journal-title>Current Neuropharmacology</journal-title></journal-title-group><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5997866</article-id><article-id pub-id-type="pmid">29173175</article-id><article-id pub-id-type="publisher-id">CN-16-533</article-id><article-id pub-id-type="doi">10.2174/1570159X15666171123201142</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Imaging the Role of Inflammation in Mood and Anxiety-related Disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Felger</surname><given-names>Jennifer C.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff>
<target id="aff1" target-type="aff"><sup>1</sup></target>Department of Psychiatry and Behavioral Sciences, <institution>Emory University School of Medicine</institution>, <addr-line><city>Atlanta</city>, <state>GA</state></addr-line>, <country>USA</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Winship Cancer Institute, <institution>Emory University</institution>, <addr-line><city>Atlanta</city>, <state>GA</state></addr-line>, <country>USA</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, Clinic B 5103, Atlanta, GA 30322, USA; Tel: (404) 727-3987; Fax: (404) 778-3965;, E-mail: <email xlink:href="jfelger@gmail.com">jfelger@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><month>6</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><volume>16</volume><issue>5</issue><fpage>533</fpage><lpage>558</lpage><history><date date-type="received"><day>03</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>23</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#169; 2018 Bentham Science Publishers</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode"><license-p> This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (<uri xlink:href="https://creativecommons.org/licenses/by-nc/4.0/legalcode">https://creativecommons.org/licenses/by-nc/4.0/legalcode</uri>), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Studies investigating the impact of a variety of inflammatory stimuli on the brain and behavior have reported evidence that inflammation and release of inflammatory cytokines affect circuitry relevant to both reward and threat sensitivity to contribute to behavioral change. Of relevance to mood and anxiety-related disorders, biomarkers of inflammation such as inflammatory cytokines and acute-phase proteins are reliably elevated in a significant proportion of patients with major depressive disorder (MDD), bipolar disorder, anxiety disorders and post-traumatic stress disorder (PTSD).</p></sec><sec><title>Methods</title><p>This review summarized clinical and translational work demonstrating the impact of peripheral inflammation on brain regions and neurotransmitter systems relevant to both reward and threat sensitivity, with a focus on neuroimaging studies involving administration of inflammatory stimuli. Recent translation of these findings to further understand the role of inflammation in mood and anxiety-related disorders is also discussed.</p></sec><sec><title>Results</title><p>Inflammation was consistently found to affect basal ganglia and cortical reward and motor circuits to drive reduced motivation and motor activity, as well as anxiety-related brain regions including amygdala, insula and anterior cingulate cortex, which may result from cytokine effects on monoamines and glutamate. Similar relationships between inflammation and altered neurocircuitry have been observed in MDD patients with increased peripheral inflammatory markers, and such work is on the horizon for anxiety disorders and PTSD.</p></sec><sec><title>Conclusion</title><p>Neuroimaging effects of inflammation on reward and threat circuitry may be used as biomarkers of inflammation for future development of novel therapeutic strategies to better treat mood and anxiety-related disorders in patients with high inflammation.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Neuroimaging</kwd><kwd>inflammation</kwd><kwd>cytokines</kwd><kwd>microglia</kwd><kwd>depression</kwd><kwd>anxiety</kwd><kwd>PTSD</kwd><kwd>motivation</kwd><kwd>motor slowing</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>Findings from numerous laboratories have consistently indicated that innate immune activation and the release of inflammatory cytokines preferentially affect brain regions relevant to both reward and threat sensitivity. Indeed, cytokines have been shown to impact basal ganglia and cortical reward and motor circuitry, as well as to affect fear and anxiety-related structures including amygdala, insula and anterior cingulate cortex (ACC) [<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r4" ref-type="bibr">4</xref>] (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>). It has recently been appreciated that the effects of inflammation and cytokines on these brain regions produce potentially adaptive and beneficial behavioral responses [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>]. While decreased motivation and motor activity may subserve the conservation of energy and allocation of resources to fight infection and heal wounds, increased vigilance and threat sensitivity may guard against future attack or trauma. Thus, these inflammation-associated behavioral changes conferred an evolutionary advantage by promoting containment of pathogens and the initiation of wound healing. Our propensity to mount aggressive immune responses, not only to pathogens but also to a host of environmental insults including psychological stress, exist as the legacy of survival and reproductive fitness in unsafe and hostile environments of ancestral times [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>].</p><p>In modern times, this bias toward inflammatory responses to both physiologic and psychological challenge in part drives the high prevalence of persons exhibiting a maladaptive, low-grade chronic inflammatory state. Chronically increased inflammation in the body is associated with risk for medical illnesses such cardiovascular disease, metabolic disorders and cancer [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r8" ref-type="bibr">8</xref>], while its effects on the brain may cause behavioral symptoms relevant to mood and anxiety disorders, which are often comorbid [<xref rid="r9" ref-type="bibr">9</xref>]. It has been well established that a significant proportion of patients with mood and anxiety-related disorders exhibit evidence of elevated inflammatory markers including increases in cerebrospinal fluid (CSF) and circulating concentrations of inflammatory cytokines, chemokines and acute phase reactants, changes in gene expression and increased presence of inflammatory immune cell phenotypes [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r12" ref-type="bibr">12</xref>]. While mood disorders may have complex pathophysiology with heterogeneous etiologies, it is thought that increased inflammation may be involved in the disease process and contribute to discreet symptomologies in a subset of patients. Although the source of inflammation may vary across patients and disorders, it is thought to often be a combination primarily of lifestyle factors such as diet, exercise and body weight, sleep impairments, genetic inflammatory bias, medical illness and exposure to psychosocial stress and/or trauma (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>) [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r13" ref-type="bibr">13</xref>]. Inflammatory signals elaborated in the body are thought to then impact the brain to drive behavioral symptoms relevant to mood and anxiety-related disorders (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>). Access of peripheral inflammatory signals to the brain may involve trafficking of peripheral immune cells to the brain as well as cytokine-induced activation of local inflammatory signaling pathways and microglia [<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r15" ref-type="bibr">15</xref>].</p><p>Interest in the role of inflammation in mood and anxiety-related disorders has prompted research on the blockade of inflammation as a potential treatment strategy [<xref rid="r16" ref-type="bibr">16</xref>]. Thus, attempts have been made to image inflammation in the brains of psychiatric patients, in part to establish imaging biomarkers of target engagement in the brain to be used in treatment trials for anti-inflammatories [<xref rid="r16" ref-type="bibr">16</xref>]. Positron emission tomography (PET) imaging of activated microglia has been reported in a number of psychiatric populations; however, an association between inflammation in the CNS and circulating inflammatory markers and/or behavioral symptoms has been less clear [<xref rid="r16" ref-type="bibr">16</xref>]. Conversely, imaging of neural activation, functional and structural connectivity and change in neurotransmitter systems in humans and non-human primates has reliably provided information about the effects of inflammation on the brain that have been highly correlated with peripheral and CSF inflammatory markers as well as inflammation-related behavioral alterations [<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r4" ref-type="bibr">4</xref>] (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>). These findings, interpreted in conjunction with a wealth of information from basic science studies, have allowed us to understand how peripheral inflammation affects the brain, even in the absence of CNS immune cell activation detectable by PET neuroimaging. These translational neuroimaging and basic science studies have elucidated a number of neurotransmitter systems affected by inflammation that may serve as more proximal targets for existing therapeutics used in psychiatry and neurology that may improve symptoms of mood and anxiety-related disorders in patients with increased inflammation [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r17" ref-type="bibr">17</xref>]. This review will highlight the wealth of clinical and translational work demonstrating the impact of peripheral inflammation on brain regions relevant to both reward and threat sensitivity, with a focus on neuroimaging studies involving administration of inflammatory stimuli and the translation of these findings to the investigation of similar relationships in patients with mood and anxiety-related disorders who exhibit high inflammation.</p></sec><sec id="sec2"><label>2</label><title>Increased inflammation in mood and anxiety-related disorders</title><sec id="sec2.1"><label>2.1</label><title>Peripheral and Central Cytokines and Acute Phase Reactants</title><p>A growing body of evidence suggests that a significant proportion of patients with mood (<italic>e.g</italic>. major depressive disorder [MDD] and bipolar disorder [BD]) and anxiety-related disorders (<italic>e.g</italic>. generalized anxiety disorder [GAD], panic disorder and post-traumatic stress disorder [PTSD]) exhibit a chronic low-grade inflammation, as measured by increased peripheral and central inflammatory cytokines, inflammatory mediators and acute phase reactants (for review see [<xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r12" ref-type="bibr">12</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r19" ref-type="bibr">19</xref>]. Numerous studies have reported increased circulating inflammatory cytokines, <italic>e.g</italic>. interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF), their soluble receptors, and acute phase reactants such as C-reactive protein (CRP), in patients with mood and anxiety-related disorders [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r22" ref-type="bibr">22</xref>]. For example, recent studies have indicated that &#8216;high inflammation&#8217; (plasma CRP concentrations &gt;3mg/L, as defined by the American Heart Association) [<xref rid="r23" ref-type="bibr">23</xref>], is consistently found in 20-40% of patients with MDD, with higher concentrations observed in patients who are resistant to standard antidepressant therapies [<xref rid="r24" ref-type="bibr">24</xref>-<xref rid="r28" ref-type="bibr">28</xref>]. These findings have been corroborated by meta-analyses in MDD [<xref rid="r29" ref-type="bibr">29</xref>, <xref rid="r30" ref-type="bibr">30</xref>], BD [<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r31" ref-type="bibr">31</xref>, <xref rid="r32" ref-type="bibr">32</xref>], and PTSD [<xref rid="r33" ref-type="bibr">33</xref>]. Increased inflammatory cytokine concentrations in the cerebrospinal fluid (CSF) of patients with MDD, BD and PTSD have also been observed [<xref rid="r34" ref-type="bibr">34</xref>-<xref rid="r38" ref-type="bibr">38</xref>]. In MDD, CSF cytokines have been shown to be associated with severity of depression, or with change in symptoms in response to successful treatment [<xref rid="r34" ref-type="bibr">34</xref>, <xref rid="r39" ref-type="bibr">39</xref>, <xref rid="r40" ref-type="bibr">40</xref>], and in BD they were higher in patients that have had more recent manic or hypomanic episodes [<xref rid="r37" ref-type="bibr">37</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>Gene Expression and Genetic Predisposition</title><p>Several functional allelic variants and single-nucleotide polymorphisms (SNPs) of genes encoding immune and inflammatory molecules have been associated with MDD, including those encoding expression of inflammatory cytokines, major histocompatibility complex proteins, B and T cells, and inflammatory mediators like cyclo-oxygenase2 [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r41" ref-type="bibr">41</xref>-<xref rid="r44" ref-type="bibr">44</xref>]. In PTSD, results from a genome-wide association study (GWAS) indicated that polymorphisms for genes involved in inflammatory pathways were enriched in women with PTSD [<xref rid="r45" ref-type="bibr">45</xref>]. Furthermore, in patients from a high risk urban setting with a history of trauma, those who carried a CRP genotype (rs1130864) that is associated with elevated CRP concentrations had higher rates of PTSD and reported higher severity of symptoms of being overly alert and losing interest in activities [<xref rid="r46" ref-type="bibr">46</xref>]. As alluded to in the introduction, such findings have engendered speculation as to whether alleles that promote enhanced inflammatory cytokine secretion were evolutionarily advantageous and thus conserved [<xref rid="r5" ref-type="bibr">5</xref>]. Indeed, heightened inflammatory responses to environmental stimuli may have improved survival by conferring greater protection from bacterial and viral infection [<xref rid="r5" ref-type="bibr">5</xref>], and genetic priming to respond to stress and the environment with increased inflammatory and antiviral responses could contribute to the high prevalence of psychiatric disorders comorbid with medical illnesses that are associated with inflammation (<italic>e.g.</italic> cardiovascular disease, metabolic disorders, and autoimmune disorders) [<xref rid="r47" ref-type="bibr">47</xref>-<xref rid="r52" ref-type="bibr">52</xref>].</p><p>In addition to genetic polymorphisms, increased inflammatory gene expression in circulating immune cells has been found in patients with MDD, PTSD and other psychiatric disorders [<xref rid="r53" ref-type="bibr">53</xref>-<xref rid="r55" ref-type="bibr">55</xref>], and may predict treatment response in MDD. For instance, a targeted analysis of leukocyte mRNA expression of a subset of genes related to inflammation, glucocorticoid receptor signaling, and neuroplasticity revealed higher baseline mRNA levels of interleukin (IL)-1&#946;, macrophage inhibitory factor (MIF), and TNF in patients with MDD who failed to respond to 8 weeks of treatment with escitalopram or nortriptyline [<xref rid="r56" ref-type="bibr">56</xref>]. Interestingly, increased expression of a number of inflammatory markers has been observed in the brains of patients with mood disorders [<xref rid="r53" ref-type="bibr">53</xref>, <xref rid="r57" ref-type="bibr">57</xref>].</p></sec><sec id="sec2.3"><label>2.3</label><title>Sources of Innate Immune Activation and Inflammation</title><p>Factors that may activate the innate immune system and contribute to increased inflammation in psychiatric patients who are otherwise medically stable include psychosocial stress (and particularly early life stress or trauma), sleep disturbance, inflammatory diet and gastrointestinal permeability, obesity and other lifestyle factors such as smoking [<xref rid="r13" ref-type="bibr">13</xref>]. Persons with a history of childhood trauma exhibit elevated inflammatory biomarkers and higher rates of depression as adults [<xref rid="r58" ref-type="bibr">58</xref>, <xref rid="r59" ref-type="bibr">59</xref>], and a &#8220;biological embedding&#8221; or imprinting of stress through inflammatory processes in childhood has been proposed [<xref rid="r60" ref-type="bibr">60</xref>, <xref rid="r61" ref-type="bibr">61</xref>]. For instance, subjects with MDD and a history of early life stress responded to psychological stress (the Trier Social Stress Test) with exaggerated circulating IL-6 production and increased DNA binding of nuclear factor (NF)-kB in peripheral blood mononuclear cells compared to non-depressed controls [<xref rid="r62" ref-type="bibr">62</xref>]. Increased IL-6 production in adolescents with histories of childhood adversity has been shown to precede subsequent development of depression 6 months later [<xref rid="r63" ref-type="bibr">63</xref>]. Similarly, peripheral CRP prior to trauma has been shown to be a significant predictor of future development of PTSD after trauma, [<xref rid="r64" ref-type="bibr">64</xref>] and inflammatory cytokine production early after trauma was also predictive of the development of PTSD [<xref rid="r65" ref-type="bibr">65</xref>]. Together these findings suggest causal relationships between early life stress or trauma, increased inflammation, and development of MDD and/or PTSD.</p><p>Considerable evidence now exists supporting mechanisms by which stress activates the inflammatory response [<xref rid="r66" ref-type="bibr">66</xref>, <xref rid="r67" ref-type="bibr">67</xref>]. On a cellular level, the immune system can detect danger signals in the absence of a pathogen through the release of danger associated molecular patterns (DAMPs) such as heat shock protein-72, uric acid, and adenosine triphosphate (ATP), through a process termed &#8220;sterile inflammation&#8221; [<xref rid="r66" ref-type="bibr">66</xref>, <xref rid="r68" ref-type="bibr">68</xref>]. These DAMPS are released during psychological stress, and one key mechanism by which they may elicit an immune response is through the NLRP3 inflammasome (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>), a multi-protein complex that is involved in the processing of IL-1beta. DAMPs are known to stimulate the inflammasome in the presence of endotoxin to activate caspase-1, which cleaves the immature precursor of interleukin IL-1beta as well as IL-18 into their mature, releasable forms [<xref rid="r67" ref-type="bibr">67</xref>, <xref rid="r68" ref-type="bibr">68</xref>]. This release of IL-1beta can then induce the production of other inflammatory cytokines that are produced during stress [<xref rid="r67" ref-type="bibr">67</xref>]. Therefore, DAMPS and the NLRP3 inflammasome may serve as a primary link by which stress is translated into damage signals that promote inflammatory activity in patients exposed to chronic psychological stress and trauma.</p><p>Sleep disturbance may be another variable that is related to inflammation [<xref rid="r69" ref-type="bibr">69</xref>-<xref rid="r72" ref-type="bibr">72</xref>]. Sleep deprivation results in increased circulating levels of IL-6, TNF, and CRP when compared to periods of undisturbed sleep [<xref rid="r73" ref-type="bibr">73</xref>-<xref rid="r75" ref-type="bibr">75</xref>]. Disturbed sleep also increase circulating IL-6, TNF and CRP [<xref rid="r73" ref-type="bibr">73</xref>-<xref rid="r75" ref-type="bibr">75</xref>], and sleep impairments in psychiatric illnesses such as MDD have been associated with increased inflammation [<xref rid="r69" ref-type="bibr">69</xref>-<xref rid="r72" ref-type="bibr">72</xref>]. In terms of lifestyle factors, inflammatory diets that promote gut permeability and changes in the microbiota, smoking, and increased body mass index (BMI) all contribute to increased inflammation and may interact with genetics and stress to contribute to behavioral symptoms and poor overall health outcomes in patients with psychiatric illness [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r76" ref-type="bibr">76</xref>]. For example, obesity from consumption of a high-fat diet in rodents induces changes in the gut microbiota and increases ileal inflammation and permeability [<xref rid="r77" ref-type="bibr">77</xref>]. Obesity and high BMI are associated with increased concentrations of IL-6 and other inflammatory markers in humans [<xref rid="r78" ref-type="bibr">78</xref>, <xref rid="r79" ref-type="bibr">79</xref>] thought to be the result of macrophage accumulation in adipose tissue, and especially visceral adiposity, which can release cytokines into portal circulation [<xref rid="r80" ref-type="bibr">80</xref>-<xref rid="r82" ref-type="bibr">82</xref>]. Interestingly, adiposity has been suggested as a link between psychiatric illness, increased inflammatory markers and increased risk of coronary heart disease [<xref rid="r83" ref-type="bibr">83</xref>, <xref rid="r84" ref-type="bibr">84</xref>].</p></sec><sec id="sec2.4"><label>2.4</label><title>Peripheral and Central Immune Cell Activation</title><p>Peripheral inflammatory cytokines may access the CNS to initiate local immune activation by several mechanisms, including 1.) passage through leaky regions in the blood-brain-barrier at circumventricular organs [<xref rid="r85" ref-type="bibr">85</xref>, <xref rid="r86" ref-type="bibr">86</xref>], 2.) active uptake mechanisms of cytokines across the blood-brain-barrier [<xref rid="r87" ref-type="bibr">87</xref>-<xref rid="r89" ref-type="bibr">89</xref>], and 3.) local actions at peripheral vagal nerve afferents that relay cytokine signals to relevant brain regions, including the nucleus of the solitary tract and hypothalamus (the so called &#8216;neural route&#8217;) [<xref rid="r90" ref-type="bibr">90</xref>-<xref rid="r93" ref-type="bibr">93</xref>]. However, recent translational data indicates that during peripheral inflammation, activated monocytes/macrophages traffic to the brain in response to monocyte chemoattractant protein (MCP-1), a chemokine produced by activated microglial cells in response to cytokine signaling in from the periphery [<xref rid="r14" ref-type="bibr">14</xref>, <xref rid="r94" ref-type="bibr">94</xref>]. These monocytes/macrophages traffic primarily to perivascular and meningeal spaces, and have been shown to contribute to behavioral changes in rodent models of stress-induced depressive and anxiety behaviors [<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r95" ref-type="bibr">95</xref>, <xref rid="r96" ref-type="bibr">96</xref>]. Interestingly, patterns of gene expression in the peripheral blood of patients with psychiatric disorders exhibit increased signatures consistent with pro-inflammatory &#8220;M1&#8221; activation of monocyte/macrophages [<xref rid="r55" ref-type="bibr">55</xref>, <xref rid="r97" ref-type="bibr">97</xref>, <xref rid="r98" ref-type="bibr">98</xref>]. Furthermore, recruitment of activated peripheral macrophages to perivascular spaces, as well as localized activation of microglia neighboring theses blood vessels and increased expression of MCP-1, has been observed in the dorsal ACC of post mortem tissue from suicide patients with mood disorders [<xref rid="r99" ref-type="bibr">99</xref>, <xref rid="r100" ref-type="bibr">100</xref>]. These findings indicate that accumulation of peripheral immune cells in vascular compartments in association with restricted and/or regionally specific activation of microglia may be characteristic of patients with mood disorders who exhibit high inflammation.</p></sec></sec><sec id="sec3"><label>3</label><title>
<italic>In vivo</italic> imaging of CNS immune cell activation in psychiatric disorders</title><p>To better understand the consequence of increased inflammation in the periphery of patients with psychiatric illness, there has been growing interest in measuring microglial activation using neuroimaging strategies including positron emission tomography (PET). These strategies have aimed to understand the role of inflammation in the CNS in psychiatric disorders over time as well as the ability to determine whether anti-inflammatory therapies reduce inflammation in the brain. One primary strategy has been the development of radioligands that bind to macrophage as well as microglia in the brain when they become activated and increase surface expression of the translocator protein (TSPO) [<xref rid="r101" ref-type="bibr">101</xref>]. PET ligands that bind TSPO are used as potential markers of activated microglia, such as [<sup>11</sup>C]PK 11195, which show elevated non-displaceable binding potential (BP<sub>ND</sub>) [<xref rid="r102" ref-type="bibr">102</xref>] in animal models of neuroinflammation [<xref rid="r103" ref-type="bibr">103</xref>, <xref rid="r104" ref-type="bibr">104</xref>]. Unfortunately, the specific-activity of PK 11195 has proved too low to detect subtler inflammatory effects. However, structurally similar second-generation TSPO ligands such as [<sup>11</sup>C]PBR28 [<xref rid="r105" ref-type="bibr">105</xref>] and [<sup>18</sup>F]FEPPA [<xref rid="r106" ref-type="bibr">106</xref>] have been developed that have improved sensitivity and have been used to examine activated CNS macrophage and microglia in patients with mood disorders with mixed results [<xref rid="r107" ref-type="bibr">107</xref>-<xref rid="r110" ref-type="bibr">110</xref>]. [<xref rid="r111" ref-type="bibr">111</xref>].</p><p>In mild to moderate depression, [<sup>11</sup>C]PBR28 binding was not different between patients and controls in BP<sub>ND</sub>, though the sample was small and the depression severity was relatively low [<xref rid="r108" ref-type="bibr">108</xref>]. In contrast the 18F analogue of [<sup>11</sup>C]PBR28, [<sup>18</sup>F]FEPPA, was used to examine microglia activity in a more severely depressed sample, and showed significant increases in BP<sub>ND</sub> in the striatum, hippocampus, insula and prefrontal areas [<xref rid="r107" ref-type="bibr">107</xref>] that correlated with depression symptom severity [<xref rid="r112" ref-type="bibr">112</xref>]. However, in this study, no significant relationship was found between peripheral inflammatory markers and central TSPO binding. Similarly, although marked increases in TSPO binding were observed after administration of endotoxin to humans, no correlations between increased peripheral blood cytokine concentrations or increased symptoms of depression and increased TSPO binding in the brain were found [<xref rid="r113" ref-type="bibr">113</xref>]. This is in contrast to the measurement of TSPO binding in nonhuman primates administered endotoxin which demonstrated increased TSPO binding in the brain that correlated with increased peripheral blood concentrations of IL-1 beta, IL-6 and TNF depending on the time point examined post endotoxin administration [<xref rid="r114" ref-type="bibr">114</xref>]. Moreover, histological examination in non-human primates confirmed that TSPO binding following endotoxin was primarily increased in microglia as opposed astrocytes, which also express TSPO [<xref rid="r114" ref-type="bibr">114</xref>].</p><p>The inconsistencies between TSPO binding and circulating levels of inflammatory markers in humans, considering they are highly correlated in animal studies, raise questions about what TSPO binding is actually measuring in the brain of patients. Currently it is also unknown, yet highly plausible, that elaboration of immune signals such as cytokines, prostaglandins, nitric oxide and kynurenine pathway metabolites across the blood brain barrier may be sufficient to drive behavioral changes in the absence of appreciable CNS immune cell activation that is detectable by PET. Additional caveats of PET imaging to measure potential microglia activation are worth mentioning. Even at rest, microglia are now known to play a variety of ongoing sentinel-type functions [<xref rid="r101" ref-type="bibr">101</xref>]. Moreover, microglia exhibit graded activation responses [<xref rid="r115" ref-type="bibr">115</xref>], and increases in some activation markers&#8211;such as TSPO&#8211; may not indicate a pure inflammatory phenotype [<xref rid="r116" ref-type="bibr">116</xref>, <xref rid="r117" ref-type="bibr">117</xref>], thus complicating interpretation of TSPO expression. Additionally, lack of correlation between TSPO BP<sub>ND</sub> and peripheral cytokine concentrations may be an artifact of the volume transmission analysis model, as TSPO BP<sub>ND</sub> is determined through the use of an arterial input function. It is possible that evidence of increased inflammation may also be associated with elevated TSPO expression in peripheral blood cells outside the CNS. In this light, the use of an arterial input function may obscure associations between peripheral and central inflammatory measures. Additionally, the assessment of TSPO binding is complicated by the presence of a TSPO polymorphism (rs6971) that is known to influence the TSPO binding, leading to high-affinity, mixed-affinity and low-affinity binders [<xref rid="r111" ref-type="bibr">111</xref>]. Low affinity binders are typically excluded from study analyses, albeit they represent only about 10% of the population in North America. In sum, while PET measures of CNS immune cell activation provide some evidence that macrophage and microglia are activated in mood disorders, further studies are needed to validate the efficiency of TSPO-ligands as markers of inflammation in the brain, in mood as well as anxiety-related disorders, and their relationships with peripheral measures of inflammation and behavioral symptom profiles.</p></sec><sec id="sec4"><label>4</label><title>Inflammation effects on reward and motor circuitry</title><p>Findings from numerous laboratories have consistently indicated that innate immune activation and the release of inflammatory cytokines preferentially affect reward circuitry and dopamine (DA) in the basal ganglia to contribute to reduced motivation and motor slowing [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r118" ref-type="bibr">118</xref>-<xref rid="r124" ref-type="bibr">124</xref>]. In humans, this evidence stems primarily from studies using PET and functional magnetic resonance imaging (fMRI) neuroimaging strategies to investigate the effects of cytokines in healthy volunteers acutely administered cytokine inducers (<italic>e.g</italic>. endotoxin or typhoid vaccination) [<xref rid="r121" ref-type="bibr">121</xref>, <xref rid="r123" ref-type="bibr">123</xref>], and from patients chronically administered inflammatory cytokines (<italic>e.g</italic>. interferon [IFN]-&#945;) as therapy for some cancers and infectious diseases [<xref rid="r118" ref-type="bibr">118</xref>, <xref rid="r119" ref-type="bibr">119</xref>]. In terms of effects on behavior, depending on the dose, up to 50% of patients administered IFN-&#945; as treatment for hepatitis C virus (HCV) or malignant melanoma meet symptom criteria for major depression, and up to 80% experience significant fatigue, lack of energy and motor slowing [<xref rid="r125" ref-type="bibr">125</xref>-<xref rid="r132" ref-type="bibr">132</xref>]. Additionally, reduced motivation and anhedonia are frequently reported in IFN-&#945;-treated patients [<xref rid="r118" ref-type="bibr">118</xref>, <xref rid="r122" ref-type="bibr">122</xref>, <xref rid="r126" ref-type="bibr">126</xref>]. Indeed, targeted instruments that assess aspects of anhedonia, including the Snaith&#8211;Hamilton Pleasure Scale (SHAPS) and Reduced Motivation subscale of the Multidimensional Fatigue Inventory (MFI), have yielded comparable effect sizes (all r=0.47-0.49) as for increases in self-reported depression or fatigue scores after chronic IFN-&#945; treatment [<xref rid="r118" ref-type="bibr">118</xref>, <xref rid="r122" ref-type="bibr">122</xref>].</p><p>Preclinical neuroimaging and high performance liquid chromatography (HPLC) data in non-human primates and rodents suggest that the effects of inflammation on reward circuitry and motivation are mediated by cytokine-induced reductions in striatal DA [<xref rid="r133" ref-type="bibr">133</xref>-<xref rid="r135" ref-type="bibr">135</xref>]. Additionally, a wealth of <italic>in vitro</italic> and <italic>in vivo</italic> studies in laboratory animals have demonstrated a myriad of mechanisms by which inflammation may affect the glutamate system to increase both extracellular glutamate concentrations and glutamate receptor signaling to ultimately contribute to excitotoxicity (as discussed in section 6 below) [<xref rid="r17" ref-type="bibr">17</xref>]. Increased glutamate may contribute to inflammation-related functional changes in the striatum and medical prefrontal cortex, and/or drive some of the observed changes in the DA system either directly or through increasing excitetoxicity and oxidative stress, and is consistent with neuroimaging findings in patients administered IFN-alpha [<xref rid="r136" ref-type="bibr">136</xref>, <xref rid="r137" ref-type="bibr">137</xref>]. Table <bold><xref ref-type="table" rid="T1">1</xref></bold> summarizes findings from studies investigating the effects of administration of cytokines and inflammatory stimuli on neural activation, structural changes, and DA and glutamate transmission in reward circuitry including regions of striatum and prefrontal cortex (PFC). Studies were identified by pubmed (NLM) query using search terms for inflammatory stimuli (typhoid OR endotoxin OR interferon) AND technique (neuroimaging OR PET OR spectroscopy) AND brain region (striatum OR basal ganglia OR substantia nigra OR prefrontal cortex). Studies were limited to those primary papers that involved administration of inflammatory stimuli to humans or nonhuman primates. Review papers were used to provide cross-references of papers not identified by the query. Translation of these findings to investigate associations between inflammation and changes in neural activity and neurotransmitters in patients with mood disorders is also discussed.</p><sec id="sec4.1"><label>4.1</label><title>Translational Biochemical and Neuroimaging Studies</title><p>Initial evidence that inflammation can affect brain DA originates from neurochemical and behavioral studies in rodents administered acute or sub-chronic IFN-&#945; that measured DA and/or DA metabolites in concert with depressive behaviors and changes in locomotor activity [<xref rid="r134" ref-type="bibr">134</xref>, <xref rid="r138" ref-type="bibr">138</xref>-<xref rid="r141" ref-type="bibr">141</xref>]. Some studies reported increases [<xref rid="r138" ref-type="bibr">138</xref>, <xref rid="r140" ref-type="bibr">140</xref>] while others have reported decreases [<xref rid="r134" ref-type="bibr">134</xref>, <xref rid="r139" ref-type="bibr">139</xref>, <xref rid="r141" ref-type="bibr">141</xref>] in brain DA and/or metabolites following acute or sub-chronic IFN-&#945; administration. These discrepancies were likely due to differences in dosing, length of exposure, and most importantly, the fact that species-specific IFN-&#945; was variably used and rodents do not respond to human IFN-&#945; with activation of classic type I IFN receptor signaling [<xref rid="r142" ref-type="bibr">142</xref>-<xref rid="r144" ref-type="bibr">144</xref>]. Moreover, human IFN-&#945; administered to rodents binds to opioid receptors, which may be responsible for some of the observed changes in brain monoamines [<xref rid="r145" ref-type="bibr">145</xref>-<xref rid="r147" ref-type="bibr">147</xref>]. Moreover, chronic (6 days to 4 weeks) peripheral administration of both human and species-specific IFN-a administered to rodents has demonstrated only limited ability to reliably induce depressive behaviors (for example see [<xref rid="r142" ref-type="bibr">142</xref>, <xref rid="r144" ref-type="bibr">144</xref>, <xref rid="r148" ref-type="bibr">148</xref>-<xref rid="r154" ref-type="bibr">154</xref>].</p><p>Rhesus monkeys exposed to chronic IFN-&#945; exhibit immune, neuroendocrine and behavioral responses similar to that of cytokine-treated patients, including decreases in psychomotor activity and increases in depressive-like huddling behavior (in ~50% of animals) [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r155" ref-type="bibr">155</xref>]. Of note, depressive huddling behavior in non-human primates has been previously described following chronic administration of the monoamine-depleting agent reserpine, and DA receptor antagonists and partial agonists [<xref rid="r156" ref-type="bibr">156</xref>, <xref rid="r157" ref-type="bibr">157</xref>]. Only animals that displayed depressive behavior following IFN-&#945; administration were found to have significantly lower cerebrospinal fluid (CSF) concentrations of the DA metabolites homovanillic acid (HVA) and 3,4 dihydroxy-phenylacetic acid (DOPAC), which also correlated with decreased locomotor activity [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r155" ref-type="bibr">155</xref>]. Moreover, chronic IFN-&#945; administration reduced effort-based but not freely available sucrose consumption by the monkeys [<xref rid="r133" ref-type="bibr">133</xref>]. Similar to the effects of IFN-&#945;, peripheral administration of IL-1&#946; to rodents has been shown to decrease effortful responding for sucrose reward over freely available chow, in the absence of a decrease in preference for freely available sucrose over chow [<xref rid="r135" ref-type="bibr">135</xref>]; an effect which was reversed by lisdexamfetamine [<xref rid="r158" ref-type="bibr">158</xref>]. Interestingly, peripheral administration of IL-1beta in mice at 24 hours has been shown to decrease locomotor (wheel running) activity, which was improved by methylphenidate but not modafinil [<xref rid="r159" ref-type="bibr">159</xref>]. Furthermore, similar to IL-1beta administration, an overall decrease in responding for food reward has been reported in mice following peripheral administration of lipopolysaccharide (LPS; <italic>i.e</italic>. endotoxin) with no decrease in reward sensitivity (preference for high value sucrose rewards) [<xref rid="r160" ref-type="bibr">160</xref>].</p><p>To further explore the effects of inflammatory cytokines on synaptic availability and release of striatal DA that may underlie inflammation effects on motivation and motor function, <italic>in vivo</italic> microdialysis was conducted on IFN-&#945;-treated monkeys [<xref rid="r133" ref-type="bibr">133</xref>]. Results indicated that stimulated DA release was indeed decreased in the striatum after chronic administration of IFN-&#945; (4 weeks), which correlated with reduced effort-based sucrose consumption [<xref rid="r133" ref-type="bibr">133</xref>]. These <italic>in vivo</italic> microdialysis findings of cytokine-induced decreases in striatal DA release were corroborated by translational neuroimaging studies in IFN-&#945;-treated monkeys using [<sup>11</sup>C]raclopride PET that found decreased DA release in putamen and ventral striatum [<xref rid="r133" ref-type="bibr">133</xref>]. Furthermore, IFN-&#945;-induced decreases in striatal DA release were reversed by the DA precursor levodopa (L-DOPA) administered <italic>via</italic> reverse <italic>in vivo</italic> microdialysis, indicating that cytokines may reduced DA synthesis and availability [<xref rid="r161" ref-type="bibr">161</xref>]. In addition to IFN-&#945; administration, models of peripheral inflammation in rodents have also been shown to decrease DA availability. For example, single injections of septic doses of LPS (5 mg/kg) cause progressive neurodegeneration of the nigrostriatal DArgic system [<xref rid="r162" ref-type="bibr">162</xref>, <xref rid="r163" ref-type="bibr">163</xref>]. It should be noted that acute systemic administration of low dose LPS (~100 &#956;g/kg) has been reported to either decrease tissue DA content or increase extracellular DA metabolites in the nucleus accumbens (NAcc) [<xref rid="r164" ref-type="bibr">164</xref>, <xref rid="r165" ref-type="bibr">165</xref>]. However, these studies assessed DA and &#8220;anhedonic&#8221; behavior (sucrose preference or responding for brain stimulation) at 2 to 4 hours post-LPS [<xref rid="r164" ref-type="bibr">164</xref>-<xref rid="r166" ref-type="bibr">166</xref>], a time point that may be confounded due to febrile effects of LPS and related sickness behaviors [<xref rid="r167" ref-type="bibr">167</xref>-<xref rid="r169" ref-type="bibr">169</xref>]. These early effects of LPS may also reflect, for instance, acute activation of neuroendocrine peptides and hormones (minutes to hours) which can have stimulatory effects on turnover or release of brain catecholamines [<xref rid="r170" ref-type="bibr">170</xref>-<xref rid="r173" ref-type="bibr">173</xref>], and which may occur ahead of the more chronic mechanisms by which inflammation is thought to contribute to decreased DA availability (see Section 6 below for detailed discussion). Together, these results from animal studies indicate that a variety of inflammatory stimuli have been consistently found to affect brain DA to lead to relevant behavioral symptoms, and have prompt further investigation into inflammation effects on DA and the basal ganglia in clinical populations.</p></sec><sec id="sec4.2"><label>4.2</label><title>Human Neuroimaging Studies</title><p>Neuroimaging studies across several laboratories suggest that disruption of the basal ganglia and changes in the DA or glutamate systems are major contributors to inflammation-induced behavioral change (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). In the first study to examine IFN-&#945; effects on the brain, in addition to decreased metabolism in PFC, increased glucose metabolism was found in the basal ganglia and particularly the DA-rich putamen [<xref rid="r174" ref-type="bibr">174</xref>], as assessed by PET neuroimaging with fluorine-18-labeled-fluorodeoxyglucose (FDG). More recently, FDG PET revealed increased basal ganglia glucose metabolism in patients receiving high dose IFN-&#945; as therapy for malignant melanoma [<xref rid="r119" ref-type="bibr">119</xref>]. Increased glucose metabolism in the left putamen and left ventral striatum (NAcc) correlated significantly with reports of fatigue in these patients, as assessed by the 'energy' subscale of the Visual Analog Scale of Fatigue (VAS-F) [<xref rid="r119" ref-type="bibr">119</xref>]. This pattern of increased glucose metabolism in basal ganglia nuclei is similar to that seen in patients with Parkinson&#8217;s disease (PD) [<xref rid="r175" ref-type="bibr">175</xref>-<xref rid="r177" ref-type="bibr">177</xref>], where it is thought to reflect increased oscillatory burst activity in relevant basal ganglia nuclei secondary to loss of inhibitory nigral DA input [<xref rid="r178" ref-type="bibr">178</xref>, <xref rid="r179" ref-type="bibr">179</xref>]. Interestingly, this pattern of increased metabolism in striatum is also similar to the effects of transient catecholamine depletion in patients with MDD reported by Hasler and colleagues, which correlated with anhedonic symptoms [<xref rid="r180" ref-type="bibr">180</xref>].</p><p>In fMRI studies conducted by Capuron and colleagues decreased neural activation in the basal ganglia, including ventral striatum, was observed in response to unexpected delivery of reward (winning in a gambling task [<xref rid="r181" ref-type="bibr">181</xref>]) in HCV+ patients undergoing IFN-&#945; administration, which correlated with self-reported reduced motivation [<xref rid="r118" ref-type="bibr">118</xref>]. Acute administration of IFN-alpha has also been shown to induced an change in striatal microstructure, as measured by quantitative magnetization transfer (qMT) imaging, that predicted an increase in symptoms of fatigue [<xref rid="r182" ref-type="bibr">182</xref>]. Administration of the cytokine-inducers endotoxin and typhoid vaccination to healthy volunteers produces similar effects on the ventral striatum in response to rewarding stimuli, suggesting that findings from IFN-&#945; generalize to other inflammatory stimuli [<xref rid="r121" ref-type="bibr">121</xref>, <xref rid="r123" ref-type="bibr">123</xref>]. Indeed, Eisenberger and colleagues demonstrated that endotoxin administration led to reduced activation of ventral striatum to reward-predicting cues during a monetary incentive delay task (MIDT), which was associated with increases in self-reported depressed mood as measured by the Profile of Mood States (POMS) depression subscale [<xref rid="r121" ref-type="bibr">121</xref>]. Similar blunting of neural responses to reward anticipation have been observed following dietary depletion of precursors for DA synthesis [<xref rid="r183" ref-type="bibr">183</xref>]. Moreover, typhoid vaccination was found to cause a shift in reward versus punishment sensitivity in a probabilistic instrumental learning task combined with fMRI [<xref rid="r123" ref-type="bibr">123</xref>]. Compared to saline control, Harrison and colleagues determined that vaccination reduced behavioral attractiveness of rewards while making punishments more aversive, effects that were related to decreased neural activation of ventral striatum to RPEs and increased activation of anterior insula to punishment prediction errors [<xref rid="r123" ref-type="bibr">123</xref>]. Healthy female control subjects who have heightened stress-induced production of IL-6 have also been found to exhibit decreased ventral striatal RPE signaling during reinforcement learning [<xref rid="r184" ref-type="bibr">184</xref>], suggesting that persons with chronically elevated inflammatory responses exhibit decreased neural sensitivity to reward. Of relevance to potential effects of inflammation on DA, the magnitude of response to prediction error signaling is fundamentally modulated by DA-dependent striatal activity as determined by administration of drugs that enhance (L-DOPA) or inhibit (haloperidol) DAergic function [<xref rid="r185" ref-type="bibr">185</xref>]. Additionally, typhoid vaccination compared to saline has been shown to affect activity in the substantia nigra, including increased activation during a cognitive Stroop task and decreased activation in response to visual or novel stimuli, which correlated with both psychomotor slowing and increased peripheral blood concentrations of IL-6 [<xref rid="r120" ref-type="bibr">120</xref>, <xref rid="r186" ref-type="bibr">186</xref>]. Finally, it should be mentioned that neural activation in reward circuitry (ventral striatum and ventromedial PFC [vmPFC]) has also been shown to encode endotoxin-induced increased sensitivity to social rewards, including positive social feedback and increased approach to familiar others, in healthy control subjects [<xref rid="r187" ref-type="bibr">187</xref>, <xref rid="r188" ref-type="bibr">188</xref>]. Healthy subjects administered endotoxin were also found to have exaggerated increases in neural activation of the reward-related orbitofrontal cortex to emotional stimuli [<xref rid="r189" ref-type="bibr">189</xref>].</p><p>To further determine the role of DA in the effects of inflammation on neural activation and metabolism in reward circuitry, Capuron and colleagues conducted a PET study in HCV+, IFN-&#945;-treated subjects using [<sup>18</sup>F]fluorodopa (FDOPA). Like the DA precursor L-DOPA, FDOPA is taken up by DAergic neurons and converted by DA decarboxylase to DA, whereupon it is stored in vesicles for release. Interestingly, both increased uptake and decreased turnover of FDOPA in the caudate, putamen and ventral striatum of IFN-&#945;-treated patients was found [<xref rid="r118" ref-type="bibr">118</xref>]. Baseline and percent change in FDOPA uptake was in turn correlated with IFN-&#945;-induced behavioral alterations including depression and fatigue, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) and MFI, respectively [<xref rid="r118" ref-type="bibr">118</xref>]. Increased uptake and decreased turnover of FDOPA in the basal ganglia following IFN-&#945; administration is in stark contrast to that observed in patients with PD where decreased uptake and increased FDOPA turnover is seen. Decreased uptake of FDOPA in PD is believed to be a function of loss of DAergic neurons and/or their projections throughout the basal ganglia [<xref rid="r190" ref-type="bibr">190</xref>-<xref rid="r192" ref-type="bibr">192</xref>], and intact or increased turnover suggests that the surviving neurons are capable of normal release [<xref rid="r191" ref-type="bibr">191</xref>, <xref rid="r193" ref-type="bibr">193</xref>]. Increased FDOPA uptake during IFN-&#945; treatment suggests intact terminals that exhibit a potential depletion of DA and increased synthetic capacity. These findings are consistent with that of the above described decreases in striatal DA release observed in IFN-&#945;-treated non-human primates (rhesus monkeys), as measured by both [<sup>11</sup>C]raclopride PET with amphetamine displacement (in putamen and NAcc) and <italic>in vivo</italic> microdialysis - which was reversed by L-DOPA administration [<xref rid="r133" ref-type="bibr">133</xref>, <xref rid="r161" ref-type="bibr">161</xref>]. As mentioned above, whereas chronic administration of inflammatory stimuli to laboratory animals may decrease DA availability, acute administration of inflammatory stimuli such as LPS (<italic>i.e</italic>. endotoxin) has been shown to stimulate efflux or turnover of monoamine neurotramsitters such as DA, serotonin (5-HT) and norepinephrine (NE) [<xref rid="r138" ref-type="bibr">138</xref>, <xref rid="r140" ref-type="bibr">140</xref>, <xref rid="r194" ref-type="bibr">194</xref>-<xref rid="r196" ref-type="bibr">196</xref>]. Accordingly, acute administration of endotoxin to healthy humans was found to increase DA release at 4 hours as measured by [<sup>11</sup>C]raclopride PET [<xref rid="r197" ref-type="bibr">197</xref>].</p><p>In regard to glutamate, there is an extensive basic science literature demonstrating that inflammation can increase extracellular glutamate concentrations and glutamate receptor signaling (for further discussion see [<xref rid="r17" ref-type="bibr">17</xref>] and section 6 below). In the clinical literature, patients treated with IFN-&#945; exhibited significantly increased concentrations of glutamate in the basal ganglia, as measured by magnetic resonance spectroscopy (MRS)[<xref rid="r137" ref-type="bibr">137</xref>]. Increases in glutamate as measured by MRS were in turn associated with IFN-alpha-induced depressive symptoms, and also with increasing age [<xref rid="r136" ref-type="bibr">136</xref>, <xref rid="r137" ref-type="bibr">137</xref>].</p><p>Despite the abundance of reports indicating changes in basal ganglia, prefrontal cortex, DA and glutamate function in subjects administered cytokines and inflammatory stimuli, little work has been done to investigate similar relationships in patients who exhibit high inflammation as a function of medical or neuropsychiatric illnesses. One study in patients with chronic fatigue syndrome, who have been frequently reported to exhibit elevated inflammatory markers including cytokines, observed decreased activation of basal ganglia structures, such as caudate and globus pallidus, in response to hedonic reward [<xref rid="r198" ref-type="bibr">198</xref>] using the gambling task mentioned above [<xref rid="r118" ref-type="bibr">118</xref>]. In medically stable patients with MDD, we observed a relationship between increased inflammation and decreased functional connectivity within reward-related corticostriatal neurocircuitry [<xref rid="r24" ref-type="bibr">24</xref>]. Indeed, increased inflammation (plasma concentrations of CRP as well as cytokines and their soluble receptors) was associated with decreased functional connectivity between the ventral striatum and vmPFC, and the dorsal striatum and the vmPFC and pre-supplementary motor area (pre-SMA), which correlated with self-reported symptoms of anhedonia and objective measures of psychomotor slowing, respectively [<xref rid="r24" ref-type="bibr">24</xref>]. Interestingly, dorsal striatum and pre-SMA/SMA are key components of corticostriatal circuitry involved in linking motivation to motor output [<xref rid="r199" ref-type="bibr">199</xref>, <xref rid="r200" ref-type="bibr">200</xref>], and like the ventral striatum, vmPFC is part of classic reward circuitry that receives significant mesocorticolimbic DA innervation [<xref rid="r201" ref-type="bibr">201</xref>, <xref rid="r202" ref-type="bibr">202</xref>]. Accordingly, inflammation-related decreases in corticostriatal connectivity within reward and motor circuitry in depression may involve cytokine-induced decreases in DA, and have potential for reversal with pharmacological strategies that increase DA availability or receptor signaling (see Sections 6 below for further discussion) [<xref rid="r3" ref-type="bibr">3</xref>]. Additionally, these changes in corticostriatal circuitry may be related to inflammation effects on glutamate. Like patients chronically administered INF-&#945;, increased glutamate as measured by MRS has been observed in MDD patients with increased inflammation that correlated with anhedonia and psychomotor slowing [<xref rid="r203" ref-type="bibr">203</xref>].</p><p>Together these data from humans and laboratory animals indicate that inflammation-related decreases in DA availability and release and increased glutamate may have functional consequences on reward and motor circuitry that are associated with fundamental alterations in motivation and motor function, to contribute to symptoms of anhedonia and psychomotor retardation in mood and anxiety disorders. This work supports further consideration of the mechanisms of cytokine affects on DA and glutamate, which may lead to the development of novel therapeutic strategies for patients with increased inflammation (see section 6).</p></sec></sec><sec id="sec5"><label>5</label><title>Inflammation effects on neural circuitry relevant to fear and anxiety</title><p>Of particular interest in considering the consequences of increased inflammation in anxiety-related disorders are the effects of inflammatory cytokines on brain regions involved in fear, anxiety and threat detection, such as the amygdala, insula, medial prefrontal cortex and anterior cingulate cortex (ACC), which may contribute to anxiety and PTSD symptoms. Administration of inflammatory cytokines or cytokine-inducers is well known to induce a myriad of behavioral symptoms in laboratory animals and humans including those relevant to anxiety disorders and PTSD [<xref rid="r204" ref-type="bibr">204</xref>]. In addition to the effects on reward and motor circuitry, PET and fMRI studies employing administration of cytokines or cytokine inducers (<italic>e.g</italic>. endotoxin or vaccination) acutely to healthy subjects, as well as chronic administration of IFN-&#945; to patients with HCV, have observed effects on circuitry relevant to fear, anxiety and emotional regulation as presented in Table <bold><xref ref-type="table" rid="T2">2</xref></bold>. Studies were identified by pubmed (NLM) query using search terms for inflammatory stimuli (typhoid OR endotoxin OR interferon) AND technique (neuroimaging OR PET OR spectroscopy) AND brain region (amygdala OR cingulate OR insula), and refined using similar procedures as described above, while excluding those that were most relevant to Table <bold><xref ref-type="table" rid="T1">1</xref></bold>. Several studies have also examined alterations in neural activity associated with stress-induced peripheral inflammatory responses in healthy subjects, which are consistent with neuroimaging findings in patients with fear and anxiety-related disorders. Although no work to date has established relationships between brain function and inflammation in these disorders, based on recent interest in this area [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r33" ref-type="bibr">33</xref>, <xref rid="r205" ref-type="bibr">205</xref>], such work is currently being conducted, particularly in PTSD.</p><sec id="sec5.1"><label>5.1</label><title>Amygdala</title><p>The amygdala is a principal brain region involved in fear and anxiety, and it is thought to play a crucial role in the neural circuitry of PTSD [<xref rid="r206" ref-type="bibr">206</xref>]. Neuroimaging findings in humans indicate that not only does inflammation increase amygdala activity, but also that increased amygdala responses to stress are associated with increased production of inflammatory cytokines [<xref rid="r207" ref-type="bibr">207</xref>-<xref rid="r209" ref-type="bibr">209</xref>]. Increased IL-6 and TNF after administration of endotoxin to healthy subjects has been shown to increase amygdala activity in response to socially threatening images, which was associated with enhanced feelings of social disconnection [<xref rid="r208" ref-type="bibr">208</xref>]. Administration of typhoid vaccination, which increases IL-6 and induces behavioral changes including cognitive disturbance and fatigue, also increased activation of the amygdala during presentation of congruent and incongruent stimuli [<xref rid="r210" ref-type="bibr">210</xref>]. In terms of stress sensitivity and neural pathways involved in the inflammatory response to stress, heightened neural activity in the amygdala in response to a psychosocial laboratory stressor was associated with greater stress-induced increases in IL-6 [<xref rid="r209" ref-type="bibr">209</xref>]. Thus, greater amygdala sensitivity to stress may lead to higher inflammatory cytokine production, which may in turn affect amygdala activity to create a feed-forward effect of inflammation on neural circuitry relevant to anxiety and PTSD symptoms.</p></sec><sec id="sec5.2"><label>5.2</label><title>Medial Prefrontal Cortex and Subgenual ACC</title><p>The medial prefrontal cortex, including the rostral ACC, subgenual ACC (BA 25) and medial frontal gyrus, is extensively connected to the amygdala in primates and thought to be involved in fear extinction and emotional regulation in PTSD [<xref rid="r206" ref-type="bibr">206</xref>, <xref rid="r211" ref-type="bibr">211</xref>]. Several studies have reported a relationship between peripheral inflammatory cytokines and activity of medial prefrontal cortical regions, including the subgenual ACC, either in individuals undergoing stress or following administration of cytokine-inducers [<xref rid="r207" ref-type="bibr">207</xref>, <xref rid="r212" ref-type="bibr">212</xref>]. Indeed, administration of typhoid vaccination to healthy controls induced mood changes that correlated with enhanced activity within subgenual ACC during an implicit emotional face perception task. Typhoid vaccination also reduced task-related functional connectivity of the subgenual ACC to the amygdala and other medial prefrontal cortical regions, as well as the nucleus accumbens and superior temporal sulcus, which correlated with peripheral blood IL-6 [<xref rid="r207" ref-type="bibr">207</xref>]. As mentioned above, heightened neural activity in the amygdala was associated with increased IL-6 responses to a psychosocial laboratory stressor, and functional connectivity analyses also indicated that individuals who showed a heightened inflammatory response to the stressor exhibited stronger coupling between the amygdala and the dorsomedial prefrontal cortex [<xref rid="r209" ref-type="bibr">209</xref>]. In a separate study of women undergoing the chronic emotional stress of bereavement, elevations in salivary concentrations of IL-1beta and soluble TNF receptor II have been shown to positively correlate with the degree of ventral prefrontal activation (including subgenual ACC and the orbitofrontal cortex) to a grief-elicitation task [<xref rid="r212" ref-type="bibr">212</xref>], suggesting a relationship between stress, inflammation, and medial prefrontal cortical activation that may be relevant for emotional processing in stress and trauma-related disorders.</p></sec><sec id="sec5.3"><label>5.3</label><title>Insula</title><p>Another region associated with amygdala activity and thought to contribute to emotional distress in anxiety disorders and PTSD is the insula [<xref rid="r213" ref-type="bibr">213</xref>, <xref rid="r214" ref-type="bibr">214</xref>]. For instance, increased activation of the anterior insula and amygdala, and decreased connectivity among the anterior insula, amygdala, and ACC, have been observed in women with PTSD from intimate partner violence while matching to fearful or angry versus happy target faces [<xref rid="r215" ref-type="bibr">215</xref>]. Given the role of the insula in interoception, it is not surprising that this brain region has also been reported to be activated in response to peripheral inflammatory stimuli [<xref rid="r210" ref-type="bibr">210</xref>]. As mentioned above, in addition to activation of the amygdala, administration of typhoid vaccination increased activation of the insula during presentation of congruent and incongruent stimuli [<xref rid="r210" ref-type="bibr">210</xref>]. Among females but not males administered endotoxin, increases in IL-6 were associated with increases in neural activity in brain regions including the anterior insula in response to social exclusion during a virtual ball-tossing game [<xref rid="r216" ref-type="bibr">216</xref>]. Endotoxin administration has also been shown to increase cerebral glucose metabolism in the insula as measured by PET [<xref rid="r217" ref-type="bibr">217</xref>], and to decrease its functional connectivity with cingulate cortex [<xref rid="r218" ref-type="bibr">218</xref>]. Therefore, heightened sensitivity of the insula to inflammatory cytokines in the periphery, particularly in the presence of emotional stimuli, may contribute to altered neural circuitry involving the amygdala, medial prefrontal cortex and ACC to precipitate symptoms of fear, anxiety and emotional disturbance.</p></sec><sec id="sec5.4"><label>5.4</label><title>Dorsal anterior cingulate cortex (dACC)</title><p>A major CNS target of cytokines that has received considerable attention is the dorsal ACC (dACC). The dACC [Brodmann&#8217;s Area (BA) <xref rid="r24" ref-type="bibr">24</xref>] has been shown to play an important role in error detection and conflict monitoring [<xref rid="r219" ref-type="bibr">219</xref>]. In addition, the dACC has been found to process social pain and therefore has been suggested to comprise a neural &#8220;alarm system&#8221;, which can both detect and respond to threatening environmental stimuli in the social domain [<xref rid="r220" ref-type="bibr">220</xref>]. The dACC&#8217;s downstream activation of the autonomic arousal system provides a further component of this alarm system which can thus both identify and respond to threat cognitively, emotionally and physically [<xref rid="r221" ref-type="bibr">221</xref>]. Increased activity of the dorsal ACC has been proposed as a mediator of hyperarousal symptoms in PTSD [<xref rid="r222" ref-type="bibr">222</xref>], as well as a potential familial risk factor for PTSD development [<xref rid="r223" ref-type="bibr">223</xref>], and veterans with PTSD and their twins have also been shown to exhibit increased resting metabolic activity in the dACC, as measured by PET [<xref rid="r224" ref-type="bibr">224</xref>]. Increased dACC activation has also been found in subjects with increased neuroticism, high trait anxiety and obsessive-compulsive disorder [<xref rid="r225" ref-type="bibr">225</xref>-<xref rid="r227" ref-type="bibr">227</xref>].</p><p>Similar to increased dACC activation in anxiety disorders and PTSD, early work in patients treated with IFN-&#945; for hepatitis C virus using fMRI and a task of visuo-spatial attention demonstrated that chronic IFN-&#945; administration was associated with increased dACC activation [<xref rid="r228" ref-type="bibr">228</xref>]. Activation of the dACC was highly correlated with the number of task-related errors made by IFN-alpha-treated patients, whereas no correlation was found between dACC activation and task-related errors in controls [<xref rid="r228" ref-type="bibr">228</xref>]. Administration of typhoid vaccination has also been shown to lead to increased dACC activation using fMRI and the Stroop task, which through its presentation of congruent and non-congruent stimuli has been shown to increase blood flow to the dACC [<xref rid="r210" ref-type="bibr">210</xref>, <xref rid="r220" ref-type="bibr">220</xref>]. In participants administered endotoxin prior to a neuroimaging session in which they were socially excluded during a virtual ball-tossing game, increases in IL-6 were associated with increases in social pain-related neural activity in dACC in females but not males [<xref rid="r225" ref-type="bibr">225</xref>]. This increased interaction between emotional and neural sensitivity and inflammation is consistent with reports of increased inflammatory activity in women with PTSD [<xref rid="r229" ref-type="bibr">229</xref>, <xref rid="r230" ref-type="bibr">230</xref>]. As mentioned above, another study administering typhoid vaccination to induce IL-6 and behavioral changes found increased activation of the amygdala, but also the dACC and insula, during presentation of congruent and incongruent stimuli [<xref rid="r210" ref-type="bibr">210</xref>]. In terms of mechanisms of cytokine effects on the dACC and as discussed in section 6 below, increased glutamine and glutamate in dACC as measured by MRS has been observed in patients administered IFN-a that correlated with IFN-a-induced behavioral symptoms [<xref rid="r231" ref-type="bibr">231</xref>, <xref rid="r232" ref-type="bibr">232</xref>]. Taken together, these data indicate that cytokines can increase the reactivity of the dACC, possibly through effects on glutamate, and thereby increase sensitivity to the external environment. This heightened sensitivity of dACC in the presence of cytokines maybe further contribute to symptoms in anxiety disorders and PTSD stress and trauma-exposed patients with increased inflammation.</p></sec></sec><sec id="sec6"><label>6</label><title>Mechanisms of inflammation affects on threat and reward circuitry and translational implications</title><p>The data summarized herein demonstrate that inflammation originating in the periphery targets brain structures relevant to mood and anxiety disorders, and may be related to cytokine effects on neurotransmitters such as monoamines and particularly DA as well as glutamate. These findings are based largely on clinical and translational neuroimaging results, which have opened opportunities to develop novel treatment strategies to block inflammation or target its effects on the brain to treat these symptoms in patients with mood and anxiety-related disorders that exhibit high inflammation. Current therapies are effective for many patients with mood and anxiety disorders. However, up to 30% fail to achieve remission and even responders often exhibit significant residual symptoms that are consistent with those that are caused by exposure to cytokines and inflammation, such as anhedonia, fatigue and psychomotor retardation [<xref rid="r233" ref-type="bibr">233</xref>-<xref rid="r237" ref-type="bibr">237</xref>]. Therefore, new conceptual frameworks are needed to treat these inflammation-associated symptoms [<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r56" ref-type="bibr">56</xref>, <xref rid="r238" ref-type="bibr">238</xref>], and are discussed below.</p><sec id="sec6.1"><label>6.1</label><title>Therapies that Block Inflammation</title><p>A number of recent studies have begun to test the potential of anti-inflammatory compounds as possible antidepressant therapies. Most studies to date have focused on compounds such as cyclooxygenase (COX) inhibitors or minocycline, which have relatively mild anti-inflammatory effects and numerous &#8220;off target&#8221; effects that may confound data interpretation [<xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r239" ref-type="bibr">239</xref>]. A recent meta-analysis reported anti-depressant effects for anti-inflammatory agents in BD [<xref rid="r240" ref-type="bibr">240</xref>], however some of the selected trials used drugs that block oxidative stress, which may have many other sources in addition to inflammation. Recent meta-analyses in MDD also reported mild to moderate effect sizes showing that COX inhibitors may reduce depressive symptoms, yet heterogeneity across studies and mostly small sample sizes complicate results [<xref rid="r241" ref-type="bibr">241</xref>, <xref rid="r242" ref-type="bibr">242</xref>]. It should be noted that the majority of studies included in the meta-analyses described above have not selected patients with increased inflammation, nor have they measured peripheral inflammatory markers to establish anti-inflammatory activity of the treatments. Interestingly, a recent study tested the efficacy of infliximab, a highly-selective TNF antagonist, in treatment-resistant MDD (TRD) as a function of peripheral inflammation. Treatment with infliximab was associated with robust decreases in plasma CRP concentrations, as well as a strong anti-depressant effect, but only in patients with elevated CRP at baseline [<xref rid="r27" ref-type="bibr">27</xref>]. Moreover, the greatest area of symptom improvement was related to motivation (interest in activities), followed by motor retardation and anxiety [<xref rid="r27" ref-type="bibr">27</xref>], which is consistent with the hypothesis that blockade of inflammation may exert anti-depressant properties through reversing inflammation effects on corticostriatal reward and motor as well as anxiety circuitry.</p><p>A number of holistic and alternative strategies, such as exercise, weight reduction or diet modification, dietary supplements, yoga, massage, tai chi and meditation, that have been shown to reduce depressive and anxiety symptoms are thought to either directly or indirectly reduce inflammation [<xref rid="r243" ref-type="bibr">243</xref>]. Weight loss and exercise have been the most studied of these interventions, both of which have been shown to have antidepressant and anti-anxiety effects [<xref rid="r244" ref-type="bibr">244</xref>, <xref rid="r245" ref-type="bibr">245</xref>] and to reduce inflammation over time [<xref rid="r246" ref-type="bibr">246</xref>, <xref rid="r247" ref-type="bibr">247</xref>]. Another therapy thought to decrease inflammation is supplementation with omega-3 fatty acids, which has been shown to have antidepressant efficacy, especially for eicosapentaenoic acid (EPA) [<xref rid="r248" ref-type="bibr">248</xref>], as verified by meta-analysis [<xref rid="r249" ref-type="bibr">249</xref>]. Indeed, treatment with EPA has been shown to prevent depression induced by IFN-&#945; [<xref rid="r250" ref-type="bibr">250</xref>], and patients who are vulnerable to the development of this inflammation-induced depression have both higher risk alleles for the phospholipase A2 (PLA2) gene and lower levels of EPA in the blood [<xref rid="r251" ref-type="bibr">251</xref>]. In MDD, a recent study demonstrated that patients with high CRP and IL-1ra had a greater antidepressant response to EPA, whereas patients with increased CRP and IL-6 were less responsive to placebo [<xref rid="r28" ref-type="bibr">28</xref>]. Interestingly, omega-3 fatty acids have been shown to impact brain structure, function, and pathology in human neuroimaging studies, indicating that they may exert antidepressant efficacy in part through affecting pathways in the brain that are targeted by inflammation [<xref rid="r252" ref-type="bibr">252</xref>].</p><p>Although little work has been done to examine anti-inflammatory treatments in anxiety disorders, normalization of inflammatory cytokines in patients with remitted PTSD [<xref rid="r253" ref-type="bibr">253</xref>] or following response to selective serotonin reuptake inhibitor (SSRI) therapy [<xref rid="r254" ref-type="bibr">254</xref>], suggests a close and potentially causal association between inflammation and PTSD symptoms. Behavioral interventions that reduce stress, such as exercise, yoga or meditation, can affect the HPA and SNS axes as well as the immune system [<xref rid="r255" ref-type="bibr">255</xref>], and may also serve as potential treatments for PTSD and related comorbidities.</p></sec><sec id="sec6.2"><label>6.2</label><title>Monoamine Synthesis, Availability and Receptor Signaling</title><p>In addition to effects on DA as described above, inflammation also affects other monoamines such as 5-HT. For example, acute administration of inflammatory cytokines increased 5-HT turnover, as determined by increased 5 hydroxyindoleacetic acid (5-HIAA) or 5HIAA/5-HT ratios, in brain regions such as the cortex and nucleus accumbens [<xref rid="r194" ref-type="bibr">194</xref>, <xref rid="r195" ref-type="bibr">195</xref>], and these changes in 5-HT turnover occurred in concert with the appearance of later, more persistent depressive-like behaviors [<xref rid="r167" ref-type="bibr">167</xref>, <xref rid="r168" ref-type="bibr">168</xref>]. In patients treated chronically with IFN-a for hepatitis C virus (HCV), CSF concentrations of IL-6 negatively correlated with 5-HIAA concentrations, which in turn negatively correlated with IFN-a-induced depression severity [<xref rid="r131" ref-type="bibr">131</xref>]. Lower plasma concentrations of 5-HT and higher circulating TNF at baseline have also been associated with somatic symptoms of depression during IFN-a treatment [<xref rid="r256" ref-type="bibr">256</xref>].</p><p>One primary mechanism by which inflammation may decrease monoamine and particularly DA availability is by negatively impacting synthesis. Indeed, DA synthesis relies on the conversion of tyrosine to L-DOPA by tyrosine hydroxylase (TH), the rate-limiting enzyme for DA synthesis. A major source of tyrosine is phenylalanine, which is converted to tyrosine by phenylalanine hydroxylase (PAH). Likewise, 5-HT synthesis requires conversion of tryptophan to 5-HT by tryptophan hydroxylase (TPH). All of these enzymes, TH, PAH and TPH, require the enzyme cofactor tetrahydrobiopterin (BH4). Although inflammation and cytokines have been shown to induce GTP-cyclohydrolase I, the enzyme necessary for BH4 synthesis, inflammation may in turn decrease BH4 availability [<xref rid="r257" ref-type="bibr">257</xref>]. BH4 is also a cofactor for nitric oxide synthases (NOS). Inflammation-induced increases in inducible NOS (iNOS) activity can usurp available BH4, which results in NOS uncoupling and the generation of reactive oxygen species instead of NO [<xref rid="r258" ref-type="bibr">258</xref>, <xref rid="r259" ref-type="bibr">259</xref>]. This increase in oxidative stress can then contribute to oxidative reduction of BH4 itself (which is highly redox-sensitive), leaving even less BH4 available for monoamine synthesis (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>) [<xref rid="r258" ref-type="bibr">258</xref>]. Indeed, intramuscular injection of rats with IFN-&#945; has been shown to decrease CNS concentrations of BH4 through stimulation of NO, and inhibition of NOS was found to reverse IFN-&#945;&#8217;s inhibitory effects on brain concentrations of both BH4 and DA [<xref rid="r134" ref-type="bibr">134</xref>]. Of note, IL-6 treatment has also been shown to reduce BH4 content in sympathetic neurons [<xref rid="r260" ref-type="bibr">260</xref>].</p><p>With relevance to DA availability, concentrations of phenylalanine, tyrosine, BH4 and BH2 can be measured in the peripheral blood and CSF, and the BH4/BH2 and phenylalanine/tyrosine ratios have been proposed as indicators of BH4 availability and PAH activity, and may serve as indirect biomarkers of DA synthetic capacity [<xref rid="r257" ref-type="bibr">257</xref>, <xref rid="r261" ref-type="bibr">261</xref>-<xref rid="r264" ref-type="bibr">264</xref>]. For example, a number of patient populations with increased inflammation, including patients with trauma, sepsis, cancer, and HIV, have been found to exhibit increased peripheral blood concentrations of phenylalanine [<xref rid="r257" ref-type="bibr">257</xref>]. Evidence of reduced BH4 activity has also been observed in IFN-&#945;-treated patients [<xref rid="r265" ref-type="bibr">265</xref>, <xref rid="r266" ref-type="bibr">266</xref>]. For example, IFN-&#945; administration was associated with increased peripheral blood phenylalanine/tyrosine ratio, which in turn correlated with decreased CSF DA and its major metabolite HVA [<xref rid="r265" ref-type="bibr">265</xref>], but not CSF 5-HT or its metabolites. Increased cerebrospinal fluid (CSF) IL-6 was also correlated with decreased BH4 in CSF of IFN-&#945;-treated patients, and the phenylalanine/tyrosine ratio significantly correlated with IFN-&#945;-induced depressive symptoms [<xref rid="r265" ref-type="bibr">265</xref>]. These findings are consistent with decreased DA metabolites in the CSF of both IFN-&#945;-treated patients and monkeys [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r155" ref-type="bibr">155</xref>], and with the complete reversal of IFN-&#945;-induced decreases in DA by L-DOPA administered <italic>via</italic> reverse <italic>in vivo</italic> microdialysis in monkeys [<xref rid="r267" ref-type="bibr">267</xref>]. Of note, during L-DOPA administration, no changes were found in the DOPAC/DA ratio, which increases when DA is not properly packaged in synaptic vesicles and is subsequently metabolized <italic>via</italic> monoamine oxidase [<xref rid="r268" ref-type="bibr">268</xref>].</p><p>Considering the strong evidence presented above indicating that inflammation can inhibit key components of monoamine and DA synthesis, pharmacologic strategies that increase DA may effectively treat inflammation-related symptoms of anhedonia, fatigue and psychomotor slowing. For instance, a number of compounds are available than can boost BH4 availability or activity, which may facility the capacity of PAH and TH to synthesize DA and TPH to synthesis 5-HT. These include administration of BH4 itself [<xref rid="r269" ref-type="bibr">269</xref>], which is currently approved in a synthetic form to treat phenylketonuria [<xref rid="r270" ref-type="bibr">270</xref>-<xref rid="r272" ref-type="bibr">272</xref>], and folic acid or S-adenosyl-methionine (SAMe), which have a role in the synthesis and/or regeneration of BH4 [<xref rid="r3" ref-type="bibr">3</xref>, <xref rid="r273" ref-type="bibr">273</xref>, <xref rid="r274" ref-type="bibr">274</xref>]. Although effects of BH4 administration on behavioral symptoms have not been reported outside of case reports [<xref rid="r275" ref-type="bibr">275</xref>, <xref rid="r276" ref-type="bibr">276</xref>], folic acid (in the form of L-methylfolate) and SAMe have demonstrated efficacy as adjuvants in depression trials [<xref rid="r277" ref-type="bibr">277</xref>-<xref rid="r281" ref-type="bibr">281</xref>]. Administration of L-methylfolate (marketed as Deplin and Zervalx) to patients with MDD has been shown to augment the efficacy of standard antidepressant therapy in two studies [<xref rid="r278" ref-type="bibr">278</xref>, <xref rid="r279" ref-type="bibr">279</xref>], however mixed results were reported in two parallel-sequential trials with only one trial finding efficacy over placebo [<xref rid="r280" ref-type="bibr">280</xref>]. Treatment with SAMe adjunctive to SSRIs led to significantly higher rates of remission and 50% or greater decreases in depressive symptoms compared with placebo [<xref rid="r277" ref-type="bibr">277</xref>]. Interestingly, post-hoc analysis of the two parallel-sequential adjuvant trials of L-methylfolate in patients with MDD [<xref rid="r280" ref-type="bibr">280</xref>] considered inflammatory markers. It was found in one study that BMI &gt;30 as well as concentrations of CRP, TNF, IL-8, and leptin, alone or in combination with each other or with IL-6, predicted greater symptom improvement [<xref rid="r281" ref-type="bibr">281</xref>]. Therefore, strategies to augment BH4 activity exhibit potential for restoring monoamine availability and treating symptoms of depression in patients with increased inflammation.</p><p>In addition to compounds that may increase DA availability, adenosine (A2A) receptor antagonists, which are thought to facilitate activation of DA D2 receptors, are efficacious in reversing decreased effort-based sucrose consumption after DA depletion with tetrabenazine (a vesicular monoamine transporter inhibitor) and after peripheral administration of IL-1&#946; in rats [<xref rid="r135" ref-type="bibr">135</xref>, <xref rid="r282" ref-type="bibr">282</xref>-<xref rid="r285" ref-type="bibr">285</xref>]. The DA receptor agonist, pramipexole, has been shown to block endotoxin-induced degeneration of nigrostriatal DA cells [<xref rid="r286" ref-type="bibr">286</xref>], and has also demonstrated efficacy in unipolar MDD and BD patients with TRD [<xref rid="r287" ref-type="bibr">287</xref>-<xref rid="r290" ref-type="bibr">290</xref>].</p></sec><sec id="sec6.3"><label>6.3</label><title>Monoamine Reuptake</title><p>Attention has been paid to the effects of cytokines and inflammatory signaling pathways on monoamine reuptake pumps, and particularly the 5-HT transporter (5-HTT) [<xref rid="r291" ref-type="bibr">291</xref>-<xref rid="r294" ref-type="bibr">294</xref>]. Both <italic>in vitro</italic> and <italic>in vivo</italic> data have established that stimulation of p38 mitogen-activated protein kinase (MAPK), a major signaling pathway activated by IFN-&#945; and other cytokines, can increase the expression and function of the 5-HTT, leading to increased 5-HT reuptake [<xref rid="r292" ref-type="bibr">292</xref>-<xref rid="r294" ref-type="bibr">294</xref>]. MAPK pathways have also been found to influence the DA transporter (DAT). For example, DAT-expressing cells transfected with a constitutively activate MAPK kinase (MEK) show increased DA reuptake (Vmax), whereas treatment of rat striatal synaptosomes with MEK inhibitors was associated with decreased DA reuptake in a concentration and time-dependent manner [<xref rid="r291" ref-type="bibr">291</xref>]. Furthermore, subjects with neuropsychiatric disturbances as a result of HIV infection and subsequent neuroinflammation are thought to have increased expression of DAT [<xref rid="r295" ref-type="bibr">295</xref>, <xref rid="r296" ref-type="bibr">296</xref>]. Therefore, reduced DA turnover secondary to inflammatory cytokines may be mediated, in part, by increased DAT expression or function. However, no change in DAT binding, as measured by PET with 18F-labeled FECNT, was observed in monkeys exposed to chronic IFN-&#945; [<xref rid="r133" ref-type="bibr">133</xref>]. However, increased plasma TNF significantly correlated with higher 5-HTT binding determined by [123I]-beta-CIT SPECT imaging in healthy adult women [<xref rid="r297" ref-type="bibr">297</xref>].</p><p>In terms of treatment implications, relationships exist between high levels of inflammation and resistance to standard antidepressant therapy with SSRIs, particularly in MDD [<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r56" ref-type="bibr">56</xref>, <xref rid="r298" ref-type="bibr">298</xref>, <xref rid="r299" ref-type="bibr">299</xref>]. Non-responsiveness of inflammation-related symptoms to standard SSRI therapies has been exemplified in patients receiving IFN-&#945; and those experiencing cancer-related behavioral symptoms that are associated with increased inflammation. Indeed, SSRIs have been found to alleviate cancer-related or IFN-&#945;-induced anxiety and some depressive symptoms, but not those of fatigue or psychomotor retardation [<xref rid="r126" ref-type="bibr">126</xref>, <xref rid="r300" ref-type="bibr">300</xref>, <xref rid="r301" ref-type="bibr">301</xref>]. Moreover symptoms of anhedonia and motor slowing in psychiatric patients are difficult to treat even in SSRI responders [<xref rid="r233" ref-type="bibr">233</xref>-<xref rid="r236" ref-type="bibr">236</xref>], suggesting that other neurotransmitter systems, such as DA, may be involved in SSRI-resistant, inflammation-related symptoms [<xref rid="r302" ref-type="bibr">302</xref>].</p><p>Although classical stimulant medications that increase DA release and/or block DA reuptake increase motivation in rodent models [<xref rid="r283" ref-type="bibr">283</xref>, <xref rid="r303" ref-type="bibr">303</xref>], they have demonstrated only limited efficacy in chronically treating fatigue and other DA-related symptoms in trials for patients with cancer and other medical illnesses that are associated with inflammation [<xref rid="r304" ref-type="bibr">304</xref>-<xref rid="r313" ref-type="bibr">313</xref>]. Since stimulants act to increase DA release and block DAT function to increase synaptic levels of available DA, these drugs may not provide long-term efficacy in the context of inflammation during medical illness. However, new evidence indicates that in MDD patients with high inflammation (as measured by CRP) exhibit a greater antidepressant response to SSRIs used in combination with the DAT blocker bupropion compared to SSRI monotherapy [<xref rid="r314" ref-type="bibr">314</xref>]. Interestingly, the use of the DAT blocker methylphenidate in patients with traumatic brain injury has also been found to improve cognitive symptoms as well as those of PTSD [<xref rid="r315" ref-type="bibr">315</xref>], which is consistent with findings that the combination of methylphenidate and desipramine improved behavioral symptoms in an animal model of PTSD [<xref rid="r316" ref-type="bibr">316</xref>].</p></sec><sec id="sec6.4"><label>6.4</label><title>Glutamate Neurotransmission</title><p>Another mechanism by which cytokines may influence reward, motor and threat-related circuitry is through effects on glutamate neurotransmission. For example, inflammation is known to stimulate production of indoleamine 2,3 dioxygenase (IDO) and kynurenine pathway metabolites produced in the periphery or CNS, which can then exert downstream effects on neurotransmitters in the brain such as glutamate (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>) [<xref rid="r317" ref-type="bibr">317</xref>, <xref rid="r318" ref-type="bibr">318</xref>], and have been shown to play a role in TRD and suicide [<xref rid="r319" ref-type="bibr">319</xref>]. Immune-mediated activation of IDO catabolizes tryptophan, the primary amino-acid precursor of serotonin, to kynurenine. Kynurenine is further catabolized in the CNS into the neuroactive metabolites kynurenic acid (KA) (in astrocytes) and quinolinic acid (QUIN) (in microglia), both of which have been found to be increased in the plasma and CSF of IFN-&#945;-treated patients [<xref rid="r127" ref-type="bibr">127</xref>, <xref rid="r320" ref-type="bibr">320</xref>-<xref rid="r322" ref-type="bibr">322</xref>]. Of note, CSF QUIN significantly correlated with depressive symptoms during IFN-&#945; administration, as measured by MADRS [<xref rid="r321" ref-type="bibr">321</xref>]. In addition to increasing oxidative stress [<xref rid="r323" ref-type="bibr">323</xref>, <xref rid="r324" ref-type="bibr">324</xref>], the neurotoxic metabolite QUIN can also directly activate the n-methyl-d-aspartate (NMDA) receptor to induce the release of glutamate to lead excitotoxicity in the brain [<xref rid="r320" ref-type="bibr">320</xref>, <xref rid="r325" ref-type="bibr">325</xref>, <xref rid="r326" ref-type="bibr">326</xref>], thus further increasing inflammation and its potential effects on the monoamine systems as described above [<xref rid="r327" ref-type="bibr">327</xref>, <xref rid="r328" ref-type="bibr">328</xref>]. In contrast to QUIN, KA reduces glutamate release, and has been shown to be an antagonist of NMDA and &#945;-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors [<xref rid="r329" ref-type="bibr">329</xref>]. DA release is in part under glutamatergic control, and thereby KA may exert downstream effects on DA [<xref rid="r320" ref-type="bibr">320</xref>]. Indeed, intra-striatal administration of KA to rodents leads to marked reductions in extracellular dopamine concentrations, as determined by <italic>in vivo</italic> microdialysis [<xref rid="r330" ref-type="bibr">330</xref>].</p><p>Finally, cytokines and inflammation have been shown to increase glutamate by effects on microglia and astrocytes. A rich literature has shown that cytokines can decrease the astrocytic expression of glutamate transporters, and increase release of glutamate from astrocytes and activated microglia <italic>in vitro</italic> [<xref rid="r317" ref-type="bibr">317</xref>, <xref rid="r331" ref-type="bibr">331</xref>-<xref rid="r333" ref-type="bibr">333</xref>]. Of note, glutamate released from glia may have preferential access to extrasynaptic NMDA receptors, which lead to decreased production of trophic factors including brain-derived neurotrophic factor [<xref rid="r334" ref-type="bibr">334</xref>, <xref rid="r335" ref-type="bibr">335</xref>]. Given the sensitivity of DA neurons to oxidative stress and excitotoxicity, inflammation effects on glutamate may contribute to decreased striatal DA availability and eventual neurodegeneration [<xref rid="r336" ref-type="bibr">336</xref>, <xref rid="r337" ref-type="bibr">337</xref>].</p><p>Inhibition of the IDO pathway or glutamate may be an important target in reversing the impact of inflammation in the brain. The IDO antagonist, 1-methyl tryptophan (1-MT) has been shown to abrogate the impact of LPS, as well as an attenuated form of Mycobacterium bovis, on depressive-like behavior [<xref rid="r338" ref-type="bibr">338</xref>, <xref rid="r339" ref-type="bibr">339</xref>]. Given that the neurotoxic effects of QUIN may be mediated by excessive glutamate excitotoxicity [<xref rid="r320" ref-type="bibr">320</xref>, <xref rid="r325" ref-type="bibr">325</xref>, <xref rid="r326" ref-type="bibr">326</xref>], glutamate antagonists may be useful in preventing excitotoxic and oxidative effects and even protecting sensitive DA neurons. Indeed, metabotropic glutamate receptor antagonists that modulate glutamate transmission in the basal ganglia have been successful in reducing DA cell loss in an animal model of PD [<xref rid="r340" ref-type="bibr">340</xref>]. Antagonism of the NMDA receptor with memantine in monkeys infected with simian immunodeficiency virus (SIV) also reversed loss of DA in the striatum [<xref rid="r341" ref-type="bibr">341</xref>] that occurs during SIV and HIV infection secondary to immune cell activation in the basal ganglia [<xref rid="r342" ref-type="bibr">342</xref>, <xref rid="r343" ref-type="bibr">343</xref>], in association with increased brain derived neurotrophic factor (BDNF). Interestingly, inflammation-induced release of glutamate from glia cells may preferentially activate extrasynaptic NMDA receptors, which has been shown to decrease BDNF [<xref rid="r334" ref-type="bibr">334</xref>]. Administration of the NMDA antagonist ketamine has potent antidepressant effects in depressed patients who are resistant to standard therapies and who often exhibit increased inflammation [<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r344" ref-type="bibr">344</xref>, <xref rid="r345" ref-type="bibr">345</xref>]. Interestingly, a recent study in treatment resistant depression found that patients who were most responsive to ketamine were those with the highest concentrations of serum IL-6 [<xref rid="r346" ref-type="bibr">346</xref>]. Therefore, blockade of kynurenine pathways or modulation of glutamate neurotransmission may confer protection against inflammation and/or IDO-mediated effects to improve behavioral symptoms in patients with mood or anxiety-related disorders with increased inflammation.</p></sec><sec id="sec6.5"><label>6.5</label><title>Limitations and Future Directions</title><p>The above described literature in <bold>Sections 1-5</bold> examining the neurochemical and immunologic mechanisms of the effects of inflammation on the brain have provided much insight into the role of inflammation in depression and anxiety-related disorders and potential therapeutic targets, yet the process by which this information has been translated toward novel treatments for depression and anxiety has been slow. Although studies described in Section 6 have provided evidence that therapies which target inflammation or its effects on the brain may be efficacious in treating depressive and anxiety symptoms, important limitations in this literature exist. Considerations for future clinical trials warrant discussion in order to benefit this area and move the field forward [<xref rid="r16" ref-type="bibr">16</xref>]. Despite a number of studies showing that patients with high inflammation are more or less likely to respond to standard versus novel anti-depressant strategies [<xref rid="r27" ref-type="bibr">27</xref>, <xref rid="r56" ref-type="bibr">56</xref>, <xref rid="r346" ref-type="bibr">346</xref>, <xref rid="r347" ref-type="bibr">347</xref>], very few trials to date using anti-inflammatory or novel antidepressant or anti-anxiety treatments that are thought to be beneficial against the effects of high inflammation have used inflammatory markers to predict or inform treatment response. Neuroimaging findings from the administration studies presented in Tables <bold><xref ref-type="table" rid="T1">1</xref></bold> and <bold><xref ref-type="table" rid="T2">2</xref></bold> have been seminal in shaping our understanding of how peripheral inflammation affects neurotransmitters and circuits to lead to behavioral symptoms. However, there is a dearth of studies using this knowledge to examine whether similar pathways are affected in psychiatric patients who have increased inflammation. Moreover, careful designed of studies and trials in the future will need to 1) measure inflammatory markers to be used for targeting of treatments to select patients or stratification for statistical analysis, 2) selection of therapies based on inflammatory markers and/or the presence of select symptom profiles, and 3) the used of a combination of inflammatory biomarker, behavioral and neuroimaging tools to assess treatment effects in longitudinal studies. In sum, while the work presented herein has been invaluable in determining mechanisms and potential clinical implications for the role of inflammation in depression and anxiety-related disorders, the translation of these findings into novel treatments will rely on future intelligently designed and hypothesis-driven clinical studies that incorporate neuroimaging methodologies.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This review has presented evidence that peripheral inflammation can affect brain regions relevant to reward and threat sensitivity to lead to symptoms of reduced motivation, motor slowing and anxiety. These findings, which stem largely from over a decade of clinical and translational neuroimaging studies examining the effects of the acute and chronic administration of inflammatory stimuli on the brain, are now being translated to understand the role of inflammation in behavioral symptoms in patients with mood and anxiety-related disorders. Biomarkers of inflammation such as inflammatory cytokines and acute-phase proteins are reliably elevated in a significant proportion of patients with MDD, BD, anxiety disorders and PTSD, and may be a causal factor driving behavioral symptoms. Although attempts have been made to image local activation of CNS immune cells in these patients, evidence of the functional and neurotransmitter effects of increased inflammation on the brain as measured by fMRI, PET and MRS has more consistently been associated with increases in peripheral inflammatory markers as well as behavior. More evidence is needed regarding the mechanisms of inflammation effects on the brain in psychiatric patients, and particularly those with anxiety disorders and PTSD. Nevertheless, the use of MRI and PET imaging to assess inflammation effects on neurotransmitters and neurocircuits relevant to CNS reward and anxiety pathways may serve as brain biomarkers of treatment response in future trials blocking inflammation or reversing its effects on the brain and behavior in patients with increased inflammation.</p></sec><sec><title>Funding sources</title><p>This work was supported by funds from the National Institute of Mental Health (R21MH106904), National Institute of Mental Health (R01MH 109637) and the Dana Foundation (CADF49143). In addition, the study was supported in part by PHS Grants UL1TR000454 from the Clinical and Translational Science Award program, by Winship Cancer Institute ACS IRG #126815-IRG-14-188-01-IRG from the American Cancer Society and by the NIH/NCI under award number P30CA138292.</p></sec><sec><title>Financial Disclosure</title><p>There are no conflicts of interest to declare. In the past 3 years, JCF has consulted for Proctor and Gamble and Pfizer.</p></sec><sec><title>Consent for Publication</title><p>Not applicable.</p></sec></body><back><ack><title>Acknowledgements</title><p>Declared none.</p></ack><sec sec-type="competing-interests"><title>Conflict of Interest</title><p>The authors declare no conflict of interest, financial or otherwise.</p></sec><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name></person-group><article-title>Cytokine targets in the brain: impact on neurotransmitters and neurocircuits.</article-title><source>Depress. Anxiety</source><year>2013</year><volume>30</volume><issue>4</issue><fpage>297</fpage><lpage>306</lpage><comment>[http://dx.doi.org/10. 1002/da.22084]. [PMID: 23468190].</comment><pub-id pub-id-type="pmid">23468190</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Treadway</surname><given-names>M.T.</given-names></name></person-group><article-title>Inflammation effects on motivation and motor activity: Role of dopamine.</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>1</issue><fpage>216</fpage><lpage>241</lpage><comment>[http://dx.doi.org/10.1038/npp.2016.143]. [PMID: 27480574].</comment><pub-id pub-id-type="pmid">27480574</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.</article-title><source>Front. Neuroendocrinol.</source><year>2012</year><volume>33</volume><issue>3</issue><fpage>315</fpage><lpage>327</lpage><comment>[http://dx.doi.org/ 10.1016/j.yfrne.2012.09.003]. [PMID: 23000204].</comment><pub-id pub-id-type="pmid">23000204</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><year>2016</year></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>The evolutionary significance of depression in pathogen host defense (PATHOS-D).</article-title><source>Mol. Psychiatry</source><year>2013</year><volume>18</volume><issue>1</issue><fpage>15</fpage><lpage>37</lpage><comment>[http://dx.doi.org/10.1038/mp.2012.2]. [PMID: 22290120].</comment><pub-id pub-id-type="pmid">22290120</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Pathogen-host defense in the evolution of depression: Insights into epidemiology, genetics, bioregional differences and female preponderance.</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>1</issue><fpage>5</fpage><lpage>27</lpage><comment>[http://dx.doi.org/10.1038/npp.2016.194]. [PMID: 27629366].</comment><pub-id pub-id-type="pmid">27629366</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P.M.</given-names></name></person-group><article-title>Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.</article-title><source>Nutr. Rev.</source><year>2007</year><volume>65</volume><issue>12 Pt 2</issue><fpage>S253</fpage><lpage>S259</lpage><comment>[http://dx.doi. org/10.1301/nr.2007.dec.S253-S259]. [PMID: 18240558].</comment><pub-id pub-id-type="pmid">18240558</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P.M.</given-names></name></person-group><article-title>Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.</article-title><source>Circulation</source><year>2003</year><volume>108</volume><issue>12</issue><fpage>e81</fpage><lpage>e85</lpage><comment>[http://dx.doi.org/10.1161/01.CIR.0000093381. 57779.67]. [PMID: 14504253].</comment><pub-id pub-id-type="pmid">14504253</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>J.M.</given-names></name></person-group><article-title>Comorbid depression and anxiety spectrum disorders.</article-title><source>Depress. Anxiety</source><year>1996-1997</year><volume>4</volume><issue>4</issue><fpage>160</fpage><lpage>168</lpage><comment>[http://dx.doi. org/10.1002/(SICI)1520-6394(1996)4:4&lt;160:AID-DA2&gt;3.0.CO;2-J]. [PMID: 9166648].</comment></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michopoulos</surname><given-names>V.</given-names></name><name><surname>Powers</surname><given-names>A.</given-names></name><name><surname>Gillespie</surname><given-names>C.F.</given-names></name><name><surname>Ressler</surname><given-names>K.J.</given-names></name><name><surname>Jovanovic</surname><given-names>T.</given-names></name></person-group><article-title>Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond.</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>1</issue><fpage>254</fpage><lpage>270</lpage><comment>[http://dx.doi.org/10.1038/npp.2016.146]. [PMID: 27510423].</comment><pub-id pub-id-type="pmid">27510423</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Lotrich</surname><given-names>F.E.</given-names></name></person-group><article-title>Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.</article-title><source>Neuroscience</source><year>2013</year><volume>246</volume><fpage>199</fpage><lpage>229</lpage><comment>[http://dx.doi.org/10.1016/j.neuroscience. 2013.04.060]. [PMID: 23644052].</comment><pub-id pub-id-type="pmid">23644052</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior.</article-title><source>Neuropsychopharmacology</source><year>2012</year><volume>37</volume><issue>1</issue><fpage>137</fpage><lpage>162</lpage><comment>[http://dx.doi.org/10.1038/npp.2011.205]. [PMID: 21918508].</comment><pub-id pub-id-type="pmid">21918508</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>L.J.</given-names></name><name><surname>Jacka</surname><given-names>F.N.</given-names></name><name><surname>O&#8217;Neil</surname><given-names>A.</given-names></name><name><surname>Pasco</surname><given-names>J.A.</given-names></name><name><surname>Moylan</surname><given-names>S.</given-names></name><name><surname>Allen</surname><given-names>N.B.</given-names></name><name><surname>Stuart</surname><given-names>A.L.</given-names></name><name><surname>Hayley</surname><given-names>A.C.</given-names></name><name><surname>Byrne</surname><given-names>M.L.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>So depression is an inflammatory disease, but where does the inflammation come from?</article-title><source>BMC Med.</source><year>2013</year><volume>11</volume><fpage>200</fpage><comment>[http:// dx.doi.org/10.1186/1741-7015-11-200]. [PMID: 24228900].</comment><pub-id pub-id-type="pmid">24228900</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#8217;Mello</surname><given-names>C.</given-names></name><name><surname>Le</surname><given-names>T.</given-names></name><name><surname>Swain</surname><given-names>M.G.</given-names></name></person-group><article-title>Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation.</article-title><source>J. Neurosci.</source><year>2009</year><volume>29</volume><issue>7</issue><fpage>2089</fpage><lpage>2102</lpage><comment>[http://dx.doi.org/10.1523/JNEUROSCI.3567-08.2009]. [PMID: 19228962].</comment><pub-id pub-id-type="pmid">19228962</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohleb</surname><given-names>E.S.</given-names></name><name><surname>Fenn</surname><given-names>A.M.</given-names></name><name><surname>Pacenta</surname><given-names>A.M.</given-names></name><name><surname>Powell</surname><given-names>N.D.</given-names></name><name><surname>Sheridan</surname><given-names>J.F.</given-names></name><name><surname>Godbout</surname><given-names>J.P.</given-names></name></person-group><article-title>Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice.</article-title><source>Psychoneuroendocrinology</source><year>2012</year><volume>37</volume><issue>9</issue><fpage>1491</fpage><lpage>1505</lpage><comment>[http:// dx.doi.org/10.1016/j.psyneuen.2012.02.003]. [PMID: 22386198].</comment><pub-id pub-id-type="pmid">22386198</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name></person-group><article-title>Therapeutic implications of brain-immune interactions: Treatment in translation.</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>1</issue><fpage>334</fpage><lpage>359</lpage><comment>[http://dx.doi.org/10.1038/ npp.2016.167]. [PMID: 27555382].</comment><pub-id pub-id-type="pmid">27555382</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Sanacora</surname><given-names>G.</given-names></name></person-group><article-title>Inflammation, glutamate, and glia: A trio of trouble in mood disorders.</article-title><source>Neuropsychopharmacology</source><year>2017</year><volume>42</volume><issue>1</issue><fpage>193</fpage><lpage>215</lpage><comment>[http://dx.doi.org/10.1038/npp.2016. 199]. [PMID: 27629368].</comment><pub-id pub-id-type="pmid">27629368</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>I.G.</given-names></name><name><surname>Bauer</surname><given-names>M.E.</given-names></name><name><surname>Machado-Vieira</surname><given-names>R.</given-names></name><name><surname>Teixeira</surname><given-names>A.L.</given-names></name></person-group><article-title>Cytokines in bipolar disorder: paving the way for neuroprogression.</article-title><source>Neural Plast.</source><year>2014</year><volume>2014</volume><fpage>360481</fpage><comment>[http://dx.doi.org/10.1155/ 2014/360481]. [PMID: 25313338].</comment><pub-id pub-id-type="pmid">25313338</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldsmith</surname><given-names>D.R.</given-names></name><name><surname>Rapaport</surname><given-names>M.H.</given-names></name><name><surname>Miller</surname><given-names>B.J.</given-names></name></person-group><article-title>A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><issue>12</issue><fpage>1696</fpage><lpage>1709</lpage><comment>[http://dx.doi.org/10.1038/ mp.2016.3]. [PMID: 26903267].</comment><pub-id pub-id-type="pmid">26903267</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>Major depression and activation of the inflammatory response system.</article-title><source>Adv. Exp. Med. Biol.</source><year>1999</year><volume>461</volume><fpage>25</fpage><lpage>46</lpage><comment>[http://dx. doi.org/10.1007/978-0-585-37970-8_2]. [PMID: 10442165].</comment><pub-id pub-id-type="pmid">10442165</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>M.</given-names></name><name><surname>Lambrechts</surname><given-names>J.</given-names></name><name><surname>Bosmans</surname><given-names>E.</given-names></name><name><surname>Jacobs</surname><given-names>J.</given-names></name><name><surname>Suy</surname><given-names>E.</given-names></name><name><surname>Vandervorst</surname><given-names>C.</given-names></name><name><surname>de Jonckheere</surname><given-names>C.</given-names></name><name><surname>Minner</surname><given-names>B.</given-names></name><name><surname>Raus</surname><given-names>J.</given-names></name></person-group><article-title>Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining.</article-title><source>Psychol. Med.</source><year>1992</year><volume>22</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><comment>[http://dx.doi. org/10.1017/S0033291700032712]. [PMID: 1574566].</comment><pub-id pub-id-type="pmid">1574566</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sluzewska</surname><given-names>A.</given-names></name></person-group><article-title>Indicators of immune activation in depressed patients.</article-title><source>Adv. Exp. Med. Biol.</source><year>1999</year><volume>461</volume><fpage>59</fpage><lpage>73</lpage><comment>[http://dx.doi.org/10. 1007/978-0-585-37970-8_4]. [PMID: 10442167].</comment><pub-id pub-id-type="pmid">10442167</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>P.M.</given-names></name></person-group><article-title>Clinical application of C-reactive protein for cardiovascular disease detection and prevention.</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>3</issue><fpage>363</fpage><lpage>369</lpage><comment>[http://dx.doi.org/10.1161/01.CIR.0000053730. 47739.3C]. [PMID: 12551853].</comment><pub-id pub-id-type="pmid">12551853</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name></person-group><article-title>Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression.</article-title><source>Mol. Psychiatry</source><year>2015</year><comment>[PMID: 26552591].</comment></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Fleischer</surname><given-names>C.C.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Patel</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>X.P.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression.</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><issue>10</issue><fpage>1351</fpage><lpage>1357</lpage><comment>[http://dx.doi.org/10.1038/mp.2015.206]. [PMID: 26754953].</comment><pub-id pub-id-type="pmid">26754953</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Inflammation and treatment resistance in major depression: a perfect storm.</article-title><source>Psychiatr. Times</source><year>2013</year><fpage>12</fpage></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Rutherford</surname><given-names>R.E.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Shuo</surname><given-names>C.</given-names></name><name><surname>Schettler</surname><given-names>P.</given-names></name><name><surname>Drake</surname><given-names>D.F.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><comment>[http://dx.doi. org/10.1001/2013.jamapsychiatry.4]. [PMID: 22945416].</comment><pub-id pub-id-type="pmid">22945416</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapaport</surname><given-names>M.H.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Schettler</surname><given-names>P.J.</given-names></name><name><surname>Kinkead</surname><given-names>B.</given-names></name><name><surname>Cardoos</surname><given-names>A.</given-names></name><name><surname>Walker</surname><given-names>R.</given-names></name><name><surname>Mischoulon</surname><given-names>D.</given-names></name></person-group><article-title>Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><issue>1</issue><fpage>71</fpage><lpage>79</lpage><comment>[http://dx.doi.org/10.1038/mp.2015.22]. [PMID: 25802980].</comment><pub-id pub-id-type="pmid">25802980</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howren</surname><given-names>M.B.</given-names></name><name><surname>Lamkin</surname><given-names>D.M.</given-names></name><name><surname>Suls</surname><given-names>J.</given-names></name></person-group><article-title>Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.</article-title><source>Psychosom. Med.</source><year>2009</year><volume>71</volume><issue>2</issue><fpage>171</fpage><lpage>186</lpage><comment>[http://dx.doi.org/10.1097/PSY. 0b013e3181907c1b]. [PMID: 19188531].</comment><pub-id pub-id-type="pmid">19188531</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowlati</surname><given-names>Y.</given-names></name><name><surname>Herrmann</surname><given-names>N.</given-names></name><name><surname>Swardfager</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Sham</surname><given-names>L.</given-names></name><name><surname>Reim</surname><given-names>E.K.</given-names></name><name><surname>Lanct&#244;t</surname><given-names>K.L.</given-names></name></person-group><article-title>A meta-analysis of cytokines in major depression.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>67</volume><issue>5</issue><fpage>446</fpage><lpage>457</lpage><comment>[http://dx.doi. org/10.1016/j.biopsych.2009.09.033]. [PMID: 20015486].</comment><pub-id pub-id-type="pmid">20015486</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potvin</surname><given-names>S.</given-names></name><name><surname>Stip</surname><given-names>E.</given-names></name><name><surname>Sepehry</surname><given-names>A.A.</given-names></name><name><surname>Gendron</surname><given-names>A.</given-names></name><name><surname>Bah</surname><given-names>R.</given-names></name><name><surname>Kouassi</surname><given-names>E.</given-names></name></person-group><article-title>Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.</article-title><source>Biol. Psychiatry</source><year>2008</year><volume>63</volume><issue>8</issue><fpage>801</fpage><lpage>808</lpage><comment>[http:// dx.doi.org/10.1016/j.biopsych.2007.09.024]. [PMID: 18005941].</comment><pub-id pub-id-type="pmid">18005941</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>B.J.</given-names></name><name><surname>Buckley</surname><given-names>P.</given-names></name><name><surname>Seabolt</surname><given-names>W.</given-names></name><name><surname>Mellor</surname><given-names>A.</given-names></name><name><surname>Kirkpatrick</surname><given-names>B.</given-names></name></person-group><article-title>Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.</article-title><source>Biol. Psychiatry</source><year>2011</year><volume>70</volume><issue>7</issue><fpage>663</fpage><lpage>671</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych.2011.04.013]. [PMID: 21641581].</comment><pub-id pub-id-type="pmid">21641581</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passos</surname><given-names>I.C.</given-names></name><name><surname>Vasconcelos-Moreno</surname><given-names>M.P.</given-names></name><name><surname>Costa</surname><given-names>L.G.</given-names></name><name><surname>Kunz</surname><given-names>M.</given-names></name><name><surname>Brietzke</surname><given-names>E.</given-names></name><name><surname>Quevedo</surname><given-names>J.</given-names></name><name><surname>Salum</surname><given-names>G.</given-names></name><name><surname>Magalh&#227;es</surname><given-names>P.V.</given-names></name><name><surname>Kapczinski</surname><given-names>F.</given-names></name><name><surname>Kauer-Sant&#8217;Anna</surname><given-names>M.</given-names></name></person-group><article-title>Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression.</article-title><source>Lancet Psychiatry</source><year>2015</year><volume>2</volume><issue>11</issue><fpage>1002</fpage><lpage>1012</lpage><comment>[http://dx. doi.org/10.1016/S2215-0366(15)00309-0]. [PMID: 26544749].</comment><pub-id pub-id-type="pmid">26544749</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>J.</given-names></name><name><surname>Barak</surname><given-names>Y.</given-names></name><name><surname>Chengappa</surname><given-names>K.N.</given-names></name><name><surname>Rapoport</surname><given-names>A.</given-names></name><name><surname>Rebey</surname><given-names>M.</given-names></name><name><surname>Barak</surname><given-names>V.</given-names></name></person-group><article-title>Cerebrospinal cytokine levels in patients with acute depression.</article-title><source>Neuropsychobiology</source><year>1999</year><volume>40</volume><issue>4</issue><fpage>171</fpage><lpage>176</lpage><comment>[http://dx.doi. org/10.1159/000026615]. [PMID: 10559698].</comment><pub-id pub-id-type="pmid">10559698</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwieler</surname><given-names>L.</given-names></name><name><surname>Larsson</surname><given-names>M.K.</given-names></name><name><surname>Skogh</surname><given-names>E.</given-names></name><name><surname>Kegel</surname><given-names>M.E.</given-names></name><name><surname>Orhan</surname><given-names>F.</given-names></name><name><surname>Abdelmoaty</surname><given-names>S.</given-names></name><name><surname>Finn</surname><given-names>A.</given-names></name><name><surname>Bhat</surname><given-names>M.</given-names></name><name><surname>Samuelsson</surname><given-names>M.</given-names></name><name><surname>Lundberg</surname><given-names>K.</given-names></name><name><surname>Dahl</surname><given-names>M.L.</given-names></name><name><surname>Sellgren</surname><given-names>C.</given-names></name><name><surname>Schuppe-Koistinen</surname><given-names>I.</given-names></name><name><surname>Svensson</surname><given-names>C.</given-names></name><name><surname>Erhardt</surname><given-names>S.</given-names></name><name><surname>Engberg</surname><given-names>G.</given-names></name></person-group><article-title>Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.</article-title><source>J. Psychiatry Neurosci.</source><year>2015</year><volume>40</volume><issue>2</issue><fpage>126</fpage><lpage>133</lpage><comment>[PMID: 25455350].</comment><pub-id pub-id-type="pmid">25455350</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garver</surname><given-names>D.L.</given-names></name><name><surname>Tamas</surname><given-names>R.L.</given-names></name><name><surname>Holcomb</surname><given-names>J.A.</given-names></name></person-group><article-title>Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype.</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><issue>8</issue><fpage>1515</fpage><lpage>1520</lpage><comment>[http://dx.doi.org/10.1038/sj.npp.1300217]. [PMID: 12799618].</comment><pub-id pub-id-type="pmid">12799618</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#246;derlund</surname><given-names>J.</given-names></name><name><surname>Olsson</surname><given-names>S.K.</given-names></name><name><surname>Samuelsson</surname><given-names>M.</given-names></name><name><surname>Walther-Jallow</surname><given-names>L.</given-names></name><name><surname>Johansson</surname><given-names>C.</given-names></name><name><surname>Erhardt</surname><given-names>S.</given-names></name><name><surname>Land&#233;n</surname><given-names>M.</given-names></name><name><surname>Engberg</surname><given-names>G.</given-names></name></person-group><article-title>Elevation of cerebrospinal fluid interleukin-1&#223; in bipolar disorder.</article-title><source>J. Psychiatry Neurosci.</source><year>2011</year><volume>36</volume><issue>2</issue><fpage>114</fpage><lpage>118</lpage><comment>[http://dx.doi.org/10.1503/jpn. 100080]. [PMID: 21138659].</comment><pub-id pub-id-type="pmid">21138659</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#246;derlund</surname><given-names>J.</given-names></name><name><surname>Schr&#246;der</surname><given-names>J.</given-names></name><name><surname>Nordin</surname><given-names>C.</given-names></name><name><surname>Samuelsson</surname><given-names>M.</given-names></name><name><surname>Walther-Jallow</surname><given-names>L.</given-names></name><name><surname>Karlsson</surname><given-names>H.</given-names></name><name><surname>Erhardt</surname><given-names>S.</given-names></name><name><surname>Engberg</surname><given-names>G.</given-names></name></person-group><article-title>Activation of brain interleukin-1beta in schizophrenia.</article-title><source>Mol. Psychiatry</source><year>2009</year><volume>14</volume><issue>12</issue><fpage>1069</fpage><lpage>1071</lpage><comment>[http://dx.doi.org/10.1038/mp.2009.52]. [PMID: 19920835].</comment><pub-id pub-id-type="pmid">19920835</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindqvist</surname><given-names>D.</given-names></name><name><surname>Janelidze</surname><given-names>S.</given-names></name><name><surname>Hagell</surname><given-names>P.</given-names></name><name><surname>Erhardt</surname><given-names>S.</given-names></name><name><surname>Samuelsson</surname><given-names>M.</given-names></name><name><surname>Minthon</surname><given-names>L.</given-names></name><name><surname>Hansson</surname><given-names>O.</given-names></name><name><surname>Bj&#246;rkqvist</surname><given-names>M.</given-names></name><name><surname>Tr&#228;skman-Bendz</surname><given-names>L.</given-names></name><name><surname>Brundin</surname><given-names>L.</given-names></name></person-group><article-title>Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>66</volume><issue>3</issue><fpage>287</fpage><lpage>292</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2009.01.030]. [PMID: 19268915].</comment><pub-id pub-id-type="pmid">19268915</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>J.M.</given-names></name><name><surname>Garakani</surname><given-names>A.</given-names></name><name><surname>Yehuda</surname><given-names>R.</given-names></name><name><surname>Gorman</surname><given-names>J.M.</given-names></name></person-group><article-title>Proinflammatory and &#8220;resiliency&#8221; proteins in the CSF of patients with major depression.</article-title><source>Depress. Anxiety</source><year>2012</year><volume>29</volume><issue>1</issue><fpage>32</fpage><lpage>38</lpage><comment>[http://dx. doi.org/10.1002/da.20876]. [PMID: 21898706].</comment><pub-id pub-id-type="pmid">21898706</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosker</surname><given-names>F.J.</given-names></name><name><surname>Hartman</surname><given-names>C.A.</given-names></name><name><surname>Nolte</surname><given-names>I.M.</given-names></name><name><surname>Prins</surname><given-names>B.P.</given-names></name><name><surname>Terpstra</surname><given-names>P.</given-names></name><name><surname>Posthuma</surname><given-names>D.</given-names></name><name><surname>van Veen</surname><given-names>T.</given-names></name><name><surname>Willemsen</surname><given-names>G.</given-names></name><name><surname>DeRijk</surname><given-names>R.H.</given-names></name><name><surname>de Geus</surname><given-names>E.J.</given-names></name><name><surname>Hoogendijk</surname><given-names>W.J.</given-names></name><name><surname>Sullivan</surname><given-names>P.F.</given-names></name><name><surname>Penninx</surname><given-names>B.W.</given-names></name><name><surname>Boomsma</surname><given-names>D.I.</given-names></name><name><surname>Snieder</surname><given-names>H.</given-names></name><name><surname>Nolen</surname><given-names>W.A.</given-names></name></person-group><article-title>Poor replication of candidate genes for major depressive disorder using genome-wide association data.</article-title><source>Mol. Psychiatry</source><year>2011</year><volume>16</volume><issue>5</issue><fpage>516</fpage><lpage>532</lpage><comment>[http://dx. doi.org/10.1038/mp.2010.38]. [PMID: 20351714].</comment><pub-id pub-id-type="pmid">20351714</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bufalino</surname><given-names>C.</given-names></name></person-group><article-title>The role of immune genes in the association between depression and inflammation: A review of recent clinical studies.</article-title><source>Brain Behav. Immun.</source><year>2013</year><volume>31</volume><fpage>31</fpage><lpage>47</lpage><comment>[PMID: 22580182].</comment><pub-id pub-id-type="pmid">22580182</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamne</surname><given-names>M.</given-names></name><name><surname>Wood</surname><given-names>J.</given-names></name><name><surname>Chowdari</surname><given-names>K.</given-names></name><name><surname>Watson</surname><given-names>A.M.</given-names></name><name><surname>Celik</surname><given-names>C.</given-names></name><name><surname>Mansour</surname><given-names>H.</given-names></name><name><surname>Klei</surname><given-names>L.</given-names></name><name><surname>Gur</surname><given-names>R.C.</given-names></name><name><surname>Bradford</surname><given-names>L.D.</given-names></name><name><surname>Calkins</surname><given-names>M.E.</given-names></name><name><surname>Santos</surname><given-names>A.B.</given-names></name><name><surname>Edwards</surname><given-names>N.</given-names></name><name><surname>Kwentus</surname><given-names>J.</given-names></name><name><surname>McEvoy</surname><given-names>J.P.</given-names></name><name><surname>Allen</surname><given-names>T.B.</given-names></name><name><surname>Savage</surname><given-names>R.M.</given-names></name><name><surname>Nasrallah</surname><given-names>H.A.</given-names></name><name><surname>Gur</surname><given-names>R.E.</given-names></name><name><surname>Perry</surname><given-names>R.T.</given-names></name><name><surname>Go</surname><given-names>R.C.</given-names></name><name><surname>Devlin</surname><given-names>B.</given-names></name><name><surname>Yolken</surname><given-names>R.</given-names></name><name><surname>Nimgaonkar</surname><given-names>V.L.</given-names></name></person-group><article-title>Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.</article-title><source>Schizophr. Bull.</source><year>2012</year><volume>38</volume><issue>6</issue><fpage>1149</fpage><lpage>1154</lpage><comment>[http://dx.doi.org/ 10.1093/schbul/sbs087]. [PMID: 22966150].</comment><pub-id pub-id-type="pmid">22966150</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripke</surname></name><etal/></person-group><article-title>Biological insights from 108 schizophrenia-associated genetic loci.</article-title><source>Nature</source><year>2014</year><volume>511</volume><issue>7510</issue><fpage>421</fpage><lpage>427</lpage><comment>[http://dx.doi. org/10.1038/nature13595]. [PMID: 25056061].</comment><pub-id pub-id-type="pmid">25056061</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guffanti</surname><given-names>G.</given-names></name><name><surname>Galea</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Roberts</surname><given-names>A.L.</given-names></name><name><surname>Solovieff</surname><given-names>N.</given-names></name><name><surname>Aiello</surname><given-names>A.E.</given-names></name><name><surname>Smoller</surname><given-names>J.W.</given-names></name><name><surname>De Vivo</surname><given-names>I.</given-names></name><name><surname>Ranu</surname><given-names>H.</given-names></name><name><surname>Uddin</surname><given-names>M.</given-names></name><name><surname>Wildman</surname><given-names>D.E.</given-names></name><name><surname>Purcell</surname><given-names>S.</given-names></name><name><surname>Koenen</surname><given-names>K.C.</given-names></name></person-group><article-title>Genome-wide association study implicates a novel RNA gene, the lincRNA AC068718.1, as a risk factor for post-traumatic stress disorder in women.</article-title><source>Psychoneuroendocrinology</source><year>2013</year><volume>38</volume><issue>12</issue><fpage>3029</fpage><lpage>3038</lpage><comment>[http://dx.doi. org/10.1016/j.psyneuen.2013.08.014]. [PMID: 24080187].</comment><pub-id pub-id-type="pmid">24080187</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michopoulos</surname><given-names>V.</given-names></name><name><surname>Rothbaum</surname><given-names>A.O.</given-names></name><name><surname>Jovanovic</surname><given-names>T.</given-names></name><name><surname>Almli</surname><given-names>L.M.</given-names></name><name><surname>Bradley</surname><given-names>B.</given-names></name><name><surname>Rothbaum</surname><given-names>B.O.</given-names></name><name><surname>Gillespie</surname><given-names>C.F.</given-names></name><name><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma.</article-title><source>Am. J. Psychiatry</source><year>2015</year><volume>172</volume><issue>4</issue><fpage>353</fpage><lpage>362</lpage><comment>[http://dx.doi.org/10.1176/appi.ajp.2014.14020263]. [PMID: 25827033].</comment><pub-id pub-id-type="pmid">25827033</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yirmiya</surname><given-names>R.</given-names></name><name><surname>Weidenfeld</surname><given-names>J.</given-names></name><name><surname>Pollak</surname><given-names>Y.</given-names></name><name><surname>Morag</surname><given-names>M.</given-names></name><name><surname>Morag</surname><given-names>A.</given-names></name><name><surname>Avitsur</surname><given-names>R.</given-names></name><name><surname>Barak</surname><given-names>O.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>E.</given-names></name><name><surname>Shavit</surname><given-names>Y.</given-names></name><name><surname>Ovadia</surname><given-names>H.</given-names></name></person-group><article-title>Cytokines, &#8220;depression due to a general medical condition,&#8221; and antidepressant drugs.</article-title><source>Adv. Exp. Med. Biol.</source><year>1999</year><volume>461</volume><fpage>283</fpage><lpage>316</lpage><comment>[http://dx.doi.org/10.1007/978-0-585-37970-8_16]. [PMID: 10442179].</comment><pub-id pub-id-type="pmid">10442179</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yirmiya</surname><given-names>R.</given-names></name><name><surname>Pollak</surname><given-names>Y.</given-names></name><name><surname>Morag</surname><given-names>M.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Barak</surname><given-names>O.</given-names></name><name><surname>Avitsur</surname><given-names>R.</given-names></name><name><surname>Shavit</surname><given-names>Y.</given-names></name><name><surname>Ovadia</surname><given-names>H.</given-names></name><name><surname>Weidenfeld</surname><given-names>J.</given-names></name><name><surname>Morag</surname><given-names>A.</given-names></name><name><surname>Newman</surname><given-names>M.E.</given-names></name><name><surname>Pollm&#228;cher</surname><given-names>T.</given-names></name></person-group><article-title>Illness, cytokines, and depression.</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2000</year><volume>917</volume><fpage>478</fpage><lpage>487</lpage><comment>[http://dx.doi.org/10. 1111/j.1749-6632.2000.tb05412.x]. [PMID: 11268375].</comment><pub-id pub-id-type="pmid">11268375</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Depression in cancer: new developments regarding diagnosis and treatment.</article-title><source>Biol. Psychiatry</source><year>2003</year><volume>54</volume><issue>3</issue><fpage>283</fpage><lpage>294</lpage><comment>[http://dx.doi.org/10.1016/S0006-3223(03)00413-X]. [PMID: 12893104].</comment><pub-id pub-id-type="pmid">12893104</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D.L.</given-names></name><name><surname>Staab</surname><given-names>J.P.</given-names></name><name><surname>Petitto</surname><given-names>J.M.</given-names></name><name><surname>Morrison</surname><given-names>M.F.</given-names></name><name><surname>Szuba</surname><given-names>M.P.</given-names></name><name><surname>Ward</surname><given-names>H.E.</given-names></name><name><surname>Wingate</surname><given-names>B.</given-names></name><name><surname>Luber</surname><given-names>M.P.</given-names></name><name><surname>O&#8217;Reardon</surname><given-names>J.P.</given-names></name></person-group><article-title>Depression in the medical setting: biopsychological interactions and treatment considerations.</article-title><source>J. Clin. Psychiatry</source><year>1999</year><volume>60</volume><issue>Suppl. 4</issue><fpage>40</fpage><lpage>55</lpage><comment>[PMID: 10086482].</comment><pub-id pub-id-type="pmid">10086482</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollak</surname><given-names>Y.</given-names></name><name><surname>Yirmiya</surname><given-names>R.</given-names></name></person-group><article-title>Cytokine-induced changes in mood and behaviour: implications for &#8216;depression due to a general medical condition&#8217;, immunotherapy and antidepressive treatment.</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2002</year><volume>5</volume><issue>4</issue><fpage>389</fpage><lpage>399</lpage><comment>[http://dx.doi. org/10.1017/S1461145702003152]. [PMID: 12466037].</comment><pub-id pub-id-type="pmid">12466037</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>R.C.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression.</article-title><source>Prog. Neurobiol.</source><year>2010</year><volume>91</volume><issue>4</issue><fpage>275</fpage><lpage>299</lpage><comment>[http://dx.doi.org/10.1016/j. pneurobio.2010.04.004]. [PMID: 20417247].</comment><pub-id pub-id-type="pmid">20417247</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fillman</surname><given-names>S.G.</given-names></name><name><surname>Sinclair</surname><given-names>D.</given-names></name><name><surname>Fung</surname><given-names>S.J.</given-names></name><name><surname>Webster</surname><given-names>M.J.</given-names></name><name><surname>Shannon Weickert</surname><given-names>C.</given-names></name></person-group><article-title>Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder.</article-title><source>Transl. Psychiatry</source><year>2014</year><volume>4</volume><fpage>e365</fpage><comment>[http://dx.doi.org/10.1038/tp.2014.8]. [PMID: 24569695].</comment><pub-id pub-id-type="pmid">24569695</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chase</surname><given-names>K.A.</given-names></name><name><surname>Rosen</surname><given-names>C.</given-names></name><name><surname>Gin</surname><given-names>H.</given-names></name><name><surname>Bjorkquist</surname><given-names>O.</given-names></name><name><surname>Feiner</surname><given-names>B.</given-names></name><name><surname>Marvin</surname><given-names>R.</given-names></name><name><surname>Conrin</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>R.P.</given-names></name></person-group><article-title>Metabolic and inflammatory genes in schizophrenia.</article-title><source>Psychiatry Res.</source><year>2015</year><volume>225</volume><issue>1-2</issue><fpage>208</fpage><lpage>211</lpage><comment>[http://dx. doi.org/10.1016/j.psychres.2014.11.007]. [PMID: 25433960].</comment><pub-id pub-id-type="pmid">25433960</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafavi</surname><given-names>S.</given-names></name><name><surname>Battle</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Potash</surname><given-names>J.B.</given-names></name><name><surname>Weissman</surname><given-names>M.M.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Beckman</surname><given-names>K.</given-names></name><name><surname>Haudenschild</surname><given-names>C.</given-names></name><name><surname>McCormick</surname><given-names>C.</given-names></name><name><surname>Mei</surname><given-names>R.</given-names></name><name><surname>Gameroff</surname><given-names>M.J.</given-names></name><name><surname>Gindes</surname><given-names>H.</given-names></name><name><surname>Adams</surname><given-names>P.</given-names></name><name><surname>Goes</surname><given-names>F.S.</given-names></name><name><surname>Mondimore</surname><given-names>F.M.</given-names></name><name><surname>MacKinnon</surname><given-names>D.F.</given-names></name><name><surname>Notes</surname><given-names>L.</given-names></name><name><surname>Schweizer</surname><given-names>B.</given-names></name><name><surname>Furman</surname><given-names>D.</given-names></name><name><surname>Montgomery</surname><given-names>S.B.</given-names></name><name><surname>Urban</surname><given-names>A.E.</given-names></name><name><surname>Koller</surname><given-names>D.</given-names></name><name><surname>Levinson</surname><given-names>D.F.</given-names></name></person-group><article-title>Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing.</article-title><source>Mol. Psychiatry</source><year>2014</year><volume>19</volume><issue>12</issue><fpage>1267</fpage><lpage>1274</lpage><comment>[http://dx.doi.org/10.1038/ mp.2013.161]. [PMID: 24296977].</comment><pub-id pub-id-type="pmid">24296977</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattaneo</surname><given-names>A.</given-names></name><name><surname>Gennarelli</surname><given-names>M.</given-names></name><name><surname>Uher</surname><given-names>R.</given-names></name><name><surname>Breen</surname><given-names>G.</given-names></name><name><surname>Farmer</surname><given-names>A.</given-names></name><name><surname>Aitchison</surname><given-names>K.J.</given-names></name><name><surname>Craig</surname><given-names>I.W.</given-names></name><name><surname>Anacker</surname><given-names>C.</given-names></name><name><surname>Zunsztain</surname><given-names>P.A.</given-names></name><name><surname>McGuffin</surname><given-names>P.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name></person-group><article-title>Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline &#8216;predictors&#8217; and longitudinal &#8216;targets&#8217;.</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><issue>3</issue><fpage>377</fpage><lpage>385</lpage><comment>[http://dx.doi. org/10.1038/npp.2012.191]. [PMID: 22990943].</comment><pub-id pub-id-type="pmid">22990943</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>R.C.</given-names></name><name><surname>Claiborne</surname><given-names>J.</given-names></name><name><surname>Sidoryk-Wegrzynowicz</surname><given-names>M.</given-names></name><name><surname>Reddy</surname><given-names>R.</given-names></name><name><surname>Aschner</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>D.A.</given-names></name><name><surname>Mirnics</surname><given-names>K.</given-names></name></person-group><article-title>Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression.</article-title><source>Mol. Psychiatry</source><year>2011</year><volume>16</volume><issue>7</issue><fpage>751</fpage><lpage>762</lpage><comment>[http:// dx.doi.org/10.1038/mp.2010.52]. [PMID: 20479761].</comment><pub-id pub-id-type="pmid">20479761</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname><given-names>A.</given-names></name><name><surname>Moffitt</surname><given-names>T.E.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name><name><surname>Ambler</surname><given-names>A.</given-names></name><name><surname>Poulton</surname><given-names>R.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name></person-group><article-title>Elevated inflammation levels in depressed adults with a history of childhood maltreatment.</article-title><source>Arch. Gen. Psychiatry</source><year>2008</year><volume>65</volume><issue>4</issue><fpage>409</fpage><lpage>415</lpage><comment>[http://dx.doi.org/10.1001/archpsyc.65.4.409]. [PMID: 18391129].</comment><pub-id pub-id-type="pmid">18391129</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname><given-names>A.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>A.</given-names></name><name><surname>Poulton</surname><given-names>R.</given-names></name></person-group><article-title>Childhood maltreatment predicts adult inflammation in a life-course study.</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><issue>4</issue><fpage>1319</fpage><lpage>1324</lpage><comment>[http://dx.doi.org/10.1073/pnas.0610362104]. [PMID: 17229839].</comment><pub-id pub-id-type="pmid">17229839</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname><given-names>A.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Ambler</surname><given-names>A.</given-names></name><name><surname>Sugden</surname><given-names>K.</given-names></name><name><surname>Mika</surname><given-names>J.</given-names></name><name><surname>Werts</surname><given-names>H.</given-names></name><name><surname>Freeman</surname><given-names>J.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name><name><surname>Moffitt</surname><given-names>T.E.</given-names></name><name><surname>Arseneault</surname><given-names>L.</given-names></name></person-group><article-title>Biological embedding of stress through inflammation processes in childhood.</article-title><source>Mol. Psychiatry</source><year>2011</year><volume>16</volume><issue>3</issue><fpage>244</fpage><lpage>246</lpage><comment>[http://dx.doi.org/10.1038/mp.2010.5]. [PMID: 20157309].</comment><pub-id pub-id-type="pmid">20157309</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusslock</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>G.E.</given-names></name></person-group><article-title>Early-life adversity and physical and emotional health across the lifespan: A neuroimmune network hypothesis.</article-title><source>Biol. Psychiatry</source><year>2015</year><comment>[PMID: 26166230].</comment></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>T.W.</given-names></name><name><surname>Mletzko</surname><given-names>T.C.</given-names></name><name><surname>Alagbe</surname><given-names>O.</given-names></name><name><surname>Musselman</surname><given-names>D.L.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Heim</surname><given-names>C.M.</given-names></name></person-group><article-title>Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress.</article-title><source>Am. J. Psychiatry</source><year>2006</year><volume>163</volume><issue>9</issue><fpage>1630</fpage><lpage>1633</lpage><comment>[http://dx.doi.org/10.1176/ajp.2006.163.9.1630]. [PMID: 16946190].</comment><pub-id pub-id-type="pmid">16946190</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>G.E.</given-names></name><name><surname>Cole</surname><given-names>S.W.</given-names></name></person-group><article-title>Clustering of depression and inflammation in adolescents previously exposed to childhood adversity.</article-title><source>Biol. Psychiatry</source><year>2012</year><volume>72</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><comment>[http://dx.doi.org/10.1016/j. biopsych.2012.02.034]. [PMID: 22494534].</comment><pub-id pub-id-type="pmid">22494534</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eraly</surname><given-names>S.A.</given-names></name><name><surname>Nievergelt</surname><given-names>C.M.</given-names></name><name><surname>Maihofer</surname><given-names>A.X.</given-names></name><name><surname>Barkauskas</surname><given-names>D.A.</given-names></name><name><surname>Biswas</surname><given-names>N.</given-names></name><name><surname>Agorastos</surname><given-names>A.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>D.T.</given-names></name><name><surname>Baker</surname><given-names>D.G.</given-names></name></person-group><article-title>Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk.</article-title><source>JAMA Psychiatry</source><year>2014</year><volume>71</volume><issue>4</issue><fpage>423</fpage><lpage>431</lpage><comment>[http:// dx.doi.org/10.1001/jamapsychiatry.2013.4374]. [PMID: 24576974].</comment><pub-id pub-id-type="pmid">24576974</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pervanidou</surname><given-names>P.</given-names></name><name><surname>Kolaitis</surname><given-names>G.</given-names></name><name><surname>Charitaki</surname><given-names>S.</given-names></name><name><surname>Margeli</surname><given-names>A.</given-names></name><name><surname>Ferentinos</surname><given-names>S.</given-names></name><name><surname>Bakoula</surname><given-names>C.</given-names></name><name><surname>Lazaropoulou</surname><given-names>C.</given-names></name><name><surname>Papassotiriou</surname><given-names>I.</given-names></name><name><surname>Tsiantis</surname><given-names>J.</given-names></name><name><surname>Chrousos</surname><given-names>G.P.</given-names></name></person-group><article-title>Elevated morning serum interleukin (IL)-6 or evening salivary cortisol concentrations predict posttraumatic stress disorder in children and adolescents six months after a motor vehicle accident.</article-title><source>Psychoneuroendocrinology</source><year>2007</year><volume>32</volume><issue>8-10</issue><fpage>991</fpage><lpage>999</lpage><comment>[http://dx.doi.org/10.1016/j.psyneuen.2007.07.001]. [PMID: 17825995].</comment><pub-id pub-id-type="pmid">17825995</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleshner</surname><given-names>M.</given-names></name></person-group><article-title>Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome.</article-title><source>Brain Behav. Immun.</source><year>2013</year><volume>27</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2012.08.012]. [PMID: 22964544].</comment><pub-id pub-id-type="pmid">22964544</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>M.</given-names></name><name><surname>Ota</surname><given-names>K.T.</given-names></name><name><surname>Duman</surname><given-names>R.S.</given-names></name></person-group><article-title>The inflammasome: pathways linking psychological stress, depression, and systemic illnesses.</article-title><source>Brain Behav. Immun.</source><year>2013</year><volume>31</volume><fpage>105</fpage><lpage>114</lpage><comment>[http://dx.doi.org/10. 1016/j.bbi.2012.12.008]. [PMID: 23261775].</comment><pub-id pub-id-type="pmid">23261775</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maslanik</surname><given-names>T.</given-names></name></person-group><article-title>The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure.</article-title><source>Brain Behav. Immun.</source><year>2012</year><volume>28</volume><fpage>54</fpage><lpage>62</lpage><comment>[PMID: 23103443].</comment><pub-id pub-id-type="pmid">23103443</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>P.A.</given-names></name><name><surname>Trinder</surname><given-names>J.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Sick and tired: Does sleep have a vital role in the immune system?</article-title><source>Nat. Rev. Immunol.</source><year>2004</year><volume>4</volume><issue>6</issue><fpage>457</fpage><lpage>467</lpage><comment>[http://dx.doi.org/10.1038/nri1369]. [PMID: 15173834].</comment><pub-id pub-id-type="pmid">15173834</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motivala</surname><given-names>S.J.</given-names></name><name><surname>Sarfatti</surname><given-names>A.</given-names></name><name><surname>Olmos</surname><given-names>L.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><article-title>Inflammatory markers and sleep disturbance in major depression.</article-title><source>Psychosom. Med.</source><year>2005</year><volume>67</volume><issue>2</issue><fpage>187</fpage><lpage>194</lpage><comment>[http://dx.doi.org/10.1097/01.psy. 0000149259.72488.09]. [PMID: 15784782].</comment><pub-id pub-id-type="pmid">15784782</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Opp</surname><given-names>M.R.</given-names></name><name><surname>Born</surname><given-names>J.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><chapter-title>Irwin, Sleep and the immune system.</chapter-title><source>Academic Press.</source><person-group person-group-type="editor"><name><surname>Psychoneuroim-munology</surname><given-names>R.A.</given-names></name></person-group><publisher-loc>New York, NY</publisher-loc><year>2007</year><fpage>570</fpage><lpage>618</lpage></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suarez</surname><given-names>E.C.</given-names></name></person-group><article-title>Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity.</article-title><source>Brain Behav. Immun.</source><year>2008</year><volume>22</volume><issue>6</issue><fpage>960</fpage><lpage>968</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2008.01.011]. [PMID: 18328671].</comment><pub-id pub-id-type="pmid">18328671</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier-Ewert</surname><given-names>H.K.</given-names></name><name><surname>Ridker</surname><given-names>P.M.</given-names></name><name><surname>Rifai</surname><given-names>N.</given-names></name><name><surname>Regan</surname><given-names>M.M.</given-names></name><name><surname>Price</surname><given-names>N.J.</given-names></name><name><surname>Dinges</surname><given-names>D.F.</given-names></name><name><surname>Mullington</surname><given-names>J.M.</given-names></name></person-group><article-title>Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk.</article-title><source>J. Am. Coll. Cardiol.</source><year>2004</year><volume>43</volume><issue>4</issue><fpage>678</fpage><lpage>683</lpage><comment>[http://dx.doi.org/10. 1016/j.jacc.2003.07.050]. [PMID: 14975482].</comment><pub-id pub-id-type="pmid">14975482</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vgontzas</surname><given-names>A.N.</given-names></name><name><surname>Papanicolaou</surname><given-names>D.A.</given-names></name><name><surname>Bixler</surname><given-names>E.O.</given-names></name><name><surname>Lotsikas</surname><given-names>A.</given-names></name><name><surname>Zachman</surname><given-names>K.</given-names></name><name><surname>Kales</surname><given-names>A.</given-names></name><name><surname>Prolo</surname><given-names>P.</given-names></name><name><surname>Wong</surname><given-names>M.L.</given-names></name><name><surname>Licinio</surname><given-names>J.</given-names></name><name><surname>Gold</surname><given-names>P.W.</given-names></name><name><surname>Hermida</surname><given-names>R.C.</given-names></name><name><surname>Mastorakos</surname><given-names>G.</given-names></name><name><surname>Chrousos</surname><given-names>G.P.</given-names></name></person-group><article-title>Circadian interleukin-6 secretion and quantity and depth of sleep.</article-title><source>J. Clin. Endocrinol. Metab.</source><year>1999</year><volume>84</volume><issue>8</issue><fpage>2603</fpage><lpage>2607</lpage><comment>[http://dx.doi.org/10. 1210/jcem.84.8.5894]. [PMID: 10443646].</comment><pub-id pub-id-type="pmid">10443646</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vgontzas</surname><given-names>A.N.</given-names></name><name><surname>Zoumakis</surname><given-names>E.</given-names></name><name><surname>Bixler</surname><given-names>E.O.</given-names></name><name><surname>Lin</surname><given-names>H.M.</given-names></name><name><surname>Follett</surname><given-names>H.</given-names></name><name><surname>Kales</surname><given-names>A.</given-names></name><name><surname>Chrousos</surname><given-names>G.P.</given-names></name></person-group><article-title>Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines.</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2004</year><volume>89</volume><issue>5</issue><fpage>2119</fpage><lpage>2126</lpage><comment>[http://dx.doi.org/10. 1210/jc.2003-031562]. [PMID: 15126529].</comment><pub-id pub-id-type="pmid">15126529</pub-id></element-citation></ref><ref id="r76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamal</surname><given-names>O.</given-names></name><name><surname>Aneni</surname><given-names>E.C.</given-names></name><name><surname>Shaharyar</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>S.S.</given-names></name><name><surname>Parris</surname><given-names>D.</given-names></name><name><surname>McEvoy</surname><given-names>J.W.</given-names></name><name><surname>Veledar</surname><given-names>E.</given-names></name><name><surname>Blaha</surname><given-names>M.J.</given-names></name><name><surname>Blumenthal</surname><given-names>R.S.</given-names></name><name><surname>Agatston</surname><given-names>A.S.</given-names></name><name><surname>Concei&#231;&#227;o</surname><given-names>R.D.</given-names></name><name><surname>Feldman</surname><given-names>T.</given-names></name><name><surname>Carvalho</surname><given-names>J.A.</given-names></name><name><surname>Santos</surname><given-names>R.D.</given-names></name><name><surname>Nasir</surname><given-names>K.</given-names></name></person-group><article-title>Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome.</article-title><source>Diabetol. Metab. Syndr.</source><year>2014</year><volume>6</volume><fpage>79</fpage><lpage>86</lpage><comment>[http://dx.doi.org/10.1186/1758-5996-6-79]. [PMID: 25960769].</comment><pub-id pub-id-type="pmid">25960769</pub-id></element-citation></ref><ref id="r77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de La Serre</surname><given-names>C.B.</given-names></name><name><surname>Ellis</surname><given-names>C.L.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Hartman</surname><given-names>A.L.</given-names></name><name><surname>Rutledge</surname><given-names>J.C.</given-names></name><name><surname>Raybould</surname><given-names>H.E.</given-names></name></person-group><article-title>Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation.</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2010</year><volume>299</volume><issue>2</issue><fpage>G440</fpage><lpage>G448</lpage><comment>[http://dx.doi.org/10.1152/ajpgi.00098.2010]. [PMID: 20508158].</comment><pub-id pub-id-type="pmid">20508158</pub-id></element-citation></ref><ref id="r78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaodhiar</surname><given-names>L.</given-names></name><name><surname>Ling</surname><given-names>P.R.</given-names></name><name><surname>Blackburn</surname><given-names>G.L.</given-names></name><name><surname>Bistrian</surname><given-names>B.R.</given-names></name></person-group><article-title>Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity.</article-title><source>JPEN J. Parenter. Enteral Nutr.</source><year>2004</year><volume>28</volume><issue>6</issue><fpage>410</fpage><lpage>415</lpage><comment>[http://dx.doi.org/10.1177/ 0148607104028006410]. [PMID: 15568287].</comment><pub-id pub-id-type="pmid">15568287</pub-id></element-citation></ref><ref id="r79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Nelesen</surname><given-names>R.</given-names></name><name><surname>Dimsdale</surname><given-names>J.E.</given-names></name></person-group><article-title>The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects.</article-title><source>Arch. Intern. Med.</source><year>2005</year><volume>165</volume><issue>8</issue><fpage>910</fpage><lpage>915</lpage><comment>[http://dx.doi.org/10.1001/archinte.165.8.910]. [PMID: 15851643].</comment><pub-id pub-id-type="pmid">15851643</pub-id></element-citation></ref><ref id="r80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>S.P.</given-names></name><name><surname>McCann</surname><given-names>D.</given-names></name><name><surname>Desai</surname><given-names>M.</given-names></name><name><surname>Rosenbaum</surname><given-names>M.</given-names></name><name><surname>Leibel</surname><given-names>R.L.</given-names></name><name><surname>Ferrante</surname><given-names>A.W.</given-names><suffix>Jr</suffix></name></person-group><article-title>Obesity is associated with macrophage accumulation in adipose tissue.</article-title><source>J. Clin. Invest.</source><year>2003</year><volume>112</volume><issue>12</issue><fpage>1796</fpage><lpage>1808</lpage><comment>[http://dx.doi.org/10.1172/JCI200319246]. [PMID: 14679176].</comment><pub-id pub-id-type="pmid">14679176</pub-id></element-citation></ref><ref id="r81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suganami</surname><given-names>T.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name></person-group><article-title>Adipose tissue macrophages: their role in adipose tissue remodeling.</article-title><source>J. Leukoc. Biol.</source><year>2010</year><volume>88</volume><issue>1</issue><fpage>33</fpage><lpage>39</lpage><comment>[http://dx.doi.org/10.1189/jlb.0210072]. [PMID: 20360405].</comment><pub-id pub-id-type="pmid">20360405</pub-id></element-citation></ref><ref id="r82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.S.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name></person-group><article-title>Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6.</article-title><source>Diabetes Res. Clin. Pract.</source><year>2005</year><volume>69</volume><issue>1</issue><fpage>29</fpage><lpage>35</lpage><comment>[http://dx.doi.org/ 10.1016/j.diabres.2004.11.007]. [PMID: 15955385].</comment><pub-id pub-id-type="pmid">15955385</pub-id></element-citation></ref><ref id="r83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>G.E.</given-names></name><name><surname>Freedland</surname><given-names>K.E.</given-names></name><name><surname>Carney</surname><given-names>R.M.</given-names></name><name><surname>Stetler</surname><given-names>C.A.</given-names></name><name><surname>Banks</surname><given-names>W.A.</given-names></name></person-group><article-title>Pathways linking depression, adiposity, and inflammatory markers in healthy young adults.</article-title><source>Brain Behav. Immun.</source><year>2003</year><volume>17</volume><issue>4</issue><fpage>276</fpage><lpage>285</lpage><comment>[http://dx.doi.org/10.1016/S0889-1591(03)00057-6]. [PMID: 12831830].</comment><pub-id pub-id-type="pmid">12831830</pub-id></element-citation></ref><ref id="r84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>G.E.</given-names></name><name><surname>Stetler</surname><given-names>C.A.</given-names></name><name><surname>Carney</surname><given-names>R.M.</given-names></name><name><surname>Freedland</surname><given-names>K.E.</given-names></name><name><surname>Banks</surname><given-names>W.A.</given-names></name></person-group><article-title>Clinical depression and inflammatory risk markers for coronary heart disease.</article-title><source>Am. J. Cardiol.</source><year>2002</year><volume>90</volume><issue>12</issue><fpage>1279</fpage><lpage>1283</lpage><comment>[http:// dx.doi.org/10.1016/S0002-9149(02)02863-1]. [PMID: 12480034].</comment><pub-id pub-id-type="pmid">12480034</pub-id></element-citation></ref><ref id="r85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuura</surname><given-names>G.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Koves</surname><given-names>K.</given-names></name><name><surname>Gottschall</surname><given-names>P.E.</given-names></name></person-group><article-title>Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release.</article-title><source>Am. J. Physiol.</source><year>1990</year><volume>258</volume><issue>1 Pt 1</issue><fpage>E163</fpage><lpage>E171</lpage><comment>[PMID: 1967907].</comment><pub-id pub-id-type="pmid">1967907</pub-id></element-citation></ref><ref id="r86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>W.</given-names></name><name><surname>Kastin</surname><given-names>A.J.</given-names></name></person-group><article-title>Interactions of cytokines with the blood-brain barrier: implications for feeding.</article-title><source>Curr. Pharm. Des.</source><year>2003</year><volume>9</volume><issue>10</issue><fpage>827</fpage><lpage>831</lpage><comment>[http://dx.doi.org/10.2174/1381612033455332]. [PMID: 12678882].</comment><pub-id pub-id-type="pmid">12678882</pub-id></element-citation></ref><ref id="r87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W.A.</given-names></name><name><surname>Erickson</surname><given-names>M.A.</given-names></name></person-group><article-title>The blood-brain barrier and immune function and dysfunction.</article-title><source>Neurobiol. Dis.</source><year>2010</year><volume>37</volume><issue>1</issue><fpage>26</fpage><lpage>32</lpage><comment>[http://dx.doi.org/10.1016/j.nbd.2009.07.031]. [PMID: 19664708].</comment><pub-id pub-id-type="pmid">19664708</pub-id></element-citation></ref><ref id="r88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W.A.</given-names></name><name><surname>Farr</surname><given-names>S.A.</given-names></name><name><surname>Morley</surname><given-names>J.E.</given-names></name></person-group><article-title>Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes.</article-title><source>Neuroimmunomodulation</source><year>2002-2003</year><volume>10</volume><issue>6</issue><fpage>319</fpage><lpage>327</lpage><comment>[http://dx. doi.org/10.1159/000071472]. [PMID: 12907838].</comment></element-citation></ref><ref id="r89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>W.A.</given-names></name><name><surname>Kastin</surname><given-names>A.J.</given-names></name><name><surname>Broadwell</surname><given-names>R.D.</given-names></name></person-group><article-title>Passage of cytokines across the blood-brain barrier.</article-title><source>Neuroimmunomodulation</source><year>1995</year><volume>2</volume><issue>4</issue><fpage>241</fpage><lpage>248</lpage><comment>[http://dx.doi.org/10.1159/000097202]. [PMID: 8963753].</comment><pub-id pub-id-type="pmid">8963753</pub-id></element-citation></ref><ref id="r90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluth&#233;</surname><given-names>R.M.</given-names></name><name><surname>Walter</surname><given-names>V.</given-names></name><name><surname>Parnet</surname><given-names>P.</given-names></name><name><surname>Lay&#233;</surname><given-names>S.</given-names></name><name><surname>Lestage</surname><given-names>J.</given-names></name><name><surname>Verrier</surname><given-names>D.</given-names></name><name><surname>Poole</surname><given-names>S.</given-names></name><name><surname>Stenning</surname><given-names>B.E.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name></person-group><article-title>Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism.</article-title><source>C. R. Acad. Sci. III</source><year>1994</year><volume>317</volume><issue>6</issue><fpage>499</fpage><lpage>503</lpage><comment>[PMID: 7987701].</comment><pub-id pub-id-type="pmid">7987701</pub-id></element-citation></ref><ref id="r91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ericsson</surname><given-names>A.</given-names></name><name><surname>Kov&#225;cs</surname><given-names>K.J.</given-names></name><name><surname>Sawchenko</surname><given-names>P.E.</given-names></name></person-group><article-title>A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons.</article-title><source>J. Neurosci.</source><year>1994</year><volume>14</volume><issue>2</issue><fpage>897</fpage><lpage>913</lpage><comment>[PMID: 8301368].</comment><pub-id pub-id-type="pmid">8301368</pub-id></element-citation></ref><ref id="r92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>L.R.</given-names></name><name><surname>Goehler</surname><given-names>L.E.</given-names></name><name><surname>Relton</surname><given-names>J.K.</given-names></name><name><surname>Tartaglia</surname><given-names>N.</given-names></name><name><surname>Silbert</surname><given-names>L.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Maier</surname><given-names>S.F.</given-names></name></person-group><article-title>Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication.</article-title><source>Neurosci. Lett.</source><year>1995</year><volume>183</volume><issue>1-2</issue><fpage>27</fpage><lpage>31</lpage><comment>[http://dx.doi.org/10.1016/0304-3940(94)11105-R]. [PMID: 7746479].</comment><pub-id pub-id-type="pmid">7746479</pub-id></element-citation></ref><ref id="r93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>L.R.</given-names></name><name><surname>Wiertelak</surname><given-names>E.P.</given-names></name><name><surname>Goehler</surname><given-names>L.E.</given-names></name><name><surname>Mooney-Heiberger</surname><given-names>K.</given-names></name><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Furness</surname><given-names>L.</given-names></name><name><surname>Smith</surname><given-names>K.P.</given-names></name><name><surname>Maier</surname><given-names>S.F.</given-names></name></person-group><article-title>Neurocircuitry of illness-induced hyperalgesia.</article-title><source>Brain Res.</source><year>1994</year><volume>639</volume><issue>2</issue><fpage>283</fpage><lpage>299</lpage><comment>[http://dx.doi.org/10.1016/0006-8993(94)91742-6]. [PMID: 8205482].</comment><pub-id pub-id-type="pmid">8205482</pub-id></element-citation></ref><ref id="r94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#8217;Mello</surname><given-names>C.</given-names></name><name><surname>Ronaghan</surname><given-names>N.</given-names></name><name><surname>Zaheer</surname><given-names>R.</given-names></name><name><surname>Dicay</surname><given-names>M.</given-names></name><name><surname>Le</surname><given-names>T.</given-names></name><name><surname>MacNaughton</surname><given-names>W.K.</given-names></name><name><surname>Surrette</surname><given-names>M.G.</given-names></name><name><surname>Swain</surname><given-names>M.G.</given-names></name></person-group><article-title>Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain.</article-title><source>J. Neurosci.</source><year>2015</year><volume>35</volume><issue>30</issue><fpage>10821</fpage><lpage>10830</lpage><comment>[http://dx.doi.org/10.1523/ JNEUROSCI.0575-15.2015]. [PMID: 26224864].</comment><pub-id pub-id-type="pmid">26224864</pub-id></element-citation></ref><ref id="r95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohleb</surname><given-names>E.S.</given-names></name><name><surname>McKim</surname><given-names>D.B.</given-names></name><name><surname>Shea</surname><given-names>D.T.</given-names></name><name><surname>Powell</surname><given-names>N.D.</given-names></name><name><surname>Tarr</surname><given-names>A.J.</given-names></name><name><surname>Sheridan</surname><given-names>J.F.</given-names></name><name><surname>Godbout</surname><given-names>J.P.</given-names></name></person-group><article-title>Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain.</article-title><source>Biol. Psychiatry</source><year>2014</year><volume>75</volume><issue>12</issue><fpage>970</fpage><lpage>981</lpage><comment>[http://dx. doi.org/10.1016/j.biopsych.2013.11.029]. [PMID: 24439304].</comment><pub-id pub-id-type="pmid">24439304</pub-id></element-citation></ref><ref id="r96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodes</surname><given-names>G.E.</given-names></name><name><surname>Pfau</surname><given-names>M.L.</given-names></name><name><surname>Leboeuf</surname><given-names>M.</given-names></name><name><surname>Golden</surname><given-names>S.A.</given-names></name><name><surname>Christoffel</surname><given-names>D.J.</given-names></name><name><surname>Bregman</surname><given-names>D.</given-names></name><name><surname>Rebusi</surname><given-names>N.</given-names></name><name><surname>Heshmati</surname><given-names>M.</given-names></name><name><surname>Aleyasin</surname><given-names>H.</given-names></name><name><surname>Warren</surname><given-names>B.L.</given-names></name><name><surname>Lebont&#233;</surname><given-names>B.</given-names></name><name><surname>Horn</surname><given-names>S.</given-names></name><name><surname>Lapidus</surname><given-names>K.A.</given-names></name><name><surname>Stelzhammer</surname><given-names>V.</given-names></name><name><surname>Wong</surname><given-names>E.H.</given-names></name><name><surname>Bahn</surname><given-names>S.</given-names></name><name><surname>Krishnan</surname><given-names>V.</given-names></name><name><surname>Bola&#241;os-Guzman</surname><given-names>C.A.</given-names></name><name><surname>Murrough</surname><given-names>J.W.</given-names></name><name><surname>Merad</surname><given-names>M.</given-names></name><name><surname>Russo</surname><given-names>S.J.</given-names></name></person-group><article-title>Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress.</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><issue>45</issue><fpage>16136</fpage><lpage>16141</lpage><comment>[http://dx.doi.org/10.1073/pnas.1415191111]. [PMID: 25331895].</comment><pub-id pub-id-type="pmid">25331895</pub-id></element-citation></ref><ref id="r97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brambilla</surname><given-names>P.</given-names></name><name><surname>Bellani</surname><given-names>M.</given-names></name><name><surname>Isola</surname><given-names>M.</given-names></name><name><surname>Bergami</surname><given-names>A.</given-names></name><name><surname>Marinelli</surname><given-names>V.</given-names></name><name><surname>Dusi</surname><given-names>N.</given-names></name><name><surname>Rambaldelli</surname><given-names>G.</given-names></name><name><surname>Tansella</surname><given-names>M.</given-names></name><name><surname>Finardi</surname><given-names>A.M.</given-names></name><name><surname>Martino</surname><given-names>G.</given-names></name><name><surname>Perlini</surname><given-names>C.</given-names></name><name><surname>Furlan</surname><given-names>R.</given-names></name></person-group><article-title>Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia.</article-title><source>Transl. Psychiatry</source><year>2014</year><volume>4</volume><fpage>e406</fpage><comment>[http://dx.doi.org/10.1038/tp.2014.46]. [PMID: 24984193].</comment><pub-id pub-id-type="pmid">24984193</pub-id></element-citation></ref><ref id="r98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drago</surname><given-names>A.</given-names></name><name><surname>Crisafulli</surname><given-names>C.</given-names></name><name><surname>Calabr&#242;</surname><given-names>M.</given-names></name><name><surname>Serretti</surname><given-names>A.</given-names></name></person-group><article-title>Enrichment pathway analysis. the inflammatory genetic background in bipolar disorder.</article-title><source>J. Affect. Disord.</source><year>2015</year><volume>179</volume><fpage>88</fpage><lpage>94</lpage><comment>[http://dx.doi.org/10. 1016/j.jad.2015.03.032]. [PMID: 25855618].</comment><pub-id pub-id-type="pmid">25855618</pub-id></element-citation></ref><ref id="r99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Walter</surname><given-names>M.</given-names></name><name><surname>Gos</surname><given-names>T.</given-names></name><name><surname>Guillemin</surname><given-names>G.J.</given-names></name><name><surname>Bernstein</surname><given-names>H.G.</given-names></name><name><surname>Sarnyai</surname><given-names>Z.</given-names></name><name><surname>Mawrin</surname><given-names>C.</given-names></name><name><surname>Brisch</surname><given-names>R.</given-names></name><name><surname>Bielau</surname><given-names>H.</given-names></name><name><surname>Meyer zu Schwabedissen</surname><given-names>L.</given-names></name><name><surname>Bogerts</surname><given-names>B.</given-names></name><name><surname>Myint</surname><given-names>A.M.</given-names></name></person-group><article-title>Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?</article-title><source>J. Neuroinflammation</source><year>2011</year><volume>8</volume><fpage>94</fpage><comment>[http://dx.doi.org/10.1186/1742-2094-8-94]. [PMID: 21831269].</comment><pub-id pub-id-type="pmid">21831269</pub-id></element-citation></ref><ref id="r100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Platas</surname><given-names>S.G.</given-names></name><name><surname>Cruceanu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>G.G.</given-names></name><name><surname>Turecki</surname><given-names>G.</given-names></name><name><surname>Mechawar</surname><given-names>N.</given-names></name></person-group><article-title>Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides.</article-title><source>Brain Behav. Immun.</source><year>2014</year><volume>42</volume><fpage>50</fpage><lpage>59</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2014.05.007]. [PMID: 24858659].</comment><pub-id pub-id-type="pmid">24858659</pub-id></element-citation></ref><ref id="r101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>M.E.</given-names></name><name><surname>Stevens</surname><given-names>B.</given-names></name><name><surname>Sierra</surname><given-names>A.</given-names></name><name><surname>Wake</surname><given-names>H.</given-names></name><name><surname>Bessis</surname><given-names>A.</given-names></name><name><surname>Nimmerjahn</surname><given-names>A.</given-names></name></person-group><article-title>The role of microglia in the healthy brain.</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><issue>45</issue><fpage>16064</fpage><lpage>16069</lpage><comment>[http://dx.doi.org/10.1523/ JNEUROSCI.4158-11.2011]. [PMID: 22072657].</comment><pub-id pub-id-type="pmid">22072657</pub-id></element-citation></ref><ref id="r102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockhart</surname><given-names>A.</given-names></name><name><surname>Davis</surname><given-names>B.</given-names></name><name><surname>Matthews</surname><given-names>J.C.</given-names></name><name><surname>Rahmoune</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>G.</given-names></name><name><surname>Gee</surname><given-names>A.</given-names></name><name><surname>Earnshaw</surname><given-names>D.</given-names></name><name><surname>Brown</surname><given-names>J.</given-names></name></person-group><article-title>The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant &#945;1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker.</article-title><source>Nucl. Med. Biol.</source><year>2003</year><volume>30</volume><issue>2</issue><fpage>199</fpage><lpage>206</lpage><comment>[http://dx.doi.org/10.1016/S0969-8051(02)00410-9]. [PMID: 12623120].</comment><pub-id pub-id-type="pmid">12623120</pub-id></element-citation></ref><ref id="r103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venneti</surname><given-names>S.</given-names></name><name><surname>Lopresti</surname><given-names>B.J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Slagel</surname><given-names>S.L.</given-names></name><name><surname>Mason</surname><given-names>N.S.</given-names></name><name><surname>Mathis</surname><given-names>C.A.</given-names></name><name><surname>Fischer</surname><given-names>M.L.</given-names></name><name><surname>Larsen</surname><given-names>N.J.</given-names></name><name><surname>Mortimer</surname><given-names>A.D.</given-names></name><name><surname>Hastings</surname><given-names>T.G.</given-names></name><name><surname>Smith</surname><given-names>A.D.</given-names></name><name><surname>Zigmond</surname><given-names>M.J.</given-names></name><name><surname>Suhara</surname><given-names>T.</given-names></name><name><surname>Higuchi</surname><given-names>M.</given-names></name><name><surname>Wiley</surname><given-names>C.A.</given-names></name></person-group><article-title>A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation.</article-title><source>J. Neurochem.</source><year>2007</year><volume>102</volume><issue>6</issue><fpage>2118</fpage><lpage>2131</lpage><comment>[http://dx.doi. org/10.1111/j.1471-4159.2007.04690.x]. [PMID: 17555551].</comment><pub-id pub-id-type="pmid">17555551</pub-id></element-citation></ref><ref id="r104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagnin</surname><given-names>A.</given-names></name><name><surname>Kassiou</surname><given-names>M.</given-names></name><name><surname>Meikle</surname><given-names>S.R.</given-names></name><name><surname>Banati</surname><given-names>R.B.</given-names></name></person-group><article-title>Positron emission tomography imaging of neuroinflammation.</article-title><source>Neurotherapeutics</source><year>2007</year><volume>4</volume><issue>3</issue><fpage>443</fpage><lpage>452</lpage><comment>[http://dx.doi.org/10.1016/j.nurt.2007.04.006]. [PMID: 17599710].</comment><pub-id pub-id-type="pmid">17599710</pub-id></element-citation></ref><ref id="r105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imaizumi</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Zoghbi</surname><given-names>S.S.</given-names></name><name><surname>Briard</surname><given-names>E.</given-names></name><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Musachio</surname><given-names>J.L.</given-names></name><name><surname>Ruetzler</surname><given-names>C.</given-names></name><name><surname>Chuang</surname><given-names>D.M.</given-names></name><name><surname>Pike</surname><given-names>V.W.</given-names></name><name><surname>Innis</surname><given-names>R.B.</given-names></name><name><surname>Fujita</surname><given-names>M.</given-names></name></person-group><article-title>PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat.</article-title><source>Neurosci. Lett.</source><year>2007</year><volume>411</volume><issue>3</issue><fpage>200</fpage><lpage>205</lpage><comment>[http://dx.doi.org/10.1016/j.neulet.2006.09.093]. [PMID: 17127001].</comment><pub-id pub-id-type="pmid">17127001</pub-id></element-citation></ref><ref id="r106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>A.A.</given-names></name><name><surname>Garcia</surname><given-names>A.</given-names></name><name><surname>Parkes</surname><given-names>J.</given-names></name><name><surname>McCormick</surname><given-names>P.</given-names></name><name><surname>Stephenson</surname><given-names>K.A.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Vasdev</surname><given-names>N.</given-names></name></person-group><article-title>Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors.</article-title><source>Nucl. Med. Biol.</source><year>2008</year><volume>35</volume><issue>3</issue><fpage>305</fpage><lpage>314</lpage><comment>[http://dx.doi. org/10.1016/j.nucmedbio.2007.12.009]. [PMID: 18355686].</comment><pub-id pub-id-type="pmid">18355686</pub-id></element-citation></ref><ref id="r107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setiawan</surname><given-names>E.</given-names></name><name><surname>Wilson</surname><given-names>A.A.</given-names></name><name><surname>Mizrahi</surname><given-names>R.</given-names></name><name><surname>Rusjan</surname><given-names>P.M.</given-names></name><name><surname>Miler</surname><given-names>L.</given-names></name><name><surname>Rajkowska</surname><given-names>G.</given-names></name><name><surname>Suridjan</surname><given-names>I.</given-names></name><name><surname>Kennedy</surname><given-names>J.L.</given-names></name><name><surname>Rekkas</surname><given-names>P.V.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Meyer</surname><given-names>J.H.</given-names></name></person-group><article-title>Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><issue>3</issue><fpage>268</fpage><lpage>275</lpage><comment>[http://dx.doi.org/10.1001/ jamapsychiatry.2014.2427]. [PMID: 25629589].</comment><pub-id pub-id-type="pmid">25629589</pub-id></element-citation></ref><ref id="r108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J.</given-names></name><name><surname>Gallezot</surname><given-names>J.D.</given-names></name><name><surname>Schafbauer</surname><given-names>T.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name><name><surname>Kloczynski</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>E.D.</given-names></name><name><surname>Carson</surname><given-names>R.E.</given-names></name><name><surname>Ding</surname><given-names>Y.S.</given-names></name><name><surname>Cosgrove</surname><given-names>K.P.</given-names></name></person-group><article-title>Endotoxin-induced systemic inflammation activates microglia: [<sup>11</sup>C]PBR28 positron emission tomography in nonhuman primates.</article-title><source>Neuroimage</source><year>2012</year><volume>63</volume><issue>1</issue><fpage>232</fpage><lpage>239</lpage><comment>[http://dx.doi.org/10.1016/j.neuroimage. 2012.06.055]. [PMID: 22776451].</comment><pub-id pub-id-type="pmid">22776451</pub-id></element-citation></ref><ref id="r109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>P.S.</given-names></name></person-group><article-title>Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [11C] PBR28 PET brain imaging study.</article-title><source>Am. J. Psychiatry</source><year>2015</year><volume>173</volume><issue>1</issue><fpage>44</fpage><lpage>52</lpage><comment>[PMID: 26472628].</comment><pub-id pub-id-type="pmid">26472628</pub-id></element-citation></ref><ref id="r110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenk</surname><given-names>M.</given-names></name><name><surname>Selvanathan</surname><given-names>T.</given-names></name><name><surname>Rao</surname><given-names>N.</given-names></name><name><surname>Suridjan</surname><given-names>I.</given-names></name><name><surname>Rusjan</surname><given-names>P.</given-names></name><name><surname>Remington</surname><given-names>G.</given-names></name><name><surname>Meyer</surname><given-names>J.H.</given-names></name><name><surname>Wilson</surname><given-names>A.A.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Mizrahi</surname><given-names>R.</given-names></name></person-group><article-title>Imaging neuroinflammation in gray and white matter in schizophrenia: an <italic>in-vivo</italic> PET study with [18F]-FEPPA.</article-title><source>Schizophr. Bull.</source><year>2015</year><volume>41</volume><issue>1</issue><fpage>85</fpage><lpage>93</lpage><comment>[http://dx.doi.org/10.1093/schbul/sbu157]. [PMID: 25385788].</comment><pub-id pub-id-type="pmid">25385788</pub-id></element-citation></ref><ref id="r111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivash</surname><given-names>L.</given-names></name><name><surname>O&#8217;Brien</surname><given-names>T.J.</given-names></name></person-group><article-title>Imaging microglial activation with TSPO PET: Lighting up neurologic diseases?</article-title><source>J. Nucl. Med.</source><year>2016</year><volume>57</volume><issue>2</issue><fpage>165</fpage><lpage>168</lpage><comment>[http://dx.doi.org/10.2967/jnumed.114.141713]. [PMID: 26697963].</comment><pub-id pub-id-type="pmid">26697963</pub-id></element-citation></ref><ref id="r112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setiawan</surname><given-names>E.</given-names></name><name><surname>Wilson</surname><given-names>A.A.</given-names></name><name><surname>Mizrahi</surname><given-names>R.</given-names></name><name><surname>Rusjan</surname><given-names>P.M.</given-names></name><name><surname>Miler</surname><given-names>L.</given-names></name><name><surname>Rajkowska</surname><given-names>G.</given-names></name><name><surname>Suridjan</surname><given-names>I.</given-names></name><name><surname>Kennedy</surname><given-names>J.L.</given-names></name><name><surname>Rekkas</surname><given-names>P.V.</given-names></name><name><surname>Houle</surname><given-names>S.</given-names></name><name><surname>Meyer</surname><given-names>J.H.</given-names></name></person-group><article-title>Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><issue>3</issue><fpage>268</fpage><lpage>275</lpage><comment>[http://dx.doi.org/10.1001/ jamapsychiatry.2014.2427]. [PMID: 25629589].</comment><pub-id pub-id-type="pmid">25629589</pub-id></element-citation></ref><ref id="r113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandiego</surname><given-names>C.M.</given-names></name><name><surname>Gallezot</surname><given-names>J.D.</given-names></name><name><surname>Pittman</surname><given-names>B.</given-names></name><name><surname>Nabulsi</surname><given-names>N.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name><name><surname>Lin</surname><given-names>S.F.</given-names></name><name><surname>Matuskey</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>K.C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Carson</surname><given-names>R.E.</given-names></name><name><surname>Hannestad</surname><given-names>J.</given-names></name><name><surname>Cosgrove</surname><given-names>K.P.</given-names></name></person-group><article-title>Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><issue>40</issue><fpage>12468</fpage><lpage>12473</lpage><comment>[http://dx.doi.org/10.1073/pnas.1511003112]. [PMID: 26385967].</comment><pub-id pub-id-type="pmid">26385967</pub-id></element-citation></ref><ref id="r114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J.</given-names></name><name><surname>Gallezot</surname><given-names>J.D.</given-names></name><name><surname>Schafbauer</surname><given-names>T.</given-names></name><name><surname>Lim</surname><given-names>K.</given-names></name><name><surname>Kloczynski</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>E.D.</given-names></name><name><surname>Carson</surname><given-names>R.E.</given-names></name><name><surname>Ding</surname><given-names>Y.S.</given-names></name><name><surname>Cosgrove</surname><given-names>K.P.</given-names></name></person-group><article-title>Endotoxin-induced systemic inflammation activates microglia: [<sup>11</sup>C]PBR28 positron emission tomography in nonhuman primates.</article-title><source>Neuroimage</source><year>2012</year><volume>63</volume><issue>1</issue><fpage>232</fpage><lpage>239</lpage><comment>[http://dx.doi.org/10.1016/j. neuroimage.2012.06.055]. [PMID: 22776451].</comment><pub-id pub-id-type="pmid">22776451</pub-id></element-citation></ref><ref id="r115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raivich</surname><given-names>G.</given-names></name><name><surname>Bohatschek</surname><given-names>M.</given-names></name><name><surname>Kloss</surname><given-names>C.U.</given-names></name><name><surname>Werner</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>L.L.</given-names></name><name><surname>Kreutzberg</surname><given-names>G.W.</given-names></name></person-group><article-title>Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function.</article-title><source>Brain Res. Brain Res. Rev.</source><year>1999</year><volume>30</volume><issue>1</issue><fpage>77</fpage><lpage>105</lpage><comment>[http://dx.doi.org/10.1016/S0165-0173(99)00007-7]. [PMID: 10407127].</comment><pub-id pub-id-type="pmid">10407127</pub-id></element-citation></ref><ref id="r116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saijo</surname><given-names>K.</given-names></name><name><surname>Glass</surname><given-names>C.K.</given-names></name></person-group><article-title>Microglial cell origin and phenotypes in health and disease.</article-title><source>Nat. Rev. Immunol.</source><year>2011</year><volume>11</volume><issue>11</issue><fpage>775</fpage><lpage>787</lpage><comment>[http://dx.doi.org/10.1038/nri3086]. [PMID: 22025055].</comment><pub-id pub-id-type="pmid">22025055</pub-id></element-citation></ref><ref id="r117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>S.A.</given-names></name><name><surname>McClain</surname><given-names>J.A.</given-names></name><name><surname>Kelso</surname><given-names>M.L.</given-names></name><name><surname>Hopkins</surname><given-names>D.M.</given-names></name><name><surname>Pauly</surname><given-names>J.R.</given-names></name><name><surname>Nixon</surname><given-names>K.</given-names></name></person-group><article-title>Microglial activation is not equivalent to neuroinflammation in alcohol-induced neurodegeneration: The importance of microglia phenotype.</article-title><source>Neurobiol. Dis.</source><year>2013</year><volume>54</volume><fpage>239</fpage><lpage>251</lpage><comment>[http://dx.doi.org/10.1016/j.nbd.2012.12.016]. [PMID: 23313316].</comment><pub-id pub-id-type="pmid">23313316</pub-id></element-citation></ref><ref id="r118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name><name><surname>Drake</surname><given-names>D.F.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Crowe</surname><given-names>R.J.</given-names></name><name><surname>Votaw</surname><given-names>J.R.</given-names></name><name><surname>Goodman</surname><given-names>M.M.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.</article-title><source>Arch. Gen. Psychiatry</source><year>2012</year><volume>69</volume><issue>10</issue><fpage>1044</fpage><lpage>1053</lpage><comment>[http://dx.doi.org/10.1001/ archgenpsychiatry.2011.2094]. [PMID: 23026954].</comment><pub-id pub-id-type="pmid">23026954</pub-id></element-citation></ref><ref id="r119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name><name><surname>Demetrashvili</surname><given-names>M.F.</given-names></name><name><surname>Lawson</surname><given-names>D.H.</given-names></name><name><surname>Fornwalt</surname><given-names>F.B.</given-names></name><name><surname>Woolwine</surname><given-names>B.</given-names></name><name><surname>Berns</surname><given-names>G.S.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><issue>11</issue><fpage>2384</fpage><lpage>2392</lpage><comment>[http://dx.doi.org/10.1038/sj.npp.1301362]. [PMID: 17327884].</comment><pub-id pub-id-type="pmid">17327884</pub-id></element-citation></ref><ref id="r120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brydon</surname><given-names>L.</given-names></name><name><surname>Harrison</surname><given-names>N.A.</given-names></name><name><surname>Walker</surname><given-names>C.</given-names></name><name><surname>Steptoe</surname><given-names>A.</given-names></name><name><surname>Critchley</surname><given-names>H.D.</given-names></name></person-group><article-title>Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans.</article-title><source>Biol. Psychiatry</source><year>2008</year><volume>63</volume><issue>11</issue><fpage>1022</fpage><lpage>1029</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2007.12.007]. [PMID: 18242584].</comment><pub-id pub-id-type="pmid">18242584</pub-id></element-citation></ref><ref id="r121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name><name><surname>Berkman</surname><given-names>E.T.</given-names></name><name><surname>Inagaki</surname><given-names>T.K.</given-names></name><name><surname>Rameson</surname><given-names>L.T.</given-names></name><name><surname>Mashal</surname><given-names>N.M.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><article-title>Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>68</volume><issue>8</issue><fpage>748</fpage><lpage>754</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2010.06.010]. [PMID: 20719303].</comment><pub-id pub-id-type="pmid">20719303</pub-id></element-citation></ref><ref id="r122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majer</surname><given-names>M.</given-names></name><name><surname>Welberg</surname><given-names>L.A.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C.</article-title><source>Brain Behav. Immun.</source><year>2008</year><volume>22</volume><issue>6</issue><fpage>870</fpage><lpage>880</lpage><comment>[http://dx.doi.org/ 10.1016/j.bbi.2007.12.009]. [PMID: 18258414].</comment><pub-id pub-id-type="pmid">18258414</pub-id></element-citation></ref><ref id="r123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N.A.</given-names></name></person-group><article-title>A neurocomputational account of how inflammation enhances sensitivity to punishments versus rewards.</article-title><source>Biol. Psychiatry</source><year>2015</year><comment>[PMID: 26359113].</comment></element-citation></ref><ref id="r124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldsmith</surname><given-names>D.R.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Jung</surname><given-names>M.Y.</given-names></name><name><surname>Wommack</surname><given-names>E.C.</given-names></name><name><surname>Harvey</surname><given-names>P.D.</given-names></name><name><surname>Treadway</surname><given-names>M.T.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder.</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>56</volume><fpage>281</fpage><lpage>288</lpage><comment>[http://dx.doi.org/10.1016/j.bbi. 2016.03.025]. [PMID: 27040122].</comment><pub-id pub-id-type="pmid">27040122</pub-id></element-citation></ref><ref id="r125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>S.</given-names></name></person-group><article-title>Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.</article-title><source>Oncol. Nurs. Forum</source><year>1998</year><volume>25</volume><issue>5</issue><fpage>921</fpage><lpage>927</lpage><comment>[PMID: 9644709].</comment><pub-id pub-id-type="pmid">9644709</pub-id></element-citation></ref><ref id="r126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Gumnick</surname><given-names>J.F.</given-names></name><name><surname>Musselman</surname><given-names>D.L.</given-names></name><name><surname>Lawson</surname><given-names>D.H.</given-names></name><name><surname>Reemsnyder</surname><given-names>A.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>26</volume><issue>5</issue><fpage>643</fpage><lpage>652</lpage><comment>[http://dx.doi.org/10.1016/ S0893-133X(01)00407-9]. [PMID: 11927189].</comment><pub-id pub-id-type="pmid">11927189</pub-id></element-citation></ref><ref id="r127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Neurauter</surname><given-names>G.</given-names></name><name><surname>Musselman</surname><given-names>D.L.</given-names></name><name><surname>Lawson</surname><given-names>D.H.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Fuchs</surname><given-names>D.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.</article-title><source>Biol. Psychiatry</source><year>2003</year><volume>54</volume><issue>9</issue><fpage>906</fpage><lpage>914</lpage><comment>[http:// dx.doi.org/10.1016/S0006-3223(03)00173-2]. [PMID: 14573318].</comment><pub-id pub-id-type="pmid">14573318</pub-id></element-citation></ref><ref id="r128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musselman</surname><given-names>D.L.</given-names></name><name><surname>Lawson</surname><given-names>D.H.</given-names></name><name><surname>Gumnick</surname><given-names>J.F.</given-names></name><name><surname>Manatunga</surname><given-names>A.K.</given-names></name><name><surname>Penna</surname><given-names>S.</given-names></name><name><surname>Goodkin</surname><given-names>R.S.</given-names></name><name><surname>Greiner</surname><given-names>K.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Paroxetine for the prevention of depression induced by high-dose interferon alfa.</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>344</volume><issue>13</issue><fpage>961</fpage><lpage>966</lpage><comment>[http:// dx.doi.org/10.1056/NEJM200103293441303]. [PMID: 11274622].</comment><pub-id pub-id-type="pmid">11274622</pub-id></element-citation></ref><ref id="r129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Borisov</surname><given-names>A.S.</given-names></name><name><surname>Broadwell</surname><given-names>S.D.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Jacobson</surname><given-names>I.M.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.</article-title><source>J. Clin. Psychiatry</source><year>2005</year><volume>66</volume><issue>1</issue><fpage>41</fpage><lpage>48</lpage><comment>[http://dx.doi.org/10.4088/JCP.v66n0106]. [PMID: 15669887].</comment><pub-id pub-id-type="pmid">15669887</pub-id></element-citation></ref><ref id="r130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Rye</surname><given-names>D.B.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Vogt</surname><given-names>G.J.</given-names></name><name><surname>Bautista</surname><given-names>B.M.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>68</volume><issue>10</issue><fpage>942</fpage><lpage>949</lpage><comment>[http://dx. doi.org/10.1016/j.biopsych.2010.04.019]. [PMID: 20537611].</comment><pub-id pub-id-type="pmid">20537611</pub-id></element-citation></ref><ref id="r131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Borisov</surname><given-names>A.S.</given-names></name><name><surname>Majer</surname><given-names>M.</given-names></name><name><surname>Drake</surname><given-names>D.F.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Vogt</surname><given-names>G.J.</given-names></name><name><surname>Massung</surname><given-names>B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>65</volume><issue>4</issue><fpage>296</fpage><lpage>303</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2008.08.010]. [PMID: 18801471].</comment><pub-id pub-id-type="pmid">18801471</pub-id></element-citation></ref><ref id="r132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Hauser</surname><given-names>P.</given-names></name><name><surname>Hinze-Selch</surname><given-names>D.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Neveu</surname><given-names>P.J.</given-names></name></person-group><article-title>Treatment of cytokine-induced depression.</article-title><source>Brain Behav. Immun.</source><year>2002</year><volume>16</volume><issue>5</issue><fpage>575</fpage><lpage>580</lpage><comment>[http://dx.doi.org/10.1016/S0889-1591(02) 00007-7]. [PMID: 12401471].</comment><pub-id pub-id-type="pmid">12401471</pub-id></element-citation></ref><ref id="r133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Mun</surname><given-names>J.</given-names></name><name><surname>Kimmel</surname><given-names>H.L.</given-names></name><name><surname>Nye</surname><given-names>J.A.</given-names></name><name><surname>Drake</surname><given-names>D.F.</given-names></name><name><surname>Hernandez</surname><given-names>C.R.</given-names></name><name><surname>Freeman</surname><given-names>A.A.</given-names></name><name><surname>Rye</surname><given-names>D.B.</given-names></name><name><surname>Goodman</surname><given-names>M.M.</given-names></name><name><surname>Howell</surname><given-names>L.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Chronic interferon-&#945; decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><issue>11</issue><fpage>2179</fpage><lpage>2187</lpage><comment>[http://dx.doi.org/10.1038/ npp.2013.115]. [PMID: 23657438].</comment><pub-id pub-id-type="pmid">23657438</pub-id></element-citation></ref><ref id="r134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitagami</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>K.</given-names></name><name><surname>Miura</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Nabeshima</surname><given-names>T.</given-names></name><name><surname>Ohta</surname><given-names>T.</given-names></name></person-group><article-title>Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier.</article-title><source>Brain Res.</source><year>2003</year><volume>978</volume><issue>1-2</issue><fpage>104</fpage><lpage>114</lpage><comment>[http://dx.doi.org/10.1016/S0006-8993(03)02776-8]. [PMID: 12834904].</comment><pub-id pub-id-type="pmid">12834904</pub-id></element-citation></ref><ref id="r135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>E.J.</given-names></name><name><surname>Randall</surname><given-names>P.A.</given-names></name><name><surname>Estrada</surname><given-names>A.</given-names></name><name><surname>Epling</surname><given-names>B.</given-names></name><name><surname>Hart</surname><given-names>E.E.</given-names></name><name><surname>Lee</surname><given-names>C.A.</given-names></name><name><surname>Baqi</surname><given-names>Y.</given-names></name><name><surname>M&#252;ller</surname><given-names>C.E.</given-names></name><name><surname>Correa</surname><given-names>M.</given-names></name><name><surname>Salamone</surname><given-names>J.D.</given-names></name></person-group><article-title>Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task.</article-title><source>Psychopharmacology (Berl.)</source><year>2014</year><volume>231</volume><issue>4</issue><fpage>727</fpage><lpage>736</lpage><comment>[http://dx.doi.org/10.1007/s00213-013-3285-4]. [PMID: 24136220].</comment><pub-id pub-id-type="pmid">24136220</pub-id></element-citation></ref><ref id="r136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Parekh</surname><given-names>S.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Hu</surname><given-names>X.P.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings.</article-title><source>Brain Behav. Immun.</source><year>2015</year><volume>46</volume><fpage>17</fpage><lpage>22</lpage><comment>[http://dx. doi.org/10.1016/j.bbi.2014.12.004]. [PMID: 25500218].</comment><pub-id pub-id-type="pmid">25500218</pub-id></element-citation></ref><ref id="r137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Pace</surname><given-names>T.W.</given-names></name><name><surname>Parekh</surname><given-names>S.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Hu</surname><given-names>X.P.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><issue>7</issue><fpage>1777</fpage><lpage>1785</lpage><comment>[http://dx.doi.org/10.1038/npp.2014.25]. [PMID: 24481242].</comment><pub-id pub-id-type="pmid">24481242</pub-id></element-citation></ref><ref id="r138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumai</surname><given-names>T.</given-names></name><name><surname>Tateishi</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Kobayashi</surname><given-names>S.</given-names></name></person-group><article-title>Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats.</article-title><source>Life Sci.</source><year>2000</year><volume>67</volume><issue>6</issue><fpage>663</fpage><lpage>669</lpage><comment>[http://dx.doi.org/10.1016/S0024-3205(00)00660-3]. [PMID: 12659172].</comment><pub-id pub-id-type="pmid">12659172</pub-id></element-citation></ref><ref id="r139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamata</surname><given-names>M.</given-names></name><name><surname>Higuchi</surname><given-names>H.</given-names></name><name><surname>Yoshimoto</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name></person-group><article-title>Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain.</article-title><source>Eur. Neuropsychopharmacol.</source><year>2000</year><volume>10</volume><issue>2</issue><fpage>129</fpage><lpage>132</lpage><comment>[http://dx.doi.org/10.1016/ S0924-977X(99)00067-X]. [PMID: 10706995].</comment><pub-id pub-id-type="pmid">10706995</pub-id></element-citation></ref><ref id="r140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>E.</given-names></name><name><surname>Yokoyama</surname><given-names>M.</given-names></name><name><surname>Semba</surname><given-names>J.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name><name><surname>Miyaoka</surname><given-names>H.</given-names></name></person-group><article-title>Chronic intraperitoneal injection of interferon-alpha reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate.</article-title><source>Psychiatry Clin. Neurosci.</source><year>2006</year><volume>60</volume><issue>4</issue><fpage>499</fpage><lpage>506</lpage><comment>[http://dx.doi. org/10.1111/j.1440-1819.2006.01538.x]. [PMID: 16884454].</comment><pub-id pub-id-type="pmid">16884454</pub-id></element-citation></ref><ref id="r141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuto</surname><given-names>H.</given-names></name><name><surname>Kataoka</surname><given-names>Y.</given-names></name><name><surname>Horikawa</surname><given-names>T.</given-names></name><name><surname>Fujihara</surname><given-names>N.</given-names></name><name><surname>Oishi</surname><given-names>R.</given-names></name></person-group><article-title>Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.</article-title><source>Brain Res.</source><year>1997</year><volume>747</volume><issue>2</issue><fpage>348</fpage><lpage>351</lpage><comment>[http://dx.doi.org/10.1016/S0006-8993(96)01371-6]. [PMID: 9046014].</comment><pub-id pub-id-type="pmid">9046014</pub-id></element-citation></ref><ref id="r142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loftis</surname><given-names>J.M.</given-names></name><name><surname>Hauser</surname><given-names>P.</given-names></name><name><surname>Macey</surname><given-names>T.A.</given-names></name><name><surname>Lowe</surname><given-names>J.D.</given-names></name></person-group><article-title>Can rodents be used to model interferon-alpha-induced depressive symptoms?</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2006</year><volume>30</volume><issue>7</issue><fpage>1364</fpage><lpage>1365</lpage><comment>[http://dx.doi.org/10.1016/j.pnpbp.2006.04.004]. [PMID: 16682106].</comment><pub-id pub-id-type="pmid">16682106</pub-id></element-citation></ref><ref id="r143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Campbell</surname><given-names>I.L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system.</article-title><source>Mol. Psychiatry</source><year>2008</year><volume>13</volume><issue>3</issue><fpage>293</fpage><lpage>301</lpage><comment>[http://dx.doi.org/10.1038/ sj.mp.4002013]. [PMID: 17486106].</comment><pub-id pub-id-type="pmid">17486106</pub-id></element-citation></ref><ref id="r144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loftis</surname><given-names>J.M.</given-names></name><name><surname>Wall</surname><given-names>J.M.</given-names></name><name><surname>Pagel</surname><given-names>R.L.</given-names></name><name><surname>Hauser</surname><given-names>P.</given-names></name></person-group><article-title>Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats.</article-title><source>Psychoneuroendocrinology</source><year>2006</year><volume>31</volume><issue>10</issue><fpage>1289</fpage><lpage>1294</lpage><comment>[http://dx.doi.org/10.1016/j.psyneuen.2006.07.006]. [PMID: 17049181].</comment><pub-id pub-id-type="pmid">17049181</pub-id></element-citation></ref><ref id="r145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blalock</surname><given-names>J.E.</given-names></name><name><surname>Smith</surname><given-names>E.M.</given-names></name></person-group><article-title>Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity.</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1981</year><volume>101</volume><issue>2</issue><fpage>472</fpage><lpage>478</lpage><comment>[http://dx.doi.org/10.1016/ 0006-291X(81)91284-5]. [PMID: 6171272].</comment><pub-id pub-id-type="pmid">6171272</pub-id></element-citation></ref><ref id="r146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>B.T.</given-names></name><name><surname>Huo</surname><given-names>Y.Y.</given-names></name><name><surname>Lu</surname><given-names>J.G.</given-names></name><name><surname>Tansey</surname><given-names>L.W.</given-names></name><name><surname>Levin</surname><given-names>V.A.</given-names></name></person-group><article-title>Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha.</article-title><source>Pharmacol. Biochem. Behav.</source><year>1992</year><volume>42</volume><issue>1</issue><fpage>57</fpage><lpage>60</lpage><comment>[http://dx.doi.org/10.1016/0091-3057(92)90446-M]. [PMID: 1528947].</comment><pub-id pub-id-type="pmid">1528947</pub-id></element-citation></ref><ref id="r147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.Y.</given-names></name><name><surname>Zeng</surname><given-names>X.Y.</given-names></name><name><surname>Fan</surname><given-names>G.X.</given-names></name><name><surname>Yuan</surname><given-names>Y.K.</given-names></name><name><surname>Tang</surname><given-names>J.S.</given-names></name></person-group><article-title>mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat.</article-title><source>Neurosci. Lett.</source><year>2006</year><volume>397</volume><issue>3</issue><fpage>254</fpage><lpage>258</lpage><comment>[http://dx.doi.org/10.1016/j.neulet. 2005.12.046]. [PMID: 16406668].</comment><pub-id pub-id-type="pmid">16406668</pub-id></element-citation></ref><ref id="r148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosel</surname><given-names>M.</given-names></name><name><surname>Bilkei-Gorzo</surname><given-names>A.</given-names></name><name><surname>Zawatzky</surname><given-names>R.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name><name><surname>Schlaepfer</surname><given-names>T.E.</given-names></name></person-group><article-title>Pegylated human interferon alpha 2a does not induce depression-associated changes in mice.</article-title><source>Psychiatry Res.</source><year>2011</year><volume>185</volume><issue>1-2</issue><fpage>243</fpage><lpage>247</lpage><comment>[http://dx.doi.org/10.1016/j.psychres.2009.10. 012]. [PMID: 20580843].</comment><pub-id pub-id-type="pmid">20580843</pub-id></element-citation></ref><ref id="r149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orsal</surname><given-names>A.S.</given-names></name><name><surname>Blois</surname><given-names>S.M.</given-names></name><name><surname>Bermpohl</surname><given-names>D.</given-names></name><name><surname>Schaefer</surname><given-names>M.</given-names></name><name><surname>Coquery</surname><given-names>N.</given-names></name></person-group><article-title>Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects.</article-title><source>Neuropsychobiology</source><year>2008</year><volume>58</volume><issue>3-4</issue><fpage>211</fpage><lpage>222</lpage><comment>[http://dx.doi. org/10.1159/000201718]. [PMID: 19212136].</comment><pub-id pub-id-type="pmid">19212136</pub-id></element-citation></ref><ref id="r150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname><given-names>B.</given-names></name><name><surname>Hickey</surname><given-names>B.</given-names></name><name><surname>Kelleher</surname><given-names>D.</given-names></name><name><surname>O&#8217;Dwyer</surname><given-names>A.M.</given-names></name><name><surname>O&#8217;Mara</surname><given-names>S.M.</given-names></name></person-group><article-title>The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats.</article-title><source>Behav. Brain Res.</source><year>2007</year><volume>182</volume><issue>1</issue><fpage>80</fpage><lpage>87</lpage><comment>[http://dx.doi.org/10.1016/j.bbr.2007. 05.005]. [PMID: 17588681].</comment><pub-id pub-id-type="pmid">17588681</pub-id></element-citation></ref><ref id="r151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L.S.</given-names></name><name><surname>Hitoshi</surname><given-names>S.</given-names></name><name><surname>Kaneko</surname><given-names>N.</given-names></name><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Miyakawa</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Kalinke</surname><given-names>U.</given-names></name><name><surname>Kudo</surname><given-names>K.</given-names></name><name><surname>Kanba</surname><given-names>S.</given-names></name><name><surname>Ikenaka</surname><given-names>K.</given-names></name><name><surname>Sawamoto</surname><given-names>K.</given-names></name></person-group><article-title>Mechanisms for interferon-&#945;-induced depression and neural stem cell dysfunction.</article-title><source>Stem Cell Reports</source><year>2014</year><volume>3</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><comment>[http://dx.doi.org/10.1016/j.stemcr.2014.05.015]. [PMID: 25068123].</comment><pub-id pub-id-type="pmid">25068123</pub-id></element-citation></ref><ref id="r152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Luan</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Probable involvement of p11 with interferon alpha induced depression.</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>17029</fpage><comment>[http://dx.doi.org/10.1038/srep17029]. [PMID: 26821757].</comment><pub-id pub-id-type="pmid">26821757</pub-id></element-citation></ref><ref id="r153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>M.</given-names></name><name><surname>Kitano</surname><given-names>Y.</given-names></name><name><surname>Komiyama</surname><given-names>C.</given-names></name><name><surname>Hirohashi</surname><given-names>M.</given-names></name><name><surname>Kohno</surname><given-names>M.</given-names></name><name><surname>Moriyama</surname><given-names>M.</given-names></name><name><surname>Takasuna</surname><given-names>K.</given-names></name></person-group><article-title>Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system.</article-title><source>Brain Res.</source><year>2000</year><volume>852</volume><issue>2</issue><fpage>482</fpage><lpage>484</lpage><comment>[http://dx.doi. org/10.1016/S0006-8993(99)02235-0]. [PMID: 10678778].</comment><pub-id pub-id-type="pmid">10678778</pub-id></element-citation></ref><ref id="r154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>M.</given-names></name><name><surname>Kitano</surname><given-names>Y.</given-names></name><name><surname>Komiyama</surname><given-names>C.</given-names></name><name><surname>Takasuna</surname><given-names>K.</given-names></name></person-group><article-title>Human interferon-alpha increases immobility in the forced swimming test in rats.</article-title><source>Psychopharmacology (Berl.)</source><year>2000</year><volume>148</volume><issue>1</issue><fpage>106</fpage><lpage>110</lpage><comment>[http://dx.doi.org/10.1007/s002130050031]. [PMID: 10663424].</comment><pub-id pub-id-type="pmid">10663424</pub-id></element-citation></ref><ref id="r155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Alagbe</surname><given-names>O.</given-names></name><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Mook</surname><given-names>D.</given-names></name><name><surname>Freeman</surname><given-names>A.A.</given-names></name><name><surname>Sanchez</surname><given-names>M.M.</given-names></name><name><surname>Kalin</surname><given-names>N.H.</given-names></name><name><surname>Ratti</surname><given-names>E.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.</article-title><source>Biol. Psychiatry</source><year>2007</year><volume>62</volume><issue>11</issue><fpage>1324</fpage><lpage>1333</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2007.05.026]. [PMID: 17678633].</comment><pub-id pub-id-type="pmid">17678633</pub-id></element-citation></ref><ref id="r156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenzweig-Lipson</surname><given-names>S.</given-names></name><name><surname>Hesterberg</surname><given-names>P.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name></person-group><article-title>Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.</article-title><source>Psychopharmacology (Berl.)</source><year>1994</year><volume>116</volume><issue>1</issue><fpage>9</fpage><lpage>18</lpage><comment>[http://dx.doi.org/ 10.1007/BF02244865]. [PMID: 7862937].</comment><pub-id pub-id-type="pmid">7862937</pub-id></element-citation></ref><ref id="r157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>W.T.</given-names><suffix>Jr</suffix></name><name><surname>Eising</surname><given-names>R.G.</given-names></name><name><surname>Moran</surname><given-names>E.C.</given-names></name><name><surname>Suomi</surname><given-names>S.J.</given-names></name><name><surname>Harlow</surname><given-names>H.F.</given-names></name></person-group><article-title>Effects of reserpine on the social behavior of rhesus monkeys.</article-title><source>Dis. Nerv. Syst.</source><year>1971</year><volume>32</volume><issue>11</issue><fpage>735</fpage><lpage>741</lpage><comment>[PMID: 5002259].</comment><pub-id pub-id-type="pmid">5002259</pub-id></element-citation></ref><ref id="r158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yohn</surname><given-names>S.E.</given-names></name><name><surname>Lopez-Cruz</surname><given-names>L.</given-names></name><name><surname>Hutson</surname><given-names>P.H.</given-names></name><name><surname>Correa</surname><given-names>M.</given-names></name><name><surname>Salamone</surname><given-names>J.D.</given-names></name></person-group><article-title>Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.</article-title><source>Psychopharmacology (Berl.)</source><year>2016</year><volume>233</volume><issue>6</issue><fpage>949</fpage><lpage>960</lpage><comment>[http://dx.doi.org/ 10.1007/s00213-015-4176-7]. [PMID: 26694811].</comment><pub-id pub-id-type="pmid">26694811</pub-id></element-citation></ref><ref id="r159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonsall</surname><given-names>D.R.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Tocci</surname><given-names>C.</given-names></name><name><surname>Ndiaye</surname><given-names>A.</given-names></name><name><surname>Petronzio</surname><given-names>A.</given-names></name><name><surname>McKay-Corkum</surname><given-names>G.</given-names></name><name><surname>Molyneux</surname><given-names>P.C.</given-names></name><name><surname>Scammell</surname><given-names>T.E.</given-names></name><name><surname>Harrington</surname><given-names>M.E.</given-names></name></person-group><article-title>Suppression of locomotor activity in female C57Bl/6J mice treated with interleukin-1&#946;: Investigating a method for the study of fatigue in laboratory animals.</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>10</issue><fpage>e0140678</fpage><comment>[http://dx.doi.org/10.1371/journal.pone.0140678]. [PMID: 26469939].</comment><pub-id pub-id-type="pmid">26469939</pub-id></element-citation></ref><ref id="r160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vichaya</surname><given-names>E.G.</given-names></name><name><surname>Hunt</surname><given-names>S.C.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name></person-group><article-title>Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice.</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><issue>12</issue><fpage>2884</fpage><lpage>2890</lpage><comment>[http://dx.doi.org/10.1038/npp.2014.141]. [PMID: 24917202].</comment><pub-id pub-id-type="pmid">24917202</pub-id></element-citation></ref><ref id="r161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Hernandez</surname><given-names>C.R.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Levodopa reverses cytokine-induced reductions in striatal dopamine release.</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2015</year><volume>18</volume><issue>4</issue><fpage>pyu084</fpage><comment>[http://dx.doi.org/ 10.1093/ijnp/pyu084]. [PMID: 25638816].</comment><pub-id pub-id-type="pmid">25638816</pub-id></element-citation></ref><ref id="r162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Block</surname><given-names>M.L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Breese</surname><given-names>G.R.</given-names></name><name><surname>Hong</surname><given-names>J.S.</given-names></name><name><surname>Knapp</surname><given-names>D.J.</given-names></name><name><surname>Crews</surname><given-names>F.T.</given-names></name></person-group><article-title>Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration.</article-title><source>Glia</source><year>2007</year><volume>55</volume><issue>5</issue><fpage>453</fpage><lpage>462</lpage><comment>[http://dx.doi.org/10.1002/glia.20467]. [PMID: 17203472].</comment><pub-id pub-id-type="pmid">17203472</pub-id></element-citation></ref><ref id="r163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinert</surname><given-names>K.R.</given-names></name><name><surname>Umphlet</surname><given-names>C.D.</given-names></name><name><surname>Quattlebaum</surname><given-names>A.</given-names></name><name><surname>Boger</surname><given-names>H.A.</given-names></name></person-group><article-title>Short-term effects of an endotoxin on substantia nigra dopamine neurons.</article-title><source>Brain Res.</source><year>2014</year><volume>1557</volume><fpage>164</fpage><lpage>170</lpage><comment>[http://dx.doi.org/10.1016/j. brainres.2014.02.005]. [PMID: 24513404].</comment><pub-id pub-id-type="pmid">24513404</pub-id></element-citation></ref><ref id="r164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>K.Y.</given-names></name><name><surname>Shou</surname><given-names>S.S.</given-names></name><name><surname>Lin</surname><given-names>Y.X.</given-names></name><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Chiang</surname><given-names>C.Y.</given-names></name><name><surname>Yeh</surname><given-names>C.Y.</given-names></name></person-group><article-title>Effect of Ginkgo biloba extract on lipopolysaccharide-induced anhedonic depressive-like behavior in male rats.</article-title><source>Phytother. Res.</source><year>2015</year><volume>29</volume><issue>2</issue><fpage>260</fpage><lpage>266</lpage><comment>[http://dx.doi.org/10.1002/ptr.5247]. [PMID: 25346240].</comment><pub-id pub-id-type="pmid">25346240</pub-id></element-citation></ref><ref id="r165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Heesch</surname><given-names>F.</given-names></name><name><surname>Prins</surname><given-names>J.</given-names></name><name><surname>Konsman</surname><given-names>J.P.</given-names></name><name><surname>Korte-Bouws</surname><given-names>G.A.</given-names></name><name><surname>Westphal</surname><given-names>K.G.</given-names></name><name><surname>Rybka</surname><given-names>J.</given-names></name><name><surname>Olivier</surname><given-names>B.</given-names></name><name><surname>Kraneveld</surname><given-names>A.D.</given-names></name><name><surname>Korte</surname><given-names>S.M.</given-names></name></person-group><article-title>Lipopolysaccharide increases degradation of central monoamines: an <italic>in vivo</italic> microdialysis study in the nucleus accumbens and medial prefrontal cortex of mice.</article-title><source>Eur. J. Pharmacol.</source><year>2014</year><volume>725</volume><fpage>55</fpage><lpage>63</lpage><comment>[http://dx.doi.org/10.1016/j.ejphar.2014.01.014]. [PMID: 24444442].</comment><pub-id pub-id-type="pmid">24444442</pub-id></element-citation></ref><ref id="r166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Heesch</surname><given-names>F.</given-names></name><name><surname>Prins</surname><given-names>J.</given-names></name><name><surname>Konsman</surname><given-names>J.P.</given-names></name><name><surname>Westphal</surname><given-names>K.G.</given-names></name><name><surname>Olivier</surname><given-names>B.</given-names></name><name><surname>Kraneveld</surname><given-names>A.D.</given-names></name><name><surname>Korte</surname><given-names>S.M.</given-names></name></person-group><article-title>Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: an intracranial self-stimulation study.</article-title><source>Brain Behav. Immun.</source><year>2013</year><volume>29</volume><fpage>98</fpage><lpage>103</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2012.12.013]. [PMID: 23274951].</comment><pub-id pub-id-type="pmid">23274951</pub-id></element-citation></ref><ref id="r167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connor</surname><given-names>J.C.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Andr&#233;</surname><given-names>C.</given-names></name><name><surname>Moreau</surname><given-names>M.</given-names></name><name><surname>Lestage</surname><given-names>J.</given-names></name><name><surname>Castanon</surname><given-names>N.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name></person-group><article-title>Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.</article-title><source>Mol. Psychiatry</source><year>2009</year><volume>14</volume><issue>5</issue><fpage>511</fpage><lpage>522</lpage><comment>[http://dx.doi.org/10.1038/sj.mp.4002148]. [PMID: 18195714].</comment><pub-id pub-id-type="pmid">18195714</pub-id></element-citation></ref><ref id="r168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenois</surname><given-names>F.</given-names></name><name><surname>Moreau</surname><given-names>M.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>J.</given-names></name><name><surname>Lawson</surname><given-names>M.</given-names></name><name><surname>Micon</surname><given-names>C.</given-names></name><name><surname>Lestage</surname><given-names>J.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Castanon</surname><given-names>N.</given-names></name></person-group><article-title>Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior.</article-title><source>Psychoneuroendocrinology</source><year>2007</year><volume>32</volume><issue>5</issue><fpage>516</fpage><lpage>531</lpage><comment>[http://dx.doi.org/10.1016/ j.psyneuen.2007.03.005]. [PMID: 17482371].</comment><pub-id pub-id-type="pmid">17482371</pub-id></element-citation></ref><ref id="r169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>C.A.</given-names></name></person-group><article-title>Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed.</article-title><source>J. Endotoxin Res.</source><year>2004</year><volume>10</volume><issue>4</issue><fpage>201</fpage><lpage>222</lpage><comment>[PMID: 15373964].</comment><pub-id pub-id-type="pmid">15373964</pub-id></element-citation></ref><ref id="r170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrot</surname><given-names>M.</given-names></name><name><surname>Marinelli</surname><given-names>M.</given-names></name><name><surname>Abrous</surname><given-names>D.N.</given-names></name><name><surname>Roug&#233;-Pont</surname><given-names>F.</given-names></name><name><surname>Le Moal</surname><given-names>M.</given-names></name><name><surname>Piazza</surname><given-names>P.V.</given-names></name></person-group><article-title>The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent.</article-title><source>Eur. J. Neurosci.</source><year>2000</year><volume>12</volume><issue>3</issue><fpage>973</fpage><lpage>979</lpage><comment>[http://dx.doi.org/10.1046/j.1460-9568.2000.00996.x]. [PMID: 10762327].</comment><pub-id pub-id-type="pmid">10762327</pub-id></element-citation></ref><ref id="r171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavicky</surname><given-names>J.</given-names></name><name><surname>Dunn</surname><given-names>A.J.</given-names></name></person-group><article-title>Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis.</article-title><source>J. Neurochem.</source><year>1993</year><volume>60</volume><issue>2</issue><fpage>602</fpage><lpage>612</lpage><comment>[http://dx.doi.org/10.1111/j.1471-4159.1993. tb03191.x]. [PMID: 7678287].</comment><pub-id pub-id-type="pmid">7678287</pub-id></element-citation></ref><ref id="r172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekaouche</surname><given-names>M.</given-names></name><name><surname>Siaud</surname><given-names>P.</given-names></name><name><surname>Givalois</surname><given-names>L.</given-names></name><name><surname>Barbanel</surname><given-names>G.</given-names></name><name><surname>Malaval</surname><given-names>F.</given-names></name><name><surname>Maurel</surname><given-names>D.</given-names></name><name><surname>Assenmacher</surname><given-names>I.</given-names></name><name><surname>Ixart</surname><given-names>G.</given-names></name></person-group><article-title>Different responses of plasma ACTH and corticosterone and of plasma interleukin-1 beta to single and recurrent endotoxin challenges.</article-title><source>J. Leukoc. Biol.</source><year>1996</year><volume>59</volume><issue>3</issue><fpage>341</fpage><lpage>346</lpage><comment>[http://dx.doi.org/10.1002/jlb.59.3.341]. [PMID: 8604011].</comment><pub-id pub-id-type="pmid">8604011</pub-id></element-citation></ref><ref id="r173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>I.</given-names></name><name><surname>Takamatsu</surname><given-names>Y.</given-names></name><name><surname>Moroji</surname><given-names>T.</given-names></name></person-group><article-title>The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: behavioural and biochemical studies.</article-title><source>Neuropeptides</source><year>1989</year><volume>13</volume><issue>3</issue><fpage>147</fpage><lpage>155</lpage><comment>[http://dx.doi.org/10. 1016/0143-4179(89)90085-1]. [PMID: 2785246].</comment><pub-id pub-id-type="pmid">2785246</pub-id></element-citation></ref><ref id="r174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juengling</surname><given-names>F.D.</given-names></name><name><surname>Ebert</surname><given-names>D.</given-names></name><name><surname>Gut</surname><given-names>O.</given-names></name><name><surname>Engelbrecht</surname><given-names>M.A.</given-names></name><name><surname>Rasenack</surname><given-names>J.</given-names></name><name><surname>Nitzsche</surname><given-names>E.U.</given-names></name><name><surname>Bauer</surname><given-names>J.</given-names></name><name><surname>Lieb</surname><given-names>K.</given-names></name></person-group><article-title>Prefrontal cortical hypometabolism during low-dose interferon alpha treatment.</article-title><source>Psychopharmacology (Berl.)</source><year>2000</year><volume>152</volume><issue>4</issue><fpage>383</fpage><lpage>389</lpage><comment>[http://dx.doi.org/ 10.1007/s002130000549]. [PMID: 11140330].</comment><pub-id pub-id-type="pmid">11140330</pub-id></element-citation></ref><ref id="r175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spetsieris</surname><given-names>P.G.</given-names></name><name><surname>Moeller</surname><given-names>J.R.</given-names></name><name><surname>Dhawan</surname><given-names>V.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Eidelberg</surname><given-names>D.</given-names></name></person-group><article-title>Visualizing the evolution of abnormal metabolic networks in the brain using PET.</article-title><source>Comput. Med. Imaging Graph.</source><year>1995</year><volume>19</volume><issue>3</issue><fpage>295</fpage><lpage>306</lpage><comment>[http://dx.doi.org/10.1016/0895-6111(95)00011-E]. [PMID: 7641174].</comment><pub-id pub-id-type="pmid">7641174</pub-id></element-citation></ref><ref id="r176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eidelberg</surname><given-names>D.</given-names></name><name><surname>Moeller</surname><given-names>J.R.</given-names></name><name><surname>Dhawan</surname><given-names>V.</given-names></name><name><surname>Spetsieris</surname><given-names>P.</given-names></name><name><surname>Takikawa</surname><given-names>S.</given-names></name><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Chaly</surname><given-names>T.</given-names></name><name><surname>Robeson</surname><given-names>W.</given-names></name><name><surname>Margouleff</surname><given-names>D.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group><article-title>The metabolic topography of parkinsonism.</article-title><source>J. Cereb. Blood Flow Metab.</source><year>1994</year><volume>14</volume><issue>5</issue><fpage>783</fpage><lpage>801</lpage><comment>[http://dx.doi.org/ 10.1038/jcbfm.1994.99]. [PMID: 8063874].</comment><pub-id pub-id-type="pmid">8063874</pub-id></element-citation></ref><ref id="r177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mentis</surname><given-names>M.J.</given-names></name><name><surname>McIntosh</surname><given-names>A.R.</given-names></name><name><surname>Perrine</surname><given-names>K.</given-names></name><name><surname>Dhawan</surname><given-names>V.</given-names></name><name><surname>Berlin</surname><given-names>B.</given-names></name><name><surname>Feigin</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>C.</given-names></name><name><surname>Mattis</surname><given-names>P.</given-names></name><name><surname>Eidelberg</surname><given-names>D.</given-names></name></person-group><article-title>Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson&#8217;s disease.</article-title><source>Am. J. Psychiatry</source><year>2002</year><volume>159</volume><issue>5</issue><fpage>746</fpage><lpage>754</lpage><comment>[http://dx.doi.org/10.1176/appi.ajp. 159.5.746]. [PMID: 11986127].</comment><pub-id pub-id-type="pmid">11986127</pub-id></element-citation></ref><ref id="r178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>T.</given-names></name><name><surname>DeLong</surname><given-names>M.R.</given-names></name></person-group><article-title>Oscillations in the basal ganglia.</article-title><source>Nature</source><year>1999</year><volume>400</volume><issue>6745</issue><fpage>621</fpage><lpage>622</lpage><comment>[http://dx.doi.org/10.1038/ 23148]. [PMID: 10458157].</comment><pub-id pub-id-type="pmid">10458157</pub-id></element-citation></ref><ref id="r179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>T.</given-names></name><name><surname>DeLong</surname><given-names>M.R.</given-names></name></person-group><article-title>Functional neuroanatomy of the basal ganglia in Parkinson&#8217;s disease.</article-title><source>Adv. Neurol.</source><year>2003</year><volume>91</volume><fpage>9</fpage><lpage>18</lpage><comment>[PMID: 12442660].</comment><pub-id pub-id-type="pmid">12442660</pub-id></element-citation></ref><ref id="r180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>G.</given-names></name><name><surname>Fromm</surname><given-names>S.</given-names></name><name><surname>Carlson</surname><given-names>P.J.</given-names></name><name><surname>Luckenbaugh</surname><given-names>D.A.</given-names></name><name><surname>Waldeck</surname><given-names>T.</given-names></name><name><surname>Geraci</surname><given-names>M.</given-names></name><name><surname>Roiser</surname><given-names>J.P.</given-names></name><name><surname>Neumeister</surname><given-names>A.</given-names></name><name><surname>Meyers</surname><given-names>N.</given-names></name><name><surname>Charney</surname><given-names>D.S.</given-names></name><name><surname>Drevets</surname><given-names>W.C.</given-names></name></person-group><article-title>Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects.</article-title><source>Arch. Gen. Psychiatry</source><year>2008</year><volume>65</volume><issue>5</issue><fpage>521</fpage><lpage>531</lpage><comment>[http://dx.doi.org/10.1001/archpsyc.65.5.521]. [PMID: 18458204].</comment><pub-id pub-id-type="pmid">18458204</pub-id></element-citation></ref><ref id="r181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>J.</given-names></name><name><surname>Raedler</surname><given-names>T.</given-names></name><name><surname>Rose</surname><given-names>M.</given-names></name><name><surname>Hand</surname><given-names>I.</given-names></name><name><surname>Gl&#228;scher</surname><given-names>J.</given-names></name><name><surname>B&#252;chel</surname><given-names>C.</given-names></name></person-group><article-title>Pathological gambling is linked to reduced activation of the mesolimbic reward system.</article-title><source>Nat. Neurosci.</source><year>2005</year><volume>8</volume><issue>2</issue><fpage>147</fpage><lpage>148</lpage><comment>[http://dx.doi.org/10.1038/nn1378]. [PMID: 15643429].</comment><pub-id pub-id-type="pmid">15643429</pub-id></element-citation></ref><ref id="r182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowell</surname><given-names>N.G.</given-names></name><name><surname>Cooper</surname><given-names>E.A.</given-names></name><name><surname>Tibble</surname><given-names>J.</given-names></name><name><surname>Voon</surname><given-names>V.</given-names></name><name><surname>Critchley</surname><given-names>H.D.</given-names></name><name><surname>Cercignani</surname><given-names>M.</given-names></name><name><surname>Harrison</surname><given-names>N.A.</given-names></name></person-group><article-title>Acute changes in striatal microstructure predict the development of interferon-alpha induced fatigue.</article-title><source>Biol. Psychiatry</source><year>2016</year><volume>79</volume><issue>4</issue><fpage>320</fpage><lpage>328</lpage><comment>[http://dx.doi.org/10. 1016/j.biopsych.2015.05.015]. [PMID: 26169252].</comment><pub-id pub-id-type="pmid">26169252</pub-id></element-citation></ref><ref id="r183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjork</surname><given-names>J.M.</given-names></name><name><surname>Grant</surname><given-names>S.J.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Hommer</surname><given-names>D.W.</given-names></name></person-group><article-title>Dietary tyrosine/phenylalanine depletion effects on behavioral and brain signatures of human motivational processing.</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><issue>3</issue><fpage>595</fpage><lpage>604</lpage><comment>[http://dx.doi.org/10.1038/npp.2013. 232]. [PMID: 23995581].</comment><pub-id pub-id-type="pmid">23995581</pub-id></element-citation></ref><ref id="r184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treadway</surname><given-names>M.T.</given-names></name></person-group><article-title>Association between interleukin-6 and striatal prediction-error signals following acute stress in healthy females.</article-title><source>Biol. Psychiatry</source><comment>in press</comment></element-citation></ref><ref id="r185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pessiglione</surname><given-names>M.</given-names></name><name><surname>Seymour</surname><given-names>B.</given-names></name><name><surname>Flandin</surname><given-names>G.</given-names></name><name><surname>Dolan</surname><given-names>R.J.</given-names></name><name><surname>Frith</surname><given-names>C.D.</given-names></name></person-group><article-title>Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans.</article-title><source>Nature</source><year>2006</year><volume>442</volume><issue>7106</issue><fpage>1042</fpage><lpage>1045</lpage><comment>[http://dx.doi.org/10.1038/nature05051]. [PMID: 16929307].</comment><pub-id pub-id-type="pmid">16929307</pub-id></element-citation></ref><ref id="r186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N.A.</given-names></name><name><surname>Cercignani</surname><given-names>M.</given-names></name><name><surname>Voon</surname><given-names>V.</given-names></name><name><surname>Critchley</surname><given-names>H.D.</given-names></name></person-group><article-title>Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants.</article-title><source>Neuropsychopharmacology</source><year>2015</year><volume>40</volume><issue>4</issue><fpage>831</fpage><lpage>838</lpage><comment>[http://dx.doi.org/10.1038/npp.2014.222]. [PMID: 25154706].</comment><pub-id pub-id-type="pmid">25154706</pub-id></element-citation></ref><ref id="r187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>T.K.</given-names></name><name><surname>Muscatell</surname><given-names>K.A.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name><name><surname>Moieni</surname><given-names>M.</given-names></name><name><surname>Dutcher</surname><given-names>J.M.</given-names></name><name><surname>Jevtic</surname><given-names>I.</given-names></name><name><surname>Breen</surname><given-names>E.C.</given-names></name><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name></person-group><article-title>The role of the ventral striatum in inflammatory-induced approach toward support figures.</article-title><source>Brain Behav. Immun.</source><year>2015</year><volume>44</volume><fpage>247</fpage><lpage>252</lpage><comment>[http://dx.doi. org/10.1016/j.bbi.2014.10.006]. [PMID: 25459101].</comment><pub-id pub-id-type="pmid">25459101</pub-id></element-citation></ref><ref id="r188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscatell</surname><given-names>K.A.</given-names></name><name><surname>Moieni</surname><given-names>M.</given-names></name><name><surname>Inagaki</surname><given-names>T.K.</given-names></name><name><surname>Dutcher</surname><given-names>J.M.</given-names></name><name><surname>Jevtic</surname><given-names>I.</given-names></name><name><surname>Breen</surname><given-names>E.C.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name></person-group><article-title>Exposure to an inflammatory challenge enhances neural sensitivity to negative and positive social feedback.</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>57</volume><fpage>21</fpage><lpage>29</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2016.03.022]. [PMID: 27032568].</comment><pub-id pub-id-type="pmid">27032568</pub-id></element-citation></ref><ref id="r189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullmann</surname><given-names>J.S.</given-names></name><name><surname>Grigoleit</surname><given-names>J.S.</given-names></name><name><surname>Lichte</surname><given-names>P.</given-names></name><name><surname>Kobbe</surname><given-names>P.</given-names></name><name><surname>Rosenberger</surname><given-names>C.</given-names></name><name><surname>Banner</surname><given-names>C.</given-names></name><name><surname>Wolf</surname><given-names>O.T.</given-names></name><name><surname>Engler</surname><given-names>H.</given-names></name><name><surname>Oberbeck</surname><given-names>R.</given-names></name><name><surname>Elsenbruch</surname><given-names>S.</given-names></name><name><surname>Bingel</surname><given-names>U.</given-names></name><name><surname>Forsting</surname><given-names>M.</given-names></name><name><surname>Gizewski</surname><given-names>E.R.</given-names></name><name><surname>Schedlowski</surname><given-names>M.</given-names></name></person-group><article-title>Neural response to emotional stimuli during experimental human endotoxemia.</article-title><source>Hum. Brain Mapp.</source><year>2013</year><volume>34</volume><issue>9</issue><fpage>2217</fpage><lpage>2227</lpage><comment>[http://dx. doi.org/10.1002/hbm.22063]. [PMID: 22461242].</comment><pub-id pub-id-type="pmid">22461242</pub-id></element-citation></ref><ref id="r190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaasinen</surname><given-names>V.</given-names></name><name><surname>Nurmi</surname><given-names>E.</given-names></name><name><surname>Br&#252;ck</surname><given-names>A.</given-names></name><name><surname>Eskola</surname><given-names>O.</given-names></name><name><surname>Bergman</surname><given-names>J.</given-names></name><name><surname>Solin</surname><given-names>O.</given-names></name><name><surname>Rinne</surname><given-names>J.O.</given-names></name></person-group><article-title>Increased frontal [(18)F]fluorodopa uptake in early Parkinson&#8217;s disease: sex differences in the prefrontal cortex.</article-title><source>Brain</source><year>2001</year><volume>124</volume><issue>Pt 6</issue><fpage>1125</fpage><lpage>1130</lpage><comment>[http://dx.doi.org/10.1093/brain/124.6. 1125]. [PMID: 11353728].</comment><pub-id pub-id-type="pmid">11353728</pub-id></element-citation></ref><ref id="r191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumakura</surname><given-names>Y.</given-names></name><name><surname>Cumming</surname><given-names>P.</given-names></name></person-group><article-title>PET studies of cerebral levoaaaaaaaaadopa metabolism: a review of clinical findings and modeling approaches.</article-title><source>Neuroscientist</source><year>2009</year><volume>15</volume><issue>6</issue><fpage>635</fpage><lpage>650</lpage><comment>[http://dx.doi.org/10.1177/ 1073858409338217]. [PMID: 19793723].</comment><pub-id pub-id-type="pmid">19793723</pub-id></element-citation></ref><ref id="r192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leenders</surname><given-names>K.L.</given-names></name><name><surname>Palmer</surname><given-names>A.J.</given-names></name><name><surname>Quinn</surname><given-names>N.</given-names></name><name><surname>Clark</surname><given-names>J.C.</given-names></name><name><surname>Firnau</surname><given-names>G.</given-names></name><name><surname>Garnett</surname><given-names>E.S.</given-names></name><name><surname>Nahmias</surname><given-names>C.</given-names></name><name><surname>Jones</surname><given-names>T.</given-names></name><name><surname>Marsden</surname><given-names>C.D.</given-names></name></person-group><article-title>Brain dopamine metabolism in patients with Parkinson&#8217;s disease measured with positron emission tomography.</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>1986</year><volume>49</volume><issue>8</issue><fpage>853</fpage><lpage>860</lpage><comment>[http://dx.doi.org/10.1136/jnnp.49. 8.853]. [PMID: 3091770].</comment><pub-id pub-id-type="pmid">3091770</pub-id></element-citation></ref><ref id="r193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumakura</surname><given-names>Y.</given-names></name><name><surname>Gjedde</surname><given-names>A.</given-names></name><name><surname>Danielsen</surname><given-names>E.H.</given-names></name><name><surname>Christensen</surname><given-names>S.</given-names></name><name><surname>Cumming</surname><given-names>P.</given-names></name></person-group><article-title>Dopamine storage capacity in caudate and putamen of patients with early Parkinson&#8217;s disease: correlation with asymmetry of motor symptoms.</article-title><source>J. Cereb. Blood Flow Metab.</source><year>2006</year><volume>26</volume><issue>3</issue><fpage>358</fpage><lpage>370</lpage><comment>[http://dx.doi.org/10.1038/sj.jcbfm.9600202]. [PMID: 16079784].</comment><pub-id pub-id-type="pmid">16079784</pub-id></element-citation></ref><ref id="r194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Merali</surname><given-names>Z.</given-names></name><name><surname>Anisman</surname><given-names>H.</given-names></name></person-group><article-title>Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment.</article-title><source>Neuroscience</source><year>1999</year><volume>88</volume><issue>3</issue><fpage>823</fpage><lpage>836</lpage><comment>[http://dx.doi.org/10.1016/S0306-4522(98)00271-1]. [PMID: 10363820].</comment><pub-id pub-id-type="pmid">10363820</pub-id></element-citation></ref><ref id="r195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De La Garza</surname><given-names>R.I.I.</given-names></name><name><surname>Asnis</surname><given-names>G.M.</given-names></name></person-group><article-title>The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus.</article-title><source>Brain Res.</source><year>2003</year><volume>977</volume><issue>1</issue><fpage>70</fpage><lpage>79</lpage><comment>[http://dx.doi.org/10. 1016/S0006-8993(03)02757-4]. [PMID: 12788515].</comment><pub-id pub-id-type="pmid">12788515</pub-id></element-citation></ref><ref id="r196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>A.J.</given-names></name></person-group><article-title>Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone.</article-title><source>Life Sci.</source><year>1988</year><volume>43</volume><issue>5</issue><fpage>429</fpage><lpage>435</lpage><comment>[http://dx. doi.org/10.1016/0024-3205(88)90522-X]. [PMID: 3260987].</comment><pub-id pub-id-type="pmid">3260987</pub-id></element-citation></ref><ref id="r197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrulli</surname><given-names>J.R.</given-names></name><name><surname>Kalish</surname><given-names>B.</given-names></name><name><surname>Nabulsi</surname><given-names>N.B.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Hannestad</surname><given-names>J.</given-names></name><name><surname>Morris</surname><given-names>E.D.</given-names></name></person-group><article-title>Systemic inflammation enhances stimulant-induced striatal dopamine elevation.</article-title><source>Transl. Psychiatry</source><year>2017</year><volume>7</volume><issue>3</issue><fpage>e1076</fpage><comment>[http://dx.doi.org/10.1038/tp.2017.18]. [PMID: 28350401].</comment><pub-id pub-id-type="pmid">28350401</pub-id></element-citation></ref><ref id="r198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Jones</surname><given-names>J.F.</given-names></name><name><surname>Drake</surname><given-names>D.F.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><name><surname>Unger</surname><given-names>E.R.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name></person-group><article-title>Decreased basal ganglia activation in subjects with chronic fatigue syndrome: association with symptoms of fatigue.</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>5</issue><fpage>e98156</fpage><comment>[http://dx.doi.org/10.1371/journal.pone. 0098156]. [PMID: 24858857].</comment><pub-id pub-id-type="pmid">24858857</pub-id></element-citation></ref><ref id="r199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haber</surname><given-names>S.N.</given-names></name><name><surname>Knutson</surname><given-names>B.</given-names></name></person-group><article-title>The reward circuit: linking primate anatomy and human imaging.</article-title><source>Neuropsychopharmacology</source><year>2010</year><volume>35</volume><issue>1</issue><fpage>4</fpage><lpage>26</lpage><comment>[http://dx.doi.org/10.1038/npp.2009.129]. [PMID: 19812543].</comment><pub-id pub-id-type="pmid">19812543</pub-id></element-citation></ref><ref id="r200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samanez-Larkin</surname><given-names>G.R.</given-names></name><name><surname>Knutson</surname><given-names>B.</given-names></name></person-group><article-title>Decision making in the ageing brain: changes in affective and motivational circuits.</article-title><source>Nat. Rev. Neurosci.</source><year>2015</year><volume>16</volume><issue>5</issue><fpage>278</fpage><lpage>289</lpage><comment>[http://dx.doi.org/10.1038/nrn3917]. [PMID: 25873038].</comment><pub-id pub-id-type="pmid">25873038</pub-id></element-citation></ref><ref id="r201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>S.J.</given-names></name><name><surname>Nestler</surname><given-names>E.J.</given-names></name></person-group><article-title>The brain reward circuitry in mood disorders.</article-title><source>Nat. Rev. Neurosci.</source><year>2013</year><volume>14</volume><issue>9</issue><fpage>609</fpage><lpage>625</lpage><comment>[http://dx.doi.org/ 10.1038/nrn3381]. [PMID: 23942470].</comment><pub-id pub-id-type="pmid">23942470</pub-id></element-citation></ref><ref id="r202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diekhof</surname><given-names>E.K.</given-names></name><name><surname>Kaps</surname><given-names>L.</given-names></name><name><surname>Falkai</surname><given-names>P.</given-names></name><name><surname>Gruber</surname><given-names>O.</given-names></name></person-group><article-title>The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing.</article-title><source>Neuropsychologia</source><year>2012</year><volume>50</volume><issue>7</issue><fpage>1252</fpage><lpage>1266</lpage><comment>[http://dx.doi.org/10.1016/j.neuropsychologia.2012.02.007]. [PMID: 22366111].</comment><pub-id pub-id-type="pmid">22366111</pub-id></element-citation></ref><ref id="r203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Fleischer</surname><given-names>C.C.</given-names></name><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Patel</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>X.P.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression.</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><issue>10</issue><fpage>1351</fpage><lpage>1357</lpage><comment>[http://dx.doi.org/10.1038/mp.2015.206]. [PMID: 26754953].</comment><pub-id pub-id-type="pmid">26754953</pub-id></element-citation></ref><ref id="r204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>J.C.</given-names></name><name><surname>Freund</surname><given-names>G.G.</given-names></name><name><surname>Johnson</surname><given-names>R.W.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name></person-group><article-title>From inflammation to sickness and depression: when the immune system subjugates the brain.</article-title><source>Nat. Rev. Neurosci.</source><year>2008</year><volume>9</volume><issue>1</issue><fpage>46</fpage><lpage>56</lpage><comment>[http://dx.doi.org/10.1038/nrn2297]. [PMID: 18073775].</comment><pub-id pub-id-type="pmid">18073775</pub-id></element-citation></ref><ref id="r205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Young</surname><given-names>M.R.</given-names></name></person-group><article-title>PTSD, a disorder with an immunological component.</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><fpage>219</fpage><comment>[http://dx.doi.org/ 10.3389/fimmu.2016.00219]. [PMID: 27375619].</comment><pub-id pub-id-type="pmid">27375619</pub-id></element-citation></ref><ref id="r206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>L.M.</given-names></name><name><surname>Rauch</surname><given-names>S.L.</given-names></name><name><surname>Pitman</surname><given-names>R.K.</given-names></name></person-group><article-title>Amygdala, medial prefrontal cortex, and hippocampal function in PTSD.</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2006</year><volume>1071</volume><fpage>67</fpage><lpage>79</lpage><comment>[http://dx.doi.org/10.1196/annals.1364.007]. [PMID: 16891563].</comment><pub-id pub-id-type="pmid">16891563</pub-id></element-citation></ref><ref id="r207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N.A.</given-names></name><name><surname>Brydon</surname><given-names>L.</given-names></name><name><surname>Walker</surname><given-names>C.</given-names></name><name><surname>Gray</surname><given-names>M.A.</given-names></name><name><surname>Steptoe</surname><given-names>A.</given-names></name><name><surname>Critchley</surname><given-names>H.D.</given-names></name></person-group><article-title>Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity.</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>66</volume><issue>5</issue><fpage>407</fpage><lpage>414</lpage><comment>[http://dx.doi.org/10.1016/j. biopsych.2009.03.015]. [PMID: 19423079].</comment><pub-id pub-id-type="pmid">19423079</pub-id></element-citation></ref><ref id="r208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>T.K.</given-names></name><name><surname>Muscatell</surname><given-names>K.A.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name><name><surname>Cole</surname><given-names>S.W.</given-names></name><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name></person-group><article-title>Inflammation selectively enhances amygdala activity to socially threatening images.</article-title><source>Neuroimage</source><year>2012</year><volume>59</volume><issue>4</issue><fpage>3222</fpage><lpage>3226</lpage><comment>[http://dx.doi.org/10.1016/j.neuroimage.2011.10.090]. [PMID: 22079507].</comment><pub-id pub-id-type="pmid">22079507</pub-id></element-citation></ref><ref id="r209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muscatell</surname><given-names>K.A.</given-names></name></person-group><article-title>Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress.</article-title><source>Brain Behav. Immun.</source><year>2014</year><comment>[PMID: 25016200].</comment></element-citation></ref><ref id="r210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N.A.</given-names></name><name><surname>Brydon</surname><given-names>L.</given-names></name><name><surname>Walker</surname><given-names>C.</given-names></name><name><surname>Gray</surname><given-names>M.A.</given-names></name><name><surname>Steptoe</surname><given-names>A.</given-names></name><name><surname>Dolan</surname><given-names>R.J.</given-names></name><name><surname>Critchley</surname><given-names>H.D.</given-names></name></person-group><article-title>Neural origins of human sickness in interoceptive responses to inflammation.</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>66</volume><issue>5</issue><fpage>415</fpage><lpage>422</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych.2009.03.007]. [PMID: 19409533].</comment><pub-id pub-id-type="pmid">19409533</pub-id></element-citation></ref><ref id="r211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koenigs</surname><given-names>M.</given-names></name><name><surname>Grafman</surname><given-names>J.</given-names></name></person-group><article-title>Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdala.</article-title><source>Neuroscientist</source><year>2009</year><volume>15</volume><issue>5</issue><fpage>540</fpage><lpage>548</lpage><comment>[http://dx.doi.org/10.1177/1073858409333072]. [PMID: 19359671].</comment><pub-id pub-id-type="pmid">19359671</pub-id></element-citation></ref><ref id="r212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connor</surname><given-names>M.F.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name><name><surname>Wellisch</surname><given-names>D.K.</given-names></name></person-group><article-title>When grief heats up: pro-inflammatory cytokines predict regional brain activation.</article-title><source>Neuroimage</source><year>2009</year><volume>47</volume><issue>3</issue><fpage>891</fpage><lpage>896</lpage><comment>[http://dx.doi.org/10.1016/j. neuroimage.2009.05.049]. [PMID: 19481155].</comment><pub-id pub-id-type="pmid">19481155</pub-id></element-citation></ref><ref id="r213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>A.</given-names></name><name><surname>Strigo</surname><given-names>I.A.</given-names></name><name><surname>Matthews</surname><given-names>S.C.</given-names></name><name><surname>Paulus</surname><given-names>M.P.</given-names></name><name><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>Initial evidence of a failure to activate right anterior insula during affective set shifting in posttraumatic stress disorder.</article-title><source>Psychosom. Med.</source><year>2009</year><volume>71</volume><issue>4</issue><fpage>373</fpage><lpage>377</lpage><comment>[http://dx.doi.org/10.1097/ PSY.0b013e3181a56ed8]. [PMID: 19398499].</comment><pub-id pub-id-type="pmid">19398499</pub-id></element-citation></ref><ref id="r214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>M.P.</given-names></name><name><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>An insular view of anxiety.</article-title><source>Biol. Psychiatry</source><year>2006</year><volume>60</volume><issue>4</issue><fpage>383</fpage><lpage>387</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2006.03.042]. [PMID: 16780813].</comment><pub-id pub-id-type="pmid">16780813</pub-id></element-citation></ref><ref id="r215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonzo</surname><given-names>G.A.</given-names></name><name><surname>Simmons</surname><given-names>A.N.</given-names></name><name><surname>Thorp</surname><given-names>S.R.</given-names></name><name><surname>Norman</surname><given-names>S.B.</given-names></name><name><surname>Paulus</surname><given-names>M.P.</given-names></name><name><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>Exaggerated and disconnected insular-amygdalar blood oxygenation level-dependent response to threat-related emotional faces in women with intimate-partner violence posttraumatic stress disorder.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>68</volume><issue>5</issue><fpage>433</fpage><lpage>441</lpage><comment>[http:// dx.doi.org/10.1016/j.biopsych.2010.04.028]. [PMID: 20573339].</comment><pub-id pub-id-type="pmid">20573339</pub-id></element-citation></ref><ref id="r216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name><name><surname>Inagaki</surname><given-names>T.K.</given-names></name><name><surname>Rameson</surname><given-names>L.T.</given-names></name><name><surname>Mashal</surname><given-names>N.M.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><article-title>An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences.</article-title><source>Neuroimage</source><year>2009</year><volume>47</volume><issue>3</issue><fpage>881</fpage><lpage>890</lpage><comment>[http://dx.doi.org/10.1016/j.neuroimage.2009.04. 040]. [PMID: 19376240].</comment><pub-id pub-id-type="pmid">19376240</pub-id></element-citation></ref><ref id="r217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J.</given-names></name><name><surname>Subramanyam</surname><given-names>K.</given-names></name><name><surname>Dellagioia</surname><given-names>N.</given-names></name><name><surname>Planeta-Wilson</surname><given-names>B.</given-names></name><name><surname>Weinzimmer</surname><given-names>D.</given-names></name><name><surname>Pittman</surname><given-names>B.</given-names></name><name><surname>Carson</surname><given-names>R.E.</given-names></name></person-group><article-title>Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans.</article-title><source>J. Nucl. Med.</source><year>2012</year><volume>53</volume><issue>4</issue><fpage>601</fpage><lpage>607</lpage><comment>[http://dx. doi.org/10.2967/jnumed.111.097014]. [PMID: 22414635].</comment><pub-id pub-id-type="pmid">22414635</pub-id></element-citation></ref><ref id="r218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrenz</surname><given-names>F.</given-names></name><name><surname>Wrede</surname><given-names>K.</given-names></name><name><surname>Forsting</surname><given-names>M.</given-names></name><name><surname>Engler</surname><given-names>H.</given-names></name><name><surname>Schedlowski</surname><given-names>M.</given-names></name><name><surname>Elsenbruch</surname><given-names>S.</given-names></name><name><surname>Benson</surname><given-names>S.</given-names></name></person-group><article-title>Alterations in functional connectivity of resting state networks during experimental endotoxemia - An exploratory study in healthy men.</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>54</volume><fpage>17</fpage><lpage>26</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2015.11.010]. [PMID: 26597151].</comment><pub-id pub-id-type="pmid">26597151</pub-id></element-citation></ref><ref id="r219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>C.S.</given-names></name><name><surname>Braver</surname><given-names>T.S.</given-names></name><name><surname>Barch</surname><given-names>D.M.</given-names></name><name><surname>Botvinick</surname><given-names>M.M.</given-names></name><name><surname>Noll</surname><given-names>D.</given-names></name><name><surname>Cohen</surname><given-names>J.D.</given-names></name></person-group><article-title>Anterior cingulate cortex, error detection, and the online monitoring of performance.</article-title><source>Science</source><year>1998</year><volume>280</volume><issue>5364</issue><fpage>747</fpage><lpage>749</lpage><comment>[http://dx.doi.org/10.1126/science.280.5364.747]. [PMID: 9563953].</comment><pub-id pub-id-type="pmid">9563953</pub-id></element-citation></ref><ref id="r220"><label>220</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name><name><surname>Lieberman</surname><given-names>M.D.</given-names></name></person-group><year>2004</year></element-citation></ref><ref id="r221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Critchley</surname><given-names>H.D.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Glaser</surname><given-names>D.</given-names></name><name><surname>Butterworth</surname><given-names>B.</given-names></name><name><surname>Dolan</surname><given-names>R.J.</given-names></name></person-group><article-title>Anterior cingulate activity during error and autonomic response.</article-title><source>Neuroimage</source><year>2005</year><volume>27</volume><issue>4</issue><fpage>885</fpage><lpage>895</lpage><comment>[http://dx.doi.org/10.1016/j. neuroimage.2005.05.047]. [PMID: 15996878].</comment><pub-id pub-id-type="pmid">15996878</pub-id></element-citation></ref><ref id="r222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamner</surname><given-names>M.B.</given-names></name><name><surname>Lorberbaum</surname><given-names>J.P.</given-names></name><name><surname>George</surname><given-names>M.S.</given-names></name></person-group><article-title>Potential role of the anterior cingulate cortex in PTSD: review and hypothesis.</article-title><source>Depress. Anxiety</source><year>1999</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><comment>[http://dx.doi.org/10.1002/(SICI) 1520-6394(1999)9:1&lt;1:AID-DA1&gt;3.0.CO;2-4]. [PMID: 9989344].</comment><pub-id pub-id-type="pmid">9989344</pub-id></element-citation></ref><ref id="r223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>L.M.</given-names></name><name><surname>Bush</surname><given-names>G.</given-names></name><name><surname>Milad</surname><given-names>M.R.</given-names></name><name><surname>Lasko</surname><given-names>N.B.</given-names></name><name><surname>Brohawn</surname><given-names>K.H.</given-names></name><name><surname>Hughes</surname><given-names>K.C.</given-names></name><name><surname>Macklin</surname><given-names>M.L.</given-names></name><name><surname>Gold</surname><given-names>A.L.</given-names></name><name><surname>Karpf</surname><given-names>R.D.</given-names></name><name><surname>Orr</surname><given-names>S.P.</given-names></name><name><surname>Rauch</surname><given-names>S.L.</given-names></name><name><surname>Pitman</surname><given-names>R.K.</given-names></name></person-group><article-title>Exaggerated activation of dorsal anterior cingulate cortex during cognitive interference: a monozygotic twin study of posttraumatic stress disorder.</article-title><source>Am. J. Psychiatry</source><year>2011</year><volume>168</volume><issue>9</issue><fpage>979</fpage><lpage>985</lpage><comment>[http://dx.doi.org/10.1176/appi.ajp.2011.09121812]. [PMID: 21724666].</comment><pub-id pub-id-type="pmid">21724666</pub-id></element-citation></ref><ref id="r224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>L.M.</given-names></name><name><surname>Lasko</surname><given-names>N.B.</given-names></name><name><surname>Macklin</surname><given-names>M.L.</given-names></name><name><surname>Karpf</surname><given-names>R.D.</given-names></name><name><surname>Milad</surname><given-names>M.R.</given-names></name><name><surname>Orr</surname><given-names>S.P.</given-names></name><name><surname>Goetz</surname><given-names>J.M.</given-names></name><name><surname>Fischman</surname><given-names>A.J.</given-names></name><name><surname>Rauch</surname><given-names>S.L.</given-names></name><name><surname>Pitman</surname><given-names>R.K.</given-names></name></person-group><article-title>Resting metabolic activity in the cingulate cortex and vulnerability to posttraumatic stress disorder.</article-title><source>Arch. Gen. Psychiatry</source><year>2009</year><volume>66</volume><issue>10</issue><fpage>1099</fpage><lpage>1107</lpage><comment>[http://dx.doi.org/10.1001/archgenpsychiatry. 2009.138]. [PMID: 19805700].</comment><pub-id pub-id-type="pmid">19805700</pub-id></element-citation></ref><ref id="r225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenberger</surname><given-names>N.I.</given-names></name><name><surname>Lieberman</surname><given-names>M.D.</given-names></name><name><surname>Satpute</surname><given-names>A.B.</given-names></name></person-group><article-title>Personality from a controlled processing perspective: an fMRI study of neuroticism, extraversion, and self-consciousness.</article-title><source>Cogn. Affect. Behav. Neurosci.</source><year>2005</year><volume>5</volume><issue>2</issue><fpage>169</fpage><lpage>181</lpage><comment>[http://dx.doi.org/10.3758/CABN.5.2.169]. [PMID: 16180623].</comment><pub-id pub-id-type="pmid">16180623</pub-id></element-citation></ref><ref id="r226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursu</surname><given-names>S.</given-names></name><name><surname>Stenger</surname><given-names>V.A.</given-names></name><name><surname>Shear</surname><given-names>M.K.</given-names></name><name><surname>Jones</surname><given-names>M.R.</given-names></name><name><surname>Carter</surname><given-names>C.S.</given-names></name></person-group><article-title>Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging.</article-title><source>Psychol. Sci.</source><year>2003</year><volume>14</volume><issue>4</issue><fpage>347</fpage><lpage>353</lpage><comment>[http://dx.doi.org/10.1111/1467-9280. 24411]. [PMID: 12807408].</comment><pub-id pub-id-type="pmid">12807408</pub-id></element-citation></ref><ref id="r227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>M.P.</given-names></name><name><surname>Feinstein</surname><given-names>J.S.</given-names></name><name><surname>Simmons</surname><given-names>A.</given-names></name><name><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>Anterior cingulate activation in high trait anxious subjects is related to altered error processing during decision making.</article-title><source>Biol. Psychiatry</source><year>2004</year><volume>55</volume><issue>12</issue><fpage>1179</fpage><lpage>1187</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych. 2004.02.023]. [PMID: 15184037].</comment><pub-id pub-id-type="pmid">15184037</pub-id></element-citation></ref><ref id="r228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Pagnoni</surname><given-names>G.</given-names></name><name><surname>Demetrashvili</surname><given-names>M.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Berns</surname><given-names>G.S.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Anterior cingulate activation and error processing during interferon-alpha treatment.</article-title><source>Biol. Psychiatry</source><year>2005</year><volume>58</volume><issue>3</issue><fpage>190</fpage><lpage>196</lpage><comment>[http://dx.doi.org/10.1016/j. biopsych.2005.03.033]. [PMID: 16084839].</comment><pub-id pub-id-type="pmid">16084839</pub-id></element-citation></ref><ref id="r229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>J.M.</given-names></name><name><surname>Szanton</surname><given-names>S.L.</given-names></name><name><surname>Page</surname><given-names>G.G.</given-names></name></person-group><article-title>Biological underpinnings of health alterations in women with PTSD: a sex disparity.</article-title><source>Biol. Res. Nurs.</source><year>2005</year><volume>7</volume><issue>1</issue><fpage>44</fpage><lpage>54</lpage><comment>[http://dx.doi.org/10.1177/ 1099800405276709]. [PMID: 15920002].</comment><pub-id pub-id-type="pmid">15920002</pub-id></element-citation></ref><ref id="r230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neylan</surname><given-names>T.C.</given-names></name><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Rempel</surname><given-names>H.</given-names></name><name><surname>Ross</surname><given-names>J.</given-names></name><name><surname>Lenoci</surname><given-names>M.</given-names></name><name><surname>O&#8217;Donovan</surname><given-names>A.</given-names></name><name><surname>Pulliam</surname><given-names>L.</given-names></name></person-group><article-title>Suppressed monocyte gene expression profile in men versus women with PTSD.</article-title><source>Brain Behav. Immun.</source><year>2011</year><volume>25</volume><issue>3</issue><fpage>524</fpage><lpage>531</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2010.12.001]. [PMID: 21145962].</comment><pub-id pub-id-type="pmid">21145962</pub-id></element-citation></ref><ref id="r231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Pace</surname><given-names>T.W.</given-names></name><name><surname>Parekh</surname><given-names>S.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Hu</surname><given-names>X.P.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.</article-title><source>Neuropsychopharmacology</source><year>2014</year><volume>39</volume><issue>7</issue><fpage>1777</fpage><lpage>1785</lpage><comment>[http://dx.doi.org/10.1038/npp.2014.25]. [PMID: 24481242].</comment><pub-id pub-id-type="pmid">24481242</pub-id></element-citation></ref><ref id="r232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M.J.</given-names></name><name><surname>Godlewska</surname><given-names>B.</given-names></name><name><surname>Near</surname><given-names>J.</given-names></name><name><surname>Christmas</surname><given-names>D.</given-names></name><name><surname>Potokar</surname><given-names>J.</given-names></name><name><surname>Collier</surname><given-names>J.</given-names></name><name><surname>Klenerman</surname><given-names>P.</given-names></name><name><surname>Barnes</surname><given-names>E.</given-names></name><name><surname>Cowen</surname><given-names>P.J.</given-names></name></person-group><article-title>Effect of interferon-&#945; on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.</article-title><source>Psychol. Med.</source><year>2014</year><volume>44</volume><issue>4</issue><fpage>789</fpage><lpage>795</lpage><comment>[http://dx.doi.org/10.1017/S0033291713001062]. [PMID: 23659574].</comment><pub-id pub-id-type="pmid">23659574</pub-id></element-citation></ref><ref id="r233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targum</surname><given-names>S.D.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>Fatigue as a residual symptom of depression.</article-title><source>Innov. Clin. Neurosci.</source><year>2011</year><volume>8</volume><issue>10</issue><fpage>40</fpage><lpage>43</lpage><comment>[PMID: 22132370].</comment></element-citation></ref><ref id="r234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>A.J.</given-names></name></person-group><article-title>STAR*D: what have we learned?</article-title><source>Am. J. Psychiatry</source><year>2007</year><volume>164</volume><issue>2</issue><fpage>201</fpage><lpage>204</lpage><comment>[http://dx.doi.org/10.1176/ajp.2007.164.2. 201]. [PMID: 17267779].</comment><pub-id pub-id-type="pmid">17267779</pub-id></element-citation></ref><ref id="r235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunlop</surname><given-names>B.W.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name></person-group><article-title>The role of dopamine in the pathophysiology of depression.</article-title><source>Arch. Gen. Psychiatry</source><year>2007</year><volume>64</volume><issue>3</issue><fpage>327</fpage><lpage>337</lpage><comment>[http://dx.doi.org/10.1001/archpsyc.64.3.327]. [PMID: 17339521].</comment><pub-id pub-id-type="pmid">17339521</pub-id></element-citation></ref><ref id="r236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>M.H.</given-names></name><name><surname>Hollander</surname><given-names>E.</given-names></name><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>Blier</surname><given-names>P.</given-names></name></person-group><article-title>Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.</article-title><source>J. Clin. Psychiatry</source><year>2008</year><volume>69</volume><issue>2</issue><fpage>246</fpage><lpage>258</lpage><comment>[http://dx.doi.org/10.4088/JCP.v69n0211]. [PMID: 18363453].</comment><pub-id pub-id-type="pmid">18363453</pub-id></element-citation></ref><ref id="r237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name></person-group><article-title>Residual symptoms in depression: prevalence and impact.</article-title><source>J. Clin. Psychiatry</source><year>2015</year><volume>76</volume><issue>11</issue><fpage>e1480</fpage><comment>[http://dx.doi. org/10.4088/JCP.13097TX1C]. [PMID: 26646047].</comment><pub-id pub-id-type="pmid">26646047</pub-id></element-citation></ref><ref id="r238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Cytokines and psychopathology: lessons from interferon-alpha.</article-title><source>Biol. Psychiatry</source><year>2004</year><volume>56</volume><issue>11</issue><fpage>819</fpage><lpage>824</lpage><comment>[http:// dx.doi.org/10.1016/j.biopsych.2004.02.009]. [PMID: 15576057].</comment><pub-id pub-id-type="pmid">15576057</pub-id></element-citation></ref><ref id="r239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A.H.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name></person-group><article-title>Are anti-inflammatory therapies viable treatments for psychiatric disorders?: Where the rubber meets the road.</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><issue>6</issue><fpage>527</fpage><lpage>528</lpage><comment>[http://dx.doi.org/ 10.1001/jamapsychiatry.2015.22]. [PMID: 25853989].</comment><pub-id pub-id-type="pmid">25853989</pub-id></element-citation></ref><ref id="r240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblat</surname><given-names>J.D.</given-names></name><name><surname>Kakar</surname><given-names>R.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Kessing</surname><given-names>L.V.</given-names></name><name><surname>Vinberg</surname><given-names>M.</given-names></name><name><surname>Baune</surname><given-names>B.T.</given-names></name><name><surname>Mansur</surname><given-names>R.B.</given-names></name><name><surname>Brietzke</surname><given-names>E.</given-names></name><name><surname>Goldstein</surname><given-names>B.I.</given-names></name><name><surname>McIntyre</surname><given-names>R.S.</given-names></name></person-group><article-title>Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.</article-title><source>Bipolar Disord.</source><year>2016</year><volume>18</volume><issue>2</issue><fpage>89</fpage><lpage>101</lpage><comment>[http://dx.doi.org/10.1111/bdi.12373]. [PMID: 26990051].</comment><pub-id pub-id-type="pmid">26990051</pub-id></element-citation></ref><ref id="r241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>I.E.</given-names></name></person-group><article-title>Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? <italic>A meta-analysis.</italic></article-title><source>J. Clin. Psychol.</source><year>2011</year><volume>73</volume><issue>4</issue><fpage>478</fpage><lpage>419</lpage></element-citation></ref><ref id="r242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#246;hler</surname><given-names>O.</given-names></name><name><surname>Benros</surname><given-names>M.E.</given-names></name><name><surname>Nordentoft</surname><given-names>M.</given-names></name><name><surname>Farkouh</surname><given-names>M.E.</given-names></name><name><surname>Iyengar</surname><given-names>R.L.</given-names></name><name><surname>Mors</surname><given-names>O.</given-names></name><name><surname>Krogh</surname><given-names>J.</given-names></name></person-group><article-title>Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.</article-title><source>JAMA Psychiatry</source><year>2014</year><volume>71</volume><issue>12</issue><fpage>1381</fpage><lpage>1391</lpage><comment>[http://dx.doi.org/10.1001/ jamapsychiatry.2014.1611]. [PMID: 25322082].</comment><pub-id pub-id-type="pmid">25322082</pub-id></element-citation></ref><ref id="r243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bower</surname><given-names>J.E.</given-names></name><name><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><article-title>Mind-body therapies and control of inflammatory biology: A descriptive review.</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>51</volume><fpage>1</fpage><lpage>11</lpage><comment>[http://dx.doi.org/10.1016/j.bbi.2015.06.012]. [PMID: 26116436].</comment><pub-id pub-id-type="pmid">26116436</pub-id></element-citation></ref><ref id="r244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuch</surname><given-names>F.B.</given-names></name><name><surname>Vancampfort</surname><given-names>D.</given-names></name><name><surname>Richards</surname><given-names>J.</given-names></name><name><surname>Rosenbaum</surname><given-names>S.</given-names></name><name><surname>Ward</surname><given-names>P.B.</given-names></name><name><surname>Stubbs</surname><given-names>B.</given-names></name></person-group><article-title>Exercise as a treatment for depression: A meta-analysis adjusting for publication bias.</article-title><source>J. Psychiatr. Res.</source><year>2016</year><volume>77</volume><fpage>42</fpage><lpage>51</lpage><comment>[http://dx.doi.org/10.1016/j.jpsychires.2016.02. 023]. [PMID: 26978184].</comment><pub-id pub-id-type="pmid">26978184</pub-id></element-citation></ref><ref id="r245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabricatore</surname><given-names>A.N.</given-names></name><name><surname>Wadden</surname><given-names>T.A.</given-names></name><name><surname>Higginbotham</surname><given-names>A.J.</given-names></name><name><surname>Faulconbridge</surname><given-names>L.F.</given-names></name><name><surname>Nguyen</surname><given-names>A.M.</given-names></name><name><surname>Heymsfield</surname><given-names>S.B.</given-names></name><name><surname>Faith</surname><given-names>M.S.</given-names></name></person-group><article-title>Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis.</article-title><source>Int. J. Obes.</source><year>2011</year><volume>35</volume><issue>11</issue><fpage>1363</fpage><lpage>1376</lpage><comment>[http://dx.doi.org/10.1038/ijo.2011.2]. [PMID: 21343903].</comment></element-citation></ref><ref id="r246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsythe</surname><given-names>L.K.</given-names></name><name><surname>Wallace</surname><given-names>J.M.</given-names></name><name><surname>Livingstone</surname><given-names>M.B.</given-names></name></person-group><article-title>Obesity and inflammation: the effects of weight loss.</article-title><source>Nutr. Res. Rev.</source><year>2008</year><volume>21</volume><issue>2</issue><fpage>117</fpage><lpage>133</lpage><comment>[http://dx.doi.org/10.1017/S0954422408138732]. [PMID: 19087366].</comment><pub-id pub-id-type="pmid">19087366</pub-id></element-citation></ref><ref id="r247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>J.A.</given-names></name><name><surname>Vieira</surname><given-names>V.J.</given-names></name><name><surname>Keylock</surname><given-names>K.T.</given-names></name></person-group><article-title>Exercise, inflammation, and innate immunity.</article-title><source>Immunol. Allergy Clin. North Am.</source><year>2009</year><volume>29</volume><issue>2</issue><fpage>381</fpage><lpage>393</lpage><comment>[http://dx.doi.org/10.1016/j.iac.2009.02.011]. [PMID: 19389588].</comment><pub-id pub-id-type="pmid">19389588</pub-id></element-citation></ref><ref id="r248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapaport</surname><given-names>M.H.</given-names></name></person-group><article-title>Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.</article-title><source>Mol. Psychiatry</source><year>2015</year><comment>[PMID: 25802980].</comment></element-citation></ref><ref id="r249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocking</surname><given-names>R.J.</given-names></name><name><surname>Harmsen</surname><given-names>I.</given-names></name><name><surname>Assies</surname><given-names>J.</given-names></name><name><surname>Koeter</surname><given-names>M.W.</given-names></name><name><surname>Ruh&#233;</surname><given-names>H.G.</given-names></name><name><surname>Schene</surname><given-names>A.H.</given-names></name></person-group><article-title>Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.</article-title><source>Transl. Psychiatry</source><year>2016</year><volume>6</volume><fpage>e756</fpage><comment>[http://dx.doi.org/10.1038/ tp.2016.29]. [PMID: 26978738].</comment><pub-id pub-id-type="pmid">26978738</pub-id></element-citation></ref><ref id="r250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>K.P.</given-names></name><name><surname>Lai</surname><given-names>H.C.</given-names></name><name><surname>Yang</surname><given-names>H.T.</given-names></name><name><surname>Su</surname><given-names>W.P.</given-names></name><name><surname>Peng</surname><given-names>C.Y.</given-names></name><name><surname>Chang</surname><given-names>J.P.</given-names></name><name><surname>Chang</surname><given-names>H.C.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name></person-group><article-title>Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial.</article-title><source>Biol. Psychiatry</source><year>2014</year><volume>76</volume><issue>7</issue><fpage>559</fpage><lpage>566</lpage><comment>[http:// dx.doi.org/10.1016/j.biopsych.2014.01.008]. [PMID: 24602409].</comment><pub-id pub-id-type="pmid">24602409</pub-id></element-citation></ref><ref id="r251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>K.P.</given-names></name><name><surname>Huang</surname><given-names>S.Y.</given-names></name><name><surname>Peng</surname><given-names>C.Y.</given-names></name><name><surname>Lai</surname><given-names>H.C.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Aitchison</surname><given-names>K.J.</given-names></name><name><surname>Pariante</surname><given-names>C.M.</given-names></name></person-group><article-title>Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>67</volume><issue>6</issue><fpage>550</fpage><lpage>557</lpage><comment>[http://dx.doi.org/10. 1016/j.biopsych.2009.11.005]. [PMID: 20034614].</comment><pub-id pub-id-type="pmid">20034614</pub-id></element-citation></ref><ref id="r252"><label>252</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>R.K.</given-names></name><name><surname>Asch</surname><given-names>R.H.</given-names></name><name><surname>Lindquist</surname><given-names>D.M.</given-names></name><name><surname>Krikorian</surname><given-names>R.</given-names></name></person-group><year>2017</year></element-citation></ref><ref id="r253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>J.M.</given-names></name><name><surname>Saligan</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Rotolo</surname><given-names>S.</given-names></name><name><surname>Szanton</surname><given-names>S.</given-names></name></person-group><article-title>Women in recovery from PTSD have similar inflammation and quality of life as non-traumatized controls.</article-title><source>J. Psychosom. Res.</source><year>2013</year><volume>74</volume><issue>4</issue><fpage>301</fpage><lpage>306</lpage><comment>[http://dx.doi.org/10.1016/j.jpsychores.2012.10.013]. [PMID: 23497831].</comment><pub-id pub-id-type="pmid">23497831</pub-id></element-citation></ref><ref id="r254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tucker</surname><given-names>P.</given-names></name><name><surname>Ruwe</surname><given-names>W.D.</given-names></name><name><surname>Masters</surname><given-names>B.</given-names></name><name><surname>Parker</surname><given-names>D.E.</given-names></name><name><surname>Hossain</surname><given-names>A.</given-names></name><name><surname>Trautman</surname><given-names>R.P.</given-names></name><name><surname>Wyatt</surname><given-names>D.B.</given-names></name></person-group><article-title>Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder.</article-title><source>Biol. Psychiatry</source><year>2004</year><volume>56</volume><issue>2</issue><fpage>121</fpage><lpage>128</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych.2004.03.009]. [PMID: 15231444].</comment><pub-id pub-id-type="pmid">15231444</pub-id></element-citation></ref><ref id="r255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>T.W.</given-names></name><name><surname>Negi</surname><given-names>L.T.</given-names></name><name><surname>Adame</surname><given-names>D.D.</given-names></name><name><surname>Cole</surname><given-names>S.P.</given-names></name><name><surname>Sivilli</surname><given-names>T.I.</given-names></name><name><surname>Brown</surname><given-names>T.D.</given-names></name><name><surname>Issa</surname><given-names>M.J.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name></person-group><article-title>Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress.</article-title><source>Psychoneuroendocrinology</source><year>2009</year><volume>34</volume><issue>1</issue><fpage>87</fpage><lpage>98</lpage><comment>[http://dx.doi.org/10.1016/j.psyneuen.2008.08.011]. [PMID: 18835662].</comment><pub-id pub-id-type="pmid">18835662</pub-id></element-citation></ref><ref id="r256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loftis</surname><given-names>J.M.</given-names></name><name><surname>Patterson</surname><given-names>A.L.</given-names></name><name><surname>Wilhelm</surname><given-names>C.J.</given-names></name><name><surname>McNett</surname><given-names>H.</given-names></name><name><surname>Morasco</surname><given-names>B.J.</given-names></name><name><surname>Huckans</surname><given-names>M.</given-names></name><name><surname>Morgan</surname><given-names>T.</given-names></name><name><surname>Saperstein</surname><given-names>S.</given-names></name><name><surname>Asghar</surname><given-names>A.</given-names></name><name><surname>Hauser</surname><given-names>P.</given-names></name></person-group><article-title>Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.</article-title><source>J. Psychosom. Res.</source><year>2013</year><volume>74</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><comment>[http://dx.doi.org/10.1016/j. jpsychores.2012.10.012]. [PMID: 23272989].</comment><pub-id pub-id-type="pmid">23272989</pub-id></element-citation></ref><ref id="r257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neurauter</surname><given-names>G.</given-names></name><name><surname>Schr&#246;cksnadel</surname><given-names>K.</given-names></name><name><surname>Scholl-B&#252;rgi</surname><given-names>S.</given-names></name><name><surname>Sperner-Unterweger</surname><given-names>B.</given-names></name><name><surname>Schubert</surname><given-names>C.</given-names></name><name><surname>Ledochowski</surname><given-names>M.</given-names></name><name><surname>Fuchs</surname><given-names>D.</given-names></name></person-group><article-title>Chronic immune stimulation correlates with reduced phenylalanine turnover.</article-title><source>Curr. Drug Metab.</source><year>2008</year><volume>9</volume><issue>7</issue><fpage>622</fpage><lpage>627</lpage><comment>[http://dx.doi.org/ 10.2174/138920008785821738]. [PMID: 18781914].</comment><pub-id pub-id-type="pmid">18781914</pub-id></element-citation></ref><ref id="r258"><label>258</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunnington</surname><given-names>C.</given-names></name><name><surname>Channon</surname><given-names>K.M.</given-names></name></person-group><article-title>Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology.</article-title><source>Heart</source><year>2010</year><volume>96</volume><issue>23</issue><fpage>1872</fpage><lpage>1877</lpage><comment>[http://dx.doi.org/10.1136/hrt.2009.180430]. [PMID: 20837663].</comment><pub-id pub-id-type="pmid">20837663</pub-id></element-citation></ref><ref id="r259"><label>259</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Tsai</surname><given-names>A.L.</given-names></name><name><surname>Berka</surname><given-names>V.</given-names></name><name><surname>Zweier</surname><given-names>J.L.</given-names></name></person-group><article-title>Superoxide generation from endothelial nitric-oxide synthase. A Ca<sup>2+</sup>/calmodulin-dependent and tetrahydrobiopterin regulatory process.</article-title><source>J. Biol. Chem.</source><year>1998</year><volume>273</volume><issue>40</issue><fpage>25804</fpage><lpage>25808</lpage><comment>[http://dx.doi.org/10.1074/ jbc.273.40.25804]. [PMID: 9748253].</comment><pub-id pub-id-type="pmid">9748253</pub-id></element-citation></ref><ref id="r260"><label>260</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Knowlton</surname><given-names>D.</given-names></name><name><surname>Woodward</surname><given-names>W.R.</given-names></name><name><surname>Habecker</surname><given-names>B.A.</given-names></name></person-group><article-title>Regulation of noradrenergic function by inflammatory cytokines and depolarization.</article-title><source>J. Neurochem.</source><year>2003</year><volume>86</volume><issue>3</issue><fpage>774</fpage><lpage>783</lpage><comment>[http://dx.doi. org/10.1046/j.1471-4159.2003.01890.x]. [PMID: 12859689].</comment><pub-id pub-id-type="pmid">12859689</pub-id></element-citation></ref><ref id="r261"><label>261</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Schroecksnadel</surname><given-names>S.</given-names></name><name><surname>F&#233;art</surname><given-names>C.</given-names></name><name><surname>Aubert</surname><given-names>A.</given-names></name><name><surname>Higueret</surname><given-names>D.</given-names></name><name><surname>Barberger-Gateau</surname><given-names>P.</given-names></name><name><surname>Lay&#233;</surname><given-names>S.</given-names></name><name><surname>Fuchs</surname><given-names>D.</given-names></name></person-group><article-title>Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms.</article-title><source>Biol. Psychiatry</source><year>2011</year><volume>70</volume><issue>2</issue><fpage>175</fpage><lpage>182</lpage><comment>[http://dx.doi.org/10. 1016/j.biopsych.2010.12.006]. [PMID: 21277567].</comment><pub-id pub-id-type="pmid">21277567</pub-id></element-citation></ref><ref id="r262"><label>262</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Nagatsu</surname><given-names>T.</given-names></name><name><surname>Ohta</surname><given-names>T.</given-names></name><name><surname>Mizutani</surname><given-names>M.</given-names></name><name><surname>Omura</surname><given-names>I.</given-names></name></person-group><article-title>Changes in the concentrations of tetrahydrobiopterin, the cofactor of tyrosine hydroxylase, in blood under physical stress and in depression.</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2004</year><volume>1018</volume><fpage>378</fpage><lpage>386</lpage><comment>[http:// dx.doi.org/10.1196/annals.1296.047]. [PMID: 15240393].</comment><pub-id pub-id-type="pmid">15240393</pub-id></element-citation></ref><ref id="r263"><label>263</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candito</surname><given-names>M.</given-names></name><name><surname>Nagatsu</surname><given-names>T.</given-names></name><name><surname>Chambon</surname><given-names>P.</given-names></name><name><surname>Chatel</surname><given-names>M.</given-names></name></person-group><article-title>High-performance liquid chromatographic measurement of cerebrospinal fluid tetrahydrobiopterin, neopterin, homovanillic acid and 5-hydroxindoleacetic acid in neurological diseases.</article-title><source>J. Chromatogr. B Biomed. Appl.</source><year>1994</year><volume>657</volume><issue>1</issue><fpage>61</fpage><lpage>66</lpage><comment>[http://dx.doi.org/10.1016/ 0378-4347(94)80070-7]. [PMID: 7524948].</comment><pub-id pub-id-type="pmid">7524948</pub-id></element-citation></ref><ref id="r264"><label>264</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>K.</given-names></name><name><surname>Tajima</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><name><surname>Tokutome</surname><given-names>G.</given-names></name><name><surname>Sakagami</surname><given-names>H.</given-names></name><name><surname>Hosoya</surname><given-names>T.</given-names></name></person-group><article-title>Plasma pteridine concentrations in patients with chronic renal failure.</article-title><source>Nephrol. Dial. Transplant.</source><year>2002</year><volume>17</volume><issue>6</issue><fpage>1032</fpage><lpage>1036</lpage><comment>[http://dx.doi.org/10.1093/ndt/17.6. 1032]. [PMID: 12032193].</comment><pub-id pub-id-type="pmid">12032193</pub-id></element-citation></ref><ref id="r265"><label>265</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Marvar</surname><given-names>P.J.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Harrison</surname><given-names>D.G.</given-names></name><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.</article-title><source>Brain Behav. Immun.</source><year>2013</year><volume>31</volume><fpage>153</fpage><lpage>160</lpage><comment>[http:// dx.doi.org/10.1016/j.bbi.2012.10.010]. [PMID: 23072726].</comment><pub-id pub-id-type="pmid">23072726</pub-id></element-citation></ref><ref id="r266"><label>266</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoller</surname><given-names>H.</given-names></name><name><surname>Schloegl</surname><given-names>A.</given-names></name><name><surname>Schroecksnadel</surname><given-names>S.</given-names></name><name><surname>Vogel</surname><given-names>W.</given-names></name><name><surname>Fuchs</surname><given-names>D.</given-names></name></person-group><article-title>Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio.</article-title><source>J. Interferon Cytokine Res.</source><year>2012</year><volume>32</volume><issue>5</issue><fpage>216</fpage><lpage>220</lpage><comment>[http://dx. doi.org/10.1089/jir.2011.0093]. [PMID: 22191466].</comment><pub-id pub-id-type="pmid">22191466</pub-id></element-citation></ref><ref id="r267"><label>267</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felger</surname><given-names>J.C.</given-names></name><name><surname>Hernandez</surname><given-names>C.R.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Levodopa reverses cytokine-induced reductions in striatal dopamine release.</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2015</year><volume>18</volume><issue>4</issue><fpage>pyu084</fpage><comment>[http://dx.doi.org/ 10.1093/ijnp/pyu084]. [PMID: 25638816].</comment><pub-id pub-id-type="pmid">25638816</pub-id></element-citation></ref><ref id="r268"><label>268</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caudle</surname><given-names>W.M.</given-names></name><name><surname>Richardson</surname><given-names>J.R.</given-names></name><name><surname>Wang</surname><given-names>M.Z.</given-names></name><name><surname>Taylor</surname><given-names>T.N.</given-names></name><name><surname>Guillot</surname><given-names>T.S.</given-names></name><name><surname>McCormack</surname><given-names>A.L.</given-names></name><name><surname>Colebrooke</surname><given-names>R.E.</given-names></name><name><surname>Di Monte</surname><given-names>D.A.</given-names></name><name><surname>Emson</surname><given-names>P.C.</given-names></name><name><surname>Miller</surname><given-names>G.W.</given-names></name></person-group><article-title>Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.</article-title><source>J. Neurosci.</source><year>2007</year><volume>27</volume><issue>30</issue><fpage>8138</fpage><lpage>8148</lpage><comment>[http://dx.doi.org/10.1523/JNEUROSCI. 0319-07.2007]. [PMID: 17652604].</comment><pub-id pub-id-type="pmid">17652604</pub-id></element-citation></ref><ref id="r269"><label>269</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>T.D.</given-names></name><name><surname>Jinnah</surname><given-names>H.A.</given-names></name><name><surname>Bernhard</surname><given-names>D.</given-names></name><name><surname>Singh</surname><given-names>R.H.</given-names></name></person-group><article-title>The effects of sapropterin on urinary monoamine metabolites in phenylketonuria.</article-title><source>Mol. Genet. Metab.</source><year>2013</year><volume>109</volume><issue>3</issue><fpage>243</fpage><lpage>250</lpage><comment>[http://dx.doi.org/ 10.1016/j.ymgme.2013.04.017]. [PMID: 23712020].</comment><pub-id pub-id-type="pmid">23712020</pub-id></element-citation></ref><ref id="r270"><label>270</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>B.K.</given-names></name><name><surname>Bausell</surname><given-names>H.</given-names></name><name><surname>Katz</surname><given-names>R.</given-names></name><name><surname>Laduca</surname><given-names>H.</given-names></name><name><surname>Sullivan</surname><given-names>C.</given-names></name></person-group><article-title>Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).</article-title><source>Mol. Genet. Metab.</source><year>2010</year><volume>101</volume><issue>2-3</issue><fpage>110</fpage><lpage>114</lpage><comment>[http://dx.doi.org/10.1016/j. ymgme.2010.06.015]. [PMID: 20638313].</comment><pub-id pub-id-type="pmid">20638313</pub-id></element-citation></ref><ref id="r271"><label>271</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trefz</surname><given-names>F.K.</given-names></name><name><surname>Burton</surname><given-names>B.K.</given-names></name><name><surname>Longo</surname><given-names>N.</given-names></name><name><surname>Casanova</surname><given-names>M.M.</given-names></name><name><surname>Gruskin</surname><given-names>D.J.</given-names></name><name><surname>Dorenbaum</surname><given-names>A.</given-names></name><name><surname>Kakkis</surname><given-names>E.D.</given-names></name><name><surname>Crombez</surname><given-names>E.A.</given-names></name><name><surname>Grange</surname><given-names>D.K.</given-names></name><name><surname>Harmatz</surname><given-names>P.</given-names></name><name><surname>Lipson</surname><given-names>M.H.</given-names></name><name><surname>Milanowski</surname><given-names>A.</given-names></name><name><surname>Randolph</surname><given-names>L.M.</given-names></name><name><surname>Vockley</surname><given-names>J.</given-names></name><name><surname>Whitley</surname><given-names>C.B.</given-names></name><name><surname>Wolff</surname><given-names>J.A.</given-names></name><name><surname>Bebchuk</surname><given-names>J.</given-names></name><name><surname>Christ-Schmidt</surname><given-names>H.</given-names></name><name><surname>Hennermann</surname><given-names>J.B.</given-names></name></person-group><article-title>Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.</article-title><source>J. Pediatr.</source><year>2009</year><volume>154</volume><issue>5</issue><fpage>700</fpage><lpage>707</lpage><comment>[http://dx. doi.org/10.1016/j.jpeds.2008.11.040]. [PMID: 19261295].</comment><pub-id pub-id-type="pmid">19261295</pub-id></element-citation></ref><ref id="r272"><label>272</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utz</surname><given-names>J.R.</given-names></name><name><surname>Lorentz</surname><given-names>C.P.</given-names></name><name><surname>Markowitz</surname><given-names>D.</given-names></name><name><surname>Rudser</surname><given-names>K.D.</given-names></name><name><surname>Diethelm-Okita</surname><given-names>B.</given-names></name><name><surname>Erickson</surname><given-names>D.</given-names></name><name><surname>Whitley</surname><given-names>C.B.</given-names></name></person-group><article-title>START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.</article-title><source>Mol. Genet. Metab.</source><year>2012</year><volume>105</volume><issue>2</issue><fpage>193</fpage><lpage>197</lpage><comment>[http://dx.doi.org/10.1016/j.ymgme.2011. 10.014]. [PMID: 22112818].</comment><pub-id pub-id-type="pmid">22112818</pub-id></element-citation></ref><ref id="r273"><label>273</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent.</article-title><source>CNS Spectr.</source><year>2007</year><volume>12</volume><issue>10</issue><fpage>739</fpage><lpage>744</lpage><comment>[http://dx.doi.org/10.1017/ S1092852900015418]. [PMID: 17934378].</comment><pub-id pub-id-type="pmid">17934378</pub-id></element-citation></ref><ref id="r274"><label>274</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shintaku</surname><given-names>H.</given-names></name></person-group><article-title>Disorders of tetrahydrobiopterin metabolism and their treatment.</article-title><source>Curr. Drug Metab.</source><year>2002</year><volume>3</volume><issue>2</issue><fpage>123</fpage><lpage>131</lpage><comment>[http://dx.doi. org/10.2174/1389200024605145]. [PMID: 12003346].</comment><pub-id pub-id-type="pmid">12003346</pub-id></element-citation></ref><ref id="r275"><label>275</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name></person-group><year>2011</year></element-citation></ref><ref id="r276"><label>276</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Uematsu</surname><given-names>M.</given-names></name><name><surname>Endo</surname><given-names>W.</given-names></name><name><surname>Nakayama</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Hino-Fukuyo</surname><given-names>N.</given-names></name><name><surname>Sakamoto</surname><given-names>O.</given-names></name><name><surname>Shintaku</surname><given-names>H.</given-names></name><name><surname>Kure</surname><given-names>S.</given-names></name></person-group><article-title>Early replacement therapy in a first Japanese case with autosomal recessive guanosine triphosphate cyclohydrolase I deficiency with a novel point mutation.</article-title><source>Brain Dev.</source><year>2014</year><volume>36</volume><issue>3</issue><fpage>268</fpage><lpage>271</lpage><comment>[http://dx. doi.org/10.1016/j.braindev.2013.04.003]. [PMID: 23660475].</comment><pub-id pub-id-type="pmid">23660475</pub-id></element-citation></ref><ref id="r277"><label>277</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Mischoulon</surname><given-names>D.</given-names></name><name><surname>Shyu</surname><given-names>I.</given-names></name><name><surname>Alpert</surname><given-names>J.E.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.</article-title><source>Am. J. Psychiatry</source><year>2010</year><volume>167</volume><issue>8</issue><fpage>942</fpage><lpage>948</lpage><comment>[http://dx.doi.org/10.1176/appi.ajp. 2009.09081198]. [PMID: 20595412].</comment><pub-id pub-id-type="pmid">20595412</pub-id></element-citation></ref><ref id="r278"><label>278</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>P.S.</given-names></name><name><surname>Toone</surname><given-names>B.K.</given-names></name><name><surname>Carney</surname><given-names>M.W.</given-names></name><name><surname>Flynn</surname><given-names>T.G.</given-names></name><name><surname>Bottiglieri</surname><given-names>T.</given-names></name><name><surname>Laundy</surname><given-names>M.</given-names></name><name><surname>Chanarin</surname><given-names>I.</given-names></name><name><surname>Reynolds</surname><given-names>E.H.</given-names></name></person-group><article-title>Enhancement of recovery from psychiatric illness by methylfolate.</article-title><source>Lancet</source><year>1990</year><volume>336</volume><issue>8712</issue><fpage>392</fpage><lpage>395</lpage><comment>[http://dx.doi.org/10.1016/0140-6736(90) 91942-4]. [PMID: 1974941].</comment><pub-id pub-id-type="pmid">1974941</pub-id></element-citation></ref><ref id="r279"><label>279</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>L.D.</given-names></name><name><surname>Oubre</surname><given-names>A.Y.</given-names></name><name><surname>Daoud</surname><given-names>Y.A.</given-names></name></person-group><article-title>L-methylfolate Plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode.</article-title><source>Innov. Clin. Neurosci.</source><year>2011</year><volume>8</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><comment>[PMID: 21311704].</comment></element-citation></ref><ref id="r280"><label>280</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Shelton</surname><given-names>R.C.</given-names></name><name><surname>Zajecka</surname><given-names>J.M.</given-names></name><name><surname>Etemad</surname><given-names>B.</given-names></name><name><surname>Rickels</surname><given-names>K.</given-names></name><name><surname>Clain</surname><given-names>A.</given-names></name><name><surname>Baer</surname><given-names>L.</given-names></name><name><surname>Dalton</surname><given-names>E.D.</given-names></name><name><surname>Sacco</surname><given-names>G.R.</given-names></name><name><surname>Schoenfeld</surname><given-names>D.</given-names></name><name><surname>Pencina</surname><given-names>M.</given-names></name><name><surname>Meisner</surname><given-names>A.</given-names></name><name><surname>Bottiglieri</surname><given-names>T.</given-names></name><name><surname>Nelson</surname><given-names>E.</given-names></name><name><surname>Mischoulon</surname><given-names>D.</given-names></name><name><surname>Alpert</surname><given-names>J.E.</given-names></name><name><surname>Barbee</surname><given-names>J.G.</given-names></name><name><surname>Zisook</surname><given-names>S.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.</article-title><source>Am. J. Psychiatry</source><year>2012</year><volume>169</volume><issue>12</issue><fpage>1267</fpage><lpage>1274</lpage><comment>[http://dx.doi.org/10.1176/ appi.ajp.2012.11071114]. [PMID: 23212058].</comment><pub-id pub-id-type="pmid">23212058</pub-id></element-citation></ref><ref id="r281"><label>281</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>R.C.</given-names></name><name><surname>Pencina</surname><given-names>M.J.</given-names></name><name><surname>Barrentine</surname><given-names>L.W.</given-names></name><name><surname>Ruiz</surname><given-names>J.A.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name><name><surname>Zajecka</surname><given-names>J.M.</given-names></name><name><surname>Papakostas</surname><given-names>G.I.</given-names></name></person-group><article-title>Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.</article-title><source>J. Clin. Psychiatry</source><year>2015</year><volume>76</volume><issue>12</issue><fpage>1635</fpage><lpage>1641</lpage><comment>[http://dx.doi. org/10.4088/JCP.14m09587]. [PMID: 26613389].</comment><pub-id pub-id-type="pmid">26613389</pub-id></element-citation></ref><ref id="r282"><label>282</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>L.E.</given-names></name><name><surname>Galtieri</surname><given-names>D.J.</given-names></name><name><surname>Collins</surname><given-names>P.</given-names></name><name><surname>Jones</surname><given-names>S.K.</given-names></name><name><surname>Port</surname><given-names>R.G.</given-names></name><name><surname>Paul</surname><given-names>N.E.</given-names></name><name><surname>Hockemeyer</surname><given-names>J.</given-names></name><name><surname>M&#252;ller</surname><given-names>C.E.</given-names></name><name><surname>Salamone</surname><given-names>J.D.</given-names></name></person-group><article-title>Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity.</article-title><source>Behav. Brain Res.</source><year>2010</year><volume>211</volume><issue>2</issue><fpage>148</fpage><lpage>155</lpage><comment>[http://dx.doi.org/10.1016/j. bbr.2010.03.003]. [PMID: 20211657].</comment><pub-id pub-id-type="pmid">20211657</pub-id></element-citation></ref><ref id="r283"><label>283</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yohn</surname><given-names>S.E.</given-names></name><name><surname>Thompson</surname><given-names>C.</given-names></name><name><surname>Randall</surname><given-names>P.A.</given-names></name><name><surname>Lee</surname><given-names>C.A.</given-names></name><name><surname>M&#252;ller</surname><given-names>C.E.</given-names></name><name><surname>Baqi</surname><given-names>Y.</given-names></name><name><surname>Correa</surname><given-names>M.</given-names></name><name><surname>Salamone</surname><given-names>J.D.</given-names></name></person-group><article-title>The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.</article-title><source>Psychopharmacology (Berl.)</source><year>2015</year><volume>232</volume><issue>7</issue><fpage>1313</fpage><lpage>1323</lpage><comment>[http://dx. doi.org/10.1007/s00213-014-3766-0]. [PMID: 25323625].</comment><pub-id pub-id-type="pmid">25323625</pub-id></element-citation></ref><ref id="r284"><label>284</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.F.</given-names></name><name><surname>Moratalla</surname><given-names>R.</given-names></name><name><surname>Impagnatiello</surname><given-names>F.</given-names></name><name><surname>Grandy</surname><given-names>D.K.</given-names></name><name><surname>Cuellar</surname><given-names>B.</given-names></name><name><surname>Rubinstein</surname><given-names>M.</given-names></name><name><surname>Beilstein</surname><given-names>M.A.</given-names></name><name><surname>Hackett</surname><given-names>E.</given-names></name><name><surname>Fink</surname><given-names>J.S.</given-names></name><name><surname>Low</surname><given-names>M.J.</given-names></name><name><surname>Ongini</surname><given-names>E.</given-names></name><name><surname>Schwarzschild</surname><given-names>M.A.</given-names></name></person-group><article-title>The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><issue>4</issue><fpage>1970</fpage><lpage>1975</lpage><comment>[http://dx.doi.org/10.1073/pnas.98.4.1970]. [PMID: 11172060].</comment><pub-id pub-id-type="pmid">11172060</pub-id></element-citation></ref><ref id="r285"><label>285</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Mhaskar</surname><given-names>Y.</given-names></name><name><surname>Arbogast</surname><given-names>L.A.</given-names></name><name><surname>Trammell</surname><given-names>R.A.</given-names></name><name><surname>Hughes</surname><given-names>L.F.</given-names></name><name><surname>Toth</surname><given-names>L.A.</given-names></name></person-group><article-title>Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice.</article-title><source>Life Sci.</source><year>2009</year><volume>85</volume><issue>5-6</issue><fpage>226</fpage><lpage>234</lpage><comment>[http://dx.doi.org/10.1016/j.lfs.2009.05.016]. [PMID: 19508875].</comment><pub-id pub-id-type="pmid">19508875</pub-id></element-citation></ref><ref id="r286"><label>286</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iravani</surname><given-names>M.M.</given-names></name><name><surname>Sadeghian</surname><given-names>M.</given-names></name><name><surname>Leung</surname><given-names>C.C.</given-names></name><name><surname>Tel</surname><given-names>B.C.</given-names></name><name><surname>Rose</surname><given-names>S.</given-names></name><name><surname>Schapira</surname><given-names>A.H.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name></person-group><article-title>Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.</article-title><source>Exp. Neurol.</source><year>2008</year><volume>212</volume><issue>2</issue><fpage>522</fpage><lpage>531</lpage><comment>[http://dx.doi.org/10.1016/j. expneurol.2008.04.037]. [PMID: 18571649].</comment><pub-id pub-id-type="pmid">18571649</pub-id></element-citation></ref><ref id="r287"><label>287</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassano</surname><given-names>P.</given-names></name><name><surname>Lattanzi</surname><given-names>L.</given-names></name><name><surname>Soldani</surname><given-names>F.</given-names></name><name><surname>Navari</surname><given-names>S.</given-names></name><name><surname>Battistini</surname><given-names>G.</given-names></name><name><surname>Gemignani</surname><given-names>A.</given-names></name><name><surname>Cassano</surname><given-names>G.B.</given-names></name></person-group><article-title>Pramipexole in treatment-resistant depression: an extended follow-up.</article-title><source>Depress. Anxiety</source><year>2004</year><volume>20</volume><issue>3</issue><fpage>131</fpage><lpage>138</lpage><comment>[http://dx.doi.org/10.1002/da.20038]. [PMID: 15549689].</comment><pub-id pub-id-type="pmid">15549689</pub-id></element-citation></ref><ref id="r288"><label>288</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusin</surname><given-names>C.</given-names></name><name><surname>Iovieno</surname><given-names>N.</given-names></name><name><surname>Iosifescu</surname><given-names>D.V.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name><name><surname>Rush</surname><given-names>A.J.</given-names></name><name><surname>Perlis</surname><given-names>R.H.</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.</article-title><source>J. Clin. Psychiatry</source><year>2013</year><volume>74</volume><issue>7</issue><fpage>e636</fpage><lpage>e641</lpage><comment>[http://dx.doi.org/10.4088/JCP.12m08093]. [PMID: 23945458].</comment><pub-id pub-id-type="pmid">23945458</pub-id></element-citation></ref><ref id="r289"><label>289</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco-Chaves</surname><given-names>J.A.</given-names></name><name><surname>Mateus</surname><given-names>C.F.</given-names></name><name><surname>Luckenbaugh</surname><given-names>D.A.</given-names></name><name><surname>Martinez</surname><given-names>P.E.</given-names></name><name><surname>Mallinger</surname><given-names>A.G.</given-names></name><name><surname>Zarate</surname><given-names>C.A.</given-names><suffix>Jr</suffix></name></person-group><article-title>Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.</article-title><source>J. Affect. Disord.</source><year>2013</year><volume>149</volume><issue>1-3</issue><fpage>319</fpage><lpage>325</lpage><comment>[http://dx.doi.org/10.1016/j.jad.2013. 02.003]. [PMID: 23517885].</comment><pub-id pub-id-type="pmid">23517885</pub-id></element-citation></ref><ref id="r290"><label>290</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawcett</surname><given-names>J.</given-names></name><name><surname>Rush</surname><given-names>A.J.</given-names></name><name><surname>Vukelich</surname><given-names>J.</given-names></name><name><surname>Diaz</surname><given-names>S.H.</given-names></name><name><surname>Dunklee</surname><given-names>L.</given-names></name><name><surname>Romo</surname><given-names>P.</given-names></name><name><surname>Yarns</surname><given-names>B.C.</given-names></name><name><surname>Escalona</surname><given-names>R.</given-names></name></person-group><article-title>Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression.</article-title><source>Am. J. Psychiatry</source><year>2016</year><volume>173</volume><issue>2</issue><fpage>107</fpage><lpage>111</lpage><comment>[http://dx.doi.org/10.1176/appi.ajp.2015. 15060788]. [PMID: 26844792].</comment><pub-id pub-id-type="pmid">26844792</pub-id></element-citation></ref><ref id="r291"><label>291</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor&#243;n</surname><given-names>J.A.</given-names></name><name><surname>Zakharova</surname><given-names>I.</given-names></name><name><surname>Ferrer</surname><given-names>J.V.</given-names></name><name><surname>Merrill</surname><given-names>G.A.</given-names></name><name><surname>Hope</surname><given-names>B.</given-names></name><name><surname>Lafer</surname><given-names>E.M.</given-names></name><name><surname>Lin</surname><given-names>Z.C.</given-names></name><name><surname>Wang</surname><given-names>J.B.</given-names></name><name><surname>Javitch</surname><given-names>J.A.</given-names></name><name><surname>Galli</surname><given-names>A.</given-names></name><name><surname>Shippenberg</surname><given-names>T.S.</given-names></name></person-group><article-title>Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity.</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><issue>24</issue><fpage>8480</fpage><lpage>8488</lpage><comment>[PMID: 13679416].</comment><pub-id pub-id-type="pmid">13679416</pub-id></element-citation></ref><ref id="r292"><label>292</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C.B.</given-names></name><name><surname>Blakely</surname><given-names>R.D.</given-names></name><name><surname>Hewlett</surname><given-names>W.A.</given-names></name></person-group><article-title>The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters.</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><issue>10</issue><fpage>2121</fpage><lpage>2131</lpage><comment>[PMID: 16452991].</comment><pub-id pub-id-type="pmid">16452991</pub-id></element-citation></ref><ref id="r293"><label>293</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C.B.</given-names></name><name><surname>Carneiro</surname><given-names>A.M.</given-names></name><name><surname>Dostmann</surname><given-names>W.R.</given-names></name><name><surname>Hewlett</surname><given-names>W.A.</given-names></name><name><surname>Blakely</surname><given-names>R.D.</given-names></name></person-group><article-title>p38 MAPK activation elevates serotonin transport activity <italic>via</italic> a trafficking-independent, protein phosphatase 2A-dependent process.</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><issue>16</issue><fpage>15649</fpage><lpage>15658</lpage><comment>[http://dx.doi.org/10.1074/jbc.M410858200]. [PMID: 15728187].</comment><pub-id pub-id-type="pmid">15728187</pub-id></element-citation></ref><ref id="r294"><label>294</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C.B.</given-names></name><name><surname>Lindler</surname><given-names>K.M.</given-names></name><name><surname>Owens</surname><given-names>A.W.</given-names></name><name><surname>Daws</surname><given-names>L.C.</given-names></name><name><surname>Blakely</surname><given-names>R.D.</given-names></name><name><surname>Hewlett</surname><given-names>W.A.</given-names></name></person-group><article-title>Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters.</article-title><source>Neuropsychopharmacology</source><year>2010</year><volume>35</volume><issue>13</issue><fpage>2510</fpage><lpage>2520</lpage><comment>[http://dx.doi.org/10.1038/npp. 2010.116]. [PMID: 20827273].</comment><pub-id pub-id-type="pmid">20827273</pub-id></element-citation></ref><ref id="r295"><label>295</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>B.B.</given-names></name><name><surname>Spencer</surname><given-names>J.A.</given-names></name><name><surname>Holzer</surname><given-names>C.E.</given-names><suffix>III</suffix></name><name><surname>Soukup</surname><given-names>V.M.</given-names></name></person-group><article-title>Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis.</article-title><source>J. Neuroimmune Pharmacol.</source><year>2006</year><volume>1</volume><issue>4</issue><fpage>410</fpage><lpage>420</lpage><comment>[http://dx.doi.org/10.1007/s11481-006-9030-6]. [PMID: 18040813].</comment><pub-id pub-id-type="pmid">18040813</pub-id></element-citation></ref><ref id="r296"><label>296</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>M.J.</given-names></name><name><surname>Mactutus</surname><given-names>C.F.</given-names></name><name><surname>Booze</surname><given-names>R.M.</given-names></name></person-group><article-title>Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.</article-title><source>Neurosci. Biobehav. Rev.</source><year>2008</year><volume>32</volume><issue>5</issue><fpage>883</fpage><lpage>909</lpage><comment>[http:// dx.doi.org/10.1016/j.neubiorev.2008.01.004]. [PMID: 18430470].</comment><pub-id pub-id-type="pmid">18430470</pub-id></element-citation></ref><ref id="r297"><label>297</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnadas</surname><given-names>R.</given-names></name><name><surname>Nicol</surname><given-names>A.</given-names></name><name><surname>Sassarini</surname><given-names>J.</given-names></name><name><surname>Puri</surname><given-names>N.</given-names></name><name><surname>Burden</surname><given-names>A.D.</given-names></name><name><surname>Leman</surname><given-names>J.</given-names></name><name><surname>Combet</surname><given-names>E.</given-names></name><name><surname>Pimlott</surname><given-names>S.</given-names></name><name><surname>Hadley</surname><given-names>D.</given-names></name><name><surname>McInnes</surname><given-names>I.B.</given-names></name><name><surname>Cavanagh</surname><given-names>J.</given-names></name></person-group><article-title>Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans.</article-title><source>Brain Behav. Immun.</source><year>2016</year><volume>51</volume><fpage>29</fpage><lpage>38</lpage><comment>[http://dx.doi.org/10.1016/j.bbi. 2015.08.005]. [PMID: 26255693].</comment><pub-id pub-id-type="pmid">26255693</pub-id></element-citation></ref><ref id="r298"><label>298</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanquillon</surname><given-names>S.</given-names></name><name><surname>Krieg</surname><given-names>J.C.</given-names></name><name><surname>Bening-Abu-Shach</surname><given-names>U.</given-names></name><name><surname>Vedder</surname><given-names>H.</given-names></name></person-group><article-title>Cytokine production and treatment response in major depressive disorder.</article-title><source>Neuropsychopharmacology</source><year>2000</year><volume>22</volume><issue>4</issue><fpage>370</fpage><lpage>379</lpage><comment>[http:// dx.doi.org/10.1016/S0893-133X(99)00134-7]. [PMID: 10700656].</comment><pub-id pub-id-type="pmid">10700656</pub-id></element-citation></ref><ref id="r299"><label>299</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sluzewska</surname><given-names>A.</given-names></name><name><surname>Sobieska</surname><given-names>M.</given-names></name><name><surname>Rybakowski</surname><given-names>J.K.</given-names></name></person-group><article-title>Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression.</article-title><source>Neuropsychobiology</source><year>1997</year><volume>35</volume><issue>3</issue><fpage>123</fpage><lpage>127</lpage><comment>[http://dx.doi.org/10.1159/000119332]. [PMID: 9170116].</comment><pub-id pub-id-type="pmid">9170116</pub-id></element-citation></ref><ref id="r300"><label>300</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Demetrashvili</surname><given-names>M.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Neuropsychiatric adverse effects of interferon-alpha: recognition and management.</article-title><source>CNS Drugs</source><year>2005</year><volume>19</volume><issue>2</issue><fpage>105</fpage><lpage>123</lpage><comment>[http://dx.doi.org/ 10.2165/00023210-200519020-00002]. [PMID: 15697325].</comment><pub-id pub-id-type="pmid">15697325</pub-id></element-citation></ref><ref id="r301"><label>301</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>G.R.</given-names></name><name><surname>Hickok</surname><given-names>J.T.</given-names></name><name><surname>Roscoe</surname><given-names>J.A.</given-names></name><name><surname>Raubertas</surname><given-names>R.F.</given-names></name><name><surname>Andrews</surname><given-names>P.L.</given-names></name><name><surname>Flynn</surname><given-names>P.J.</given-names></name><name><surname>Hynes</surname><given-names>H.E.</given-names></name><name><surname>Banerjee</surname><given-names>T.K.</given-names></name><name><surname>Kirshner</surname><given-names>J.J.</given-names></name><name><surname>King</surname><given-names>D.K.</given-names></name></person-group><article-title>Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.</article-title><source>J. Clin. Oncol.</source><year>2003</year><volume>21</volume><issue>24</issue><fpage>4635</fpage><lpage>4641</lpage><comment>[http://dx.doi.org/10. 1200/JCO.2003.04.070]. [PMID: 14673053].</comment><pub-id pub-id-type="pmid">14673053</pub-id></element-citation></ref><ref id="r302"><label>302</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>Demyttenaere</surname><given-names>K.</given-names></name><name><surname>Janka</surname><given-names>Z.</given-names></name><name><surname>Aarre</surname><given-names>T.</given-names></name><name><surname>Bourin</surname><given-names>M.</given-names></name><name><surname>Canonico</surname><given-names>P.L.</given-names></name><name><surname>Carrasco</surname><given-names>J.L.</given-names></name><name><surname>Stahl</surname><given-names>S.</given-names></name></person-group><article-title>The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.</article-title><source>J. Psychopharmacol. (Oxford)</source><year>2007</year><volume>21</volume><issue>5</issue><fpage>461</fpage><lpage>471</lpage><comment>[http:// dx.doi.org/10.1177/0269881106069938]. [PMID: 17050654].</comment><pub-id pub-id-type="pmid">17050654</pub-id></element-citation></ref><ref id="r303"><label>303</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname><given-names>P.A.</given-names></name><name><surname>Lee</surname><given-names>C.A.</given-names></name><name><surname>Podurgiel</surname><given-names>S.J.</given-names></name><name><surname>Hart</surname><given-names>E.</given-names></name><name><surname>Yohn</surname><given-names>S.E.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Rowland</surname><given-names>M.</given-names></name><name><surname>L&#243;pez-Cruz</surname><given-names>L.</given-names></name><name><surname>Correa</surname><given-names>M.</given-names></name><name><surname>Salamone</surname><given-names>J.D.</given-names></name></person-group><article-title>Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort-related motivational symptoms.</article-title><source>Int. J. Neuropsychopharmacol.</source><year>2014</year><volume>18</volume><issue>2</issue><fpage>pyu017</fpage><comment>[http://dx.doi.org/ 10.1093/ijnp/pyu017]. [PMID: 25575584].</comment><pub-id pub-id-type="pmid">25575584</pub-id></element-citation></ref><ref id="r304"><label>304</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mar Fan</surname><given-names>H.G.</given-names></name><name><surname>Clemons</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chemerynsky</surname><given-names>I.</given-names></name><name><surname>Breunis</surname><given-names>H.</given-names></name><name><surname>Braganza</surname><given-names>S.</given-names></name><name><surname>Tannock</surname><given-names>I.F.</given-names></name></person-group><article-title>A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer.</article-title><source>Support. Care Cancer</source><year>2008</year><volume>16</volume><issue>6</issue><fpage>577</fpage><lpage>583</lpage><comment>[http://dx.doi.org/10.1007/s00520-007-0341-9]. [PMID: 17972110].</comment><pub-id pub-id-type="pmid">17972110</pub-id></element-citation></ref><ref id="r305"><label>305</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraska</surname><given-names>A.R.</given-names></name><name><surname>Sood</surname><given-names>A.</given-names></name><name><surname>Dakhil</surname><given-names>S.R.</given-names></name><name><surname>Sloan</surname><given-names>J.A.</given-names></name><name><surname>Barton</surname><given-names>D.</given-names></name><name><surname>Atherton</surname><given-names>P.J.</given-names></name><name><surname>Suh</surname><given-names>J.J.</given-names></name><name><surname>Griffin</surname><given-names>P.C.</given-names></name><name><surname>Johnson</surname><given-names>D.B.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Silberstein</surname><given-names>P.T.</given-names></name><name><surname>Duane</surname><given-names>S.F.</given-names></name><name><surname>Loprinzi</surname><given-names>C.L.</given-names></name></person-group><article-title>Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><issue>23</issue><fpage>3673</fpage><lpage>3679</lpage><comment>[http://dx.doi.org/10.1200/JCO.2010.28.1444]. [PMID: 20625123].</comment><pub-id pub-id-type="pmid">20625123</pub-id></element-citation></ref><ref id="r306"><label>306</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>J.M.</given-names><suffix>Jr</suffix></name><name><surname>Case</surname><given-names>L.D.</given-names></name><name><surname>Atkins</surname><given-names>J.</given-names></name><name><surname>Frizzell</surname><given-names>B.</given-names></name><name><surname>Sanders</surname><given-names>G.</given-names></name><name><surname>Griffin</surname><given-names>P.</given-names></name><name><surname>Lesser</surname><given-names>G.</given-names></name><name><surname>McMullen</surname><given-names>K.</given-names></name><name><surname>McQuellon</surname><given-names>R.</given-names></name><name><surname>Naughton</surname><given-names>M.</given-names></name><name><surname>Rapp</surname><given-names>S.</given-names></name><name><surname>Stieber</surname><given-names>V.</given-names></name><name><surname>Shaw</surname><given-names>E.G.</given-names></name></person-group><article-title>A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2007</year><volume>69</volume><issue>5</issue><fpage>1496</fpage><lpage>1501</lpage><comment>[http://dx.doi.org/10.1016/j.ijrobp.2007.05.076]. [PMID: 17869448].</comment><pub-id pub-id-type="pmid">17869448</pub-id></element-citation></ref><ref id="r307"><label>307</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>Y.</given-names></name><name><surname>Akechi</surname><given-names>T.</given-names></name><name><surname>Shima</surname><given-names>Y.</given-names></name><name><surname>Okuyama</surname><given-names>T.</given-names></name><name><surname>Akizuki</surname><given-names>N.</given-names></name><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Uchitomi</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study.</article-title><source>Palliat. Med.</source><year>2002</year><volume>16</volume><issue>3</issue><fpage>261</fpage><lpage>263</lpage><comment>[http://dx.doi.org/10.1191/0269216302pm547xx]. [PMID: 12047006].</comment><pub-id pub-id-type="pmid">12047006</pub-id></element-citation></ref><ref id="r308"><label>308</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucci</surname><given-names>E.</given-names></name></person-group><article-title>Amantadine for fatigue in multiple sclerosis. <italic>Cochrane Datab. System.</italic></article-title><source>Rev. (Online)</source><year>2007</year><volume>1</volume><fpage>CD002818</fpage><comment>[http://dx.doi. org/10.1002/14651858.CD002818.pub2].</comment></element-citation></ref><ref id="r309"><label>309</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stankoff</surname><given-names>B.</given-names></name><name><surname>Waubant</surname><given-names>E.</given-names></name><name><surname>Confavreux</surname><given-names>C.</given-names></name><name><surname>Edan</surname><given-names>G.</given-names></name><name><surname>Debouverie</surname><given-names>M.</given-names></name><name><surname>Rumbach</surname><given-names>L.</given-names></name><name><surname>Moreau</surname><given-names>T.</given-names></name><name><surname>Pelletier</surname><given-names>J.</given-names></name><name><surname>Lubetzki</surname><given-names>C.</given-names></name><name><surname>Clanet</surname><given-names>M.</given-names></name></person-group><article-title>Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>7</issue><fpage>1139</fpage><lpage>1143</lpage><comment>[http://dx.doi. org/10.1212/01.WNL.0000158272.27070.6A]. [PMID: 15824337].</comment><pub-id pub-id-type="pmid">15824337</pub-id></element-citation></ref><ref id="r310"><label>310</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruera</surname><given-names>E.</given-names></name><name><surname>Yennurajalingam</surname><given-names>S.</given-names></name><name><surname>Palmer</surname><given-names>J.L.</given-names></name><name><surname>Perez-Cruz</surname><given-names>P.E.</given-names></name><name><surname>Frisbee-Hume</surname><given-names>S.</given-names></name><name><surname>Allo</surname><given-names>J.A.</given-names></name><name><surname>Williams</surname><given-names>J.L.</given-names></name><name><surname>Cohen</surname><given-names>M.Z.</given-names></name></person-group><article-title>Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial.</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><issue>19</issue><fpage>2421</fpage><lpage>2427</lpage><comment>[http://dx. doi.org/10.1200/JCO.2012.45.3696]. [PMID: 23690414].</comment><pub-id pub-id-type="pmid">23690414</pub-id></element-citation></ref><ref id="r311"><label>311</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruddy</surname><given-names>K.J.</given-names></name><name><surname>Barton</surname><given-names>D.</given-names></name><name><surname>Loprinzi</surname><given-names>C.L.</given-names></name></person-group><article-title>Laying to rest psychostimulants for cancer-related fatigue?</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><issue>18</issue><fpage>1865</fpage><lpage>1867</lpage><comment>[http://dx.doi.org/10.1200/JCO.2014.55.8353]. [PMID: 24799492].</comment><pub-id pub-id-type="pmid">24799492</pub-id></element-citation></ref><ref id="r312"><label>312</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escalante</surname><given-names>C.P.</given-names></name><name><surname>Meyers</surname><given-names>C.</given-names></name><name><surname>Reuben</surname><given-names>J.M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Qiao</surname><given-names>W.</given-names></name><name><surname>Manzullo</surname><given-names>E.</given-names></name><name><surname>Alvarez</surname><given-names>R.H.</given-names></name><name><surname>Morrow</surname><given-names>P.K.</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>A.M.</given-names></name><name><surname>Wang</surname><given-names>X.S.</given-names></name><name><surname>Mendoza</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Holmes</surname><given-names>H.</given-names></name><name><surname>Hwang</surname><given-names>J.</given-names></name><name><surname>Pisters</surname><given-names>K.</given-names></name><name><surname>Overman</surname><given-names>M.</given-names></name><name><surname>Cleeland</surname><given-names>C.</given-names></name></person-group><article-title>A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients.</article-title><source>Cancer J.</source><year>2014</year><volume>20</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><comment>[http://dx.doi.org/10.1097/ PPO.0000000000000018]. [PMID: 24445757].</comment><pub-id pub-id-type="pmid">24445757</pub-id></element-citation></ref><ref id="r313"><label>313</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>S.</given-names></name><name><surname>Sheng</surname><given-names>P.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Qi</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>L.</given-names></name></person-group><article-title>Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis.</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>e84391</fpage><comment>[http://dx.doi.org/10.1371/journal.pone.0084391]. [PMID: 24416225].</comment><pub-id pub-id-type="pmid">24416225</pub-id></element-citation></ref><ref id="r314"><label>314</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>M.K.</given-names></name><name><surname>Minhajuddin</surname><given-names>A.</given-names></name><name><surname>Gadad</surname><given-names>B.S.</given-names></name><name><surname>Greer</surname><given-names>T.</given-names></name><name><surname>Grannemann</surname><given-names>B.</given-names></name><name><surname>Soyombo</surname><given-names>A.</given-names></name><name><surname>Mayes</surname><given-names>T.L.</given-names></name><name><surname>Rush</surname><given-names>A.J.</given-names></name><name><surname>Trivedi</surname><given-names>M.H.</given-names></name></person-group><article-title>Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.</article-title><source>Psychoneuroendocrinology</source><year>2017</year><volume>78</volume><fpage>105</fpage><lpage>113</lpage><comment>[http://dx.doi.org/10.1016/ j.psyneuen.2017.01.023]. [PMID: 28187400].</comment><pub-id pub-id-type="pmid">28187400</pub-id></element-citation></ref><ref id="r315"><label>315</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAllister</surname><given-names>T.W.</given-names></name><name><surname>Zafonte</surname><given-names>R.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Flashman</surname><given-names>L.A.</given-names></name><name><surname>George</surname><given-names>M.S.</given-names></name><name><surname>Grant</surname><given-names>G.A.</given-names></name><name><surname>He</surname><given-names>F.</given-names></name><name><surname>Lohr</surname><given-names>J.B.</given-names></name><name><surname>Andaluz</surname><given-names>N.</given-names></name><name><surname>Summerall</surname><given-names>L.</given-names></name><name><surname>Paulus</surname><given-names>M.P.</given-names></name><name><surname>Raman</surname><given-names>R.</given-names></name><name><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>Randomized placebo-controlled trial of methylphenidate or galantamine for persistent emotional and cognitive symptoms associated with PTSD and/or traumatic brain injury.</article-title><source>Neuropsychopharmacology</source><year>2016</year><volume>41</volume><issue>5</issue><fpage>1191</fpage><lpage>1198</lpage><comment>[http://dx.doi.org/10.1038/npp.2015.282]. [PMID: 26361060].</comment><pub-id pub-id-type="pmid">26361060</pub-id></element-citation></ref><ref id="r316"><label>316</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aga-Mizrachi</surname><given-names>S.</given-names></name><name><surname>Cymerblit-Sabba</surname><given-names>A.</given-names></name><name><surname>Gurman</surname><given-names>O.</given-names></name><name><surname>Balan</surname><given-names>A.</given-names></name><name><surname>Shwam</surname><given-names>G.</given-names></name><name><surname>Deshe</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>L.</given-names></name><name><surname>Gorodetsky</surname><given-names>N.</given-names></name><name><surname>Heinrich</surname><given-names>N.</given-names></name><name><surname>Tzezana</surname><given-names>O.</given-names></name><name><surname>Zubedat</surname><given-names>S.</given-names></name><name><surname>Grinstein</surname><given-names>D.</given-names></name><name><surname>Avital</surname><given-names>A.</given-names></name></person-group><article-title>Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model.</article-title><source>Transl. Psychiatry</source><year>2014</year><volume>4</volume><fpage>e447</fpage><comment>[http://dx.doi.org/10.1038/tp.2014.82]. [PMID: 25247592].</comment><pub-id pub-id-type="pmid">25247592</pub-id></element-citation></ref><ref id="r317"><label>317</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Walker</surname><given-names>A.K.</given-names></name></person-group><article-title>Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?</article-title><source>J. Neural Transm. (Vienna)</source><year>2014</year><volume>121</volume><issue>8</issue><fpage>925</fpage><lpage>932</lpage><comment>[http://dx.doi.org/10. 1007/s00702-014-1187-1]. [PMID: 24633997].</comment><pub-id pub-id-type="pmid">24633997</pub-id></element-citation></ref><ref id="r318"><label>318</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>O&#8217;Connor</surname><given-names>J.C.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name></person-group><article-title>Inflammation-associated depression: from serotonin to kynurenine.</article-title><source>Psychoneuroendocrinology</source><year>2011</year><volume>36</volume><issue>3</issue><fpage>426</fpage><lpage>436</lpage><comment>[http://dx.doi.org/ 10.1016/j.psyneuen.2010.09.012]. [PMID: 21041030].</comment><pub-id pub-id-type="pmid">21041030</pub-id></element-citation></ref><ref id="r319"><label>319</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>G.</given-names></name><name><surname>Adavastro</surname><given-names>G.</given-names></name><name><surname>Canepa</surname><given-names>G.</given-names></name><name><surname>Capobianco</surname><given-names>L.</given-names></name><name><surname>Conigliaro</surname><given-names>C.</given-names></name><name><surname>Pittaluga</surname><given-names>F.</given-names></name><name><surname>Murri</surname><given-names>M.B.</given-names></name><name><surname>Valchera</surname><given-names>A.</given-names></name><name><surname>De Berardis</surname><given-names>D.</given-names></name><name><surname>Pompili</surname><given-names>M.</given-names></name><name><surname>Lindqvist</surname><given-names>D.</given-names></name><name><surname>Brundin</surname><given-names>L.</given-names></name><name><surname>Amore</surname><given-names>M.</given-names></name></person-group><article-title>Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: A systematic review.</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2017</year><volume>16</volume><issue>4</issue><fpage>440</fpage><lpage>453</lpage><comment>[http://dx. doi.org/10.2174/1871527316666170413110605]. [PMID: 28412922].</comment><pub-id pub-id-type="pmid">28412922</pub-id></element-citation></ref><ref id="r320"><label>320</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R.</given-names></name><name><surname>Pellicciari</surname><given-names>R.</given-names></name></person-group><article-title>Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities.</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2002</year><volume>303</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><comment>[http://dx.doi.org/10.1124/ jpet.102.034439]. [PMID: 12235226].</comment><pub-id pub-id-type="pmid">12235226</pub-id></element-citation></ref><ref id="r321"><label>321</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Woolwine</surname><given-names>B.J.</given-names></name><name><surname>Vogt</surname><given-names>G.</given-names></name><name><surname>Spivey</surname><given-names>J.R.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.</article-title><source>Mol. Psychiatry</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>393</fpage><lpage>403</lpage><comment>[http://dx. doi.org/10.1038/mp.2009.116]. [PMID: 19918244].</comment><pub-id pub-id-type="pmid">19918244</pub-id></element-citation></ref><ref id="r322"><label>322</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonaccorso</surname><given-names>S.</given-names></name><name><surname>Marino</surname><given-names>V.</given-names></name><name><surname>Puzella</surname><given-names>A.</given-names></name><name><surname>Pasquini</surname><given-names>M.</given-names></name><name><surname>Biondi</surname><given-names>M.</given-names></name><name><surname>Artini</surname><given-names>M.</given-names></name><name><surname>Almerighi</surname><given-names>C.</given-names></name><name><surname>Verkerk</surname><given-names>R.</given-names></name><name><surname>Meltzer</surname><given-names>H.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.</article-title><source>J. Clin. Psychopharmacol.</source><year>2002</year><volume>22</volume><issue>1</issue><fpage>86</fpage><lpage>90</lpage><comment>[http://dx.doi.org/10.1097/ 00004714-200202000-00014]. [PMID: 11799348].</comment><pub-id pub-id-type="pmid">11799348</pub-id></element-citation></ref><ref id="r323"><label>323</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamar&#237;a</surname><given-names>A.</given-names></name><name><surname>Flores-Escart&#237;n</surname><given-names>A.</given-names></name><name><surname>Mart&#237;nez</surname><given-names>J.C.</given-names></name><name><surname>Osorio</surname><given-names>L.</given-names></name><name><surname>Galv&#225;n-Arzate</surname><given-names>S.</given-names></name><name><surname>Pedraza-Chaverr&#237;</surname><given-names>J.</given-names></name><name><surname>Maldonado</surname><given-names>P.D.</given-names></name><name><surname>Medina-Campos</surname><given-names>O.N.</given-names></name><name><surname>Jim&#233;nez-Capdeville</surname><given-names>M.E.</given-names></name><name><surname>Manjarrez</surname><given-names>J.</given-names></name><name><surname>R&#237;os</surname><given-names>C.</given-names></name></person-group><article-title>Copper blocks quinolinic acid neurotoxicity in rats: contribution of antioxidant systems.</article-title><source>Free Radic. Biol. Med.</source><year>2003</year><volume>35</volume><issue>4</issue><fpage>418</fpage><lpage>427</lpage><comment>[http://dx.doi.org/10.1016/S0891-5849(03)00317-4]. [PMID: 12899943].</comment><pub-id pub-id-type="pmid">12899943</pub-id></element-citation></ref><ref id="r324"><label>324</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behan</surname><given-names>W.M.</given-names></name><name><surname>McDonald</surname><given-names>M.</given-names></name><name><surname>Darlington</surname><given-names>L.G.</given-names></name><name><surname>Stone</surname><given-names>T.W.</given-names></name></person-group><article-title>Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl.</article-title><source>Br. J. Pharmacol.</source><year>1999</year><volume>128</volume><issue>8</issue><fpage>1754</fpage><lpage>1760</lpage><comment>[http://dx.doi.org/10.1038/ sj.bjp.0702940]. [PMID: 10588931].</comment><pub-id pub-id-type="pmid">10588931</pub-id></element-citation></ref><ref id="r325"><label>325</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>R.G.</given-names></name><name><surname>Tasca</surname><given-names>C.I.</given-names></name><name><surname>Santos</surname><given-names>C.E.</given-names></name><name><surname>Alves</surname><given-names>L.B.</given-names></name><name><surname>Porci&#250;ncula</surname><given-names>L.O.</given-names></name><name><surname>Emanuelli</surname><given-names>T.</given-names></name><name><surname>Souza</surname><given-names>D.O.</given-names></name></person-group><article-title>Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes.</article-title><source>Neurochem. Int.</source><year>2002</year><volume>40</volume><issue>7</issue><fpage>621</fpage><lpage>627</lpage><comment>[http://dx.doi.org/10. 1016/S0197-0186(01)00133-4]. [PMID: 11900857].</comment><pub-id pub-id-type="pmid">11900857</pub-id></element-citation></ref><ref id="r326"><label>326</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>R.G.</given-names></name><name><surname>Schmidt</surname><given-names>A.P.</given-names></name><name><surname>Abud</surname><given-names>J.</given-names></name><name><surname>Tasca</surname><given-names>C.I.</given-names></name><name><surname>Souza</surname><given-names>D.O.</given-names></name></person-group><article-title>
<italic>In vivo</italic> quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine.</article-title><source>Neurochem. Res.</source><year>2005</year><volume>30</volume><issue>4</issue><fpage>439</fpage><lpage>444</lpage><comment>[http://dx.doi.org/10.1007/s11064-005-2678-0]. [PMID: 16076013].</comment><pub-id pub-id-type="pmid">16076013</pub-id></element-citation></ref><ref id="r327"><label>327</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillemin</surname><given-names>G.J.</given-names></name><name><surname>Croitoru-Lamoury</surname><given-names>J.</given-names></name><name><surname>Dormont</surname><given-names>D.</given-names></name><name><surname>Armati</surname><given-names>P.J.</given-names></name><name><surname>Brew</surname><given-names>B.J.</given-names></name></person-group><article-title>Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes.</article-title><source>Glia</source><year>2003</year><volume>41</volume><issue>4</issue><fpage>371</fpage><lpage>381</lpage><comment>[http://dx.doi.org/10.1002/glia.10175]. [PMID: 12555204].</comment><pub-id pub-id-type="pmid">12555204</pub-id></element-citation></ref><ref id="r328"><label>328</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillemin</surname><given-names>G.J.</given-names></name></person-group><article-title>Quinolinic acid: neurotoxicity.</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><issue>8</issue><fpage>1355</fpage><comment>[http://dx.doi.org/10.1111/j.1742-4658.2012.08493.x]. [PMID: 22251552].</comment><pub-id pub-id-type="pmid">22251552</pub-id></element-citation></ref><ref id="r329"><label>329</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>T.W.</given-names></name></person-group><article-title>Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection.</article-title><source>Trends Pharmacol. Sci.</source><year>2000</year><volume>21</volume><issue>4</issue><fpage>149</fpage><lpage>154</lpage><comment>[http://dx.doi.org/10.1016/ S0165-6147(00)01451-6]. [PMID: 10740291].</comment><pub-id pub-id-type="pmid">10740291</pub-id></element-citation></ref><ref id="r330"><label>330</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.Q.</given-names></name><name><surname>Rassoulpour</surname><given-names>A.</given-names></name><name><surname>Schwarcz</surname><given-names>R.</given-names></name></person-group><article-title>Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?</article-title><source>J. Neural Transm. (Vienna)</source><year>2007</year><volume>114</volume><issue>1</issue><fpage>33</fpage><lpage>41</lpage><comment>[http://dx.doi.org/ 10.1007/s00702-006-0562-y]. [PMID: 16932989].</comment><pub-id pub-id-type="pmid">16932989</pub-id></element-citation></ref><ref id="r331"><label>331</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilleux</surname><given-names>S.</given-names></name><name><surname>Hermans</surname><given-names>E.</given-names></name></person-group><article-title>Neuroinflammation and regulation of glial glutamate uptake in neurological disorders.</article-title><source>J. Neurosci. Res.</source><year>2007</year><volume>85</volume><issue>10</issue><fpage>2059</fpage><lpage>2070</lpage><comment>[http://dx.doi.org/10.1002/jnr.21325]. [PMID: 17497670].</comment><pub-id pub-id-type="pmid">17497670</pub-id></element-citation></ref><ref id="r332"><label>332</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ida</surname><given-names>T.</given-names></name><name><surname>Hara</surname><given-names>M.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Kozaki</surname><given-names>S.</given-names></name><name><surname>Tsunoda</surname><given-names>S.</given-names></name><name><surname>Ihara</surname><given-names>H.</given-names></name></person-group><article-title>Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide.</article-title><source>Neurosci. Lett.</source><year>2008</year><volume>432</volume><issue>3</issue><fpage>232</fpage><lpage>236</lpage><comment>[http://dx.doi.org/10.1016/j.neulet.2007.12. 047]. [PMID: 18255223].</comment><pub-id pub-id-type="pmid">18255223</pub-id></element-citation></ref><ref id="r333"><label>333</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaki</surname><given-names>J.</given-names></name><name><surname>Fujimori</surname><given-names>K.</given-names></name><name><surname>Miura</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Sekino</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name></person-group><article-title>L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the &#8216;collusion&#8217; hypothesis for increased extracellular L-glutamate concentration in neuroinflammation.</article-title><source>J. Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>275</fpage><comment>[http://dx.doi.org/10.1186/1742-2094-9-275]. [PMID: 23259598].</comment><pub-id pub-id-type="pmid">23259598</pub-id></element-citation></ref><ref id="r334"><label>334</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardingham</surname><given-names>G.E.</given-names></name><name><surname>Fukunaga</surname><given-names>Y.</given-names></name><name><surname>Bading</surname><given-names>H.</given-names></name></person-group><article-title>Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways.</article-title><source>Nat. Neurosci.</source><year>2002</year><volume>5</volume><issue>5</issue><fpage>405</fpage><lpage>414</lpage><comment>[http://dx.doi.org/10.1038/nn835]. [PMID: 11953750].</comment><pub-id pub-id-type="pmid">11953750</pub-id></element-citation></ref><ref id="r335"><label>335</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haydon</surname><given-names>P.G.</given-names></name><name><surname>Carmignoto</surname><given-names>G.</given-names></name></person-group><article-title>Astrocyte control of synaptic transmission and neurovascular coupling.</article-title><source>Physiol. Rev.</source><year>2006</year><volume>86</volume><issue>3</issue><fpage>1009</fpage><lpage>1031</lpage><comment>[http://dx.doi.org/10.1152/physrev.00049.2005]. [PMID: 16816144].</comment><pub-id pub-id-type="pmid">16816144</pub-id></element-citation></ref><ref id="r336"><label>336</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R.</given-names></name><name><surname>K&#246;hler</surname><given-names>C.</given-names></name></person-group><article-title>Differential vulnerability of central neurons of the rat to quinolinic acid.</article-title><source>Neurosci. Lett.</source><year>1983</year><volume>38</volume><issue>1</issue><fpage>85</fpage><lpage>90</lpage><comment>[http://dx.doi.org/10.1016/0304-3940(83)90115-5]. [PMID: 6225037].</comment><pub-id pub-id-type="pmid">6225037</pub-id></element-citation></ref><ref id="r337"><label>337</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>A.F.</given-names></name><name><surname>Boegman</surname><given-names>R.J.</given-names></name><name><surname>Beninger</surname><given-names>R.J.</given-names></name><name><surname>Jhamandas</surname><given-names>K.</given-names></name></person-group><article-title>Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.</article-title><source>Neuroscience</source><year>1997</year><volume>78</volume><issue>4</issue><fpage>967</fpage><lpage>975</lpage><comment>[http://dx.doi.org/10.1016/ S0306-4522(96)00655-0]. [PMID: 9174065].</comment><pub-id pub-id-type="pmid">9174065</pub-id></element-citation></ref><ref id="r338"><label>338</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connor</surname><given-names>J.C.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Andr&#233;</surname><given-names>C.</given-names></name><name><surname>Briley</surname><given-names>E.M.</given-names></name><name><surname>Szegedi</surname><given-names>S.S.</given-names></name><name><surname>Lestage</surname><given-names>J.</given-names></name><name><surname>Castanon</surname><given-names>N.</given-names></name><name><surname>Herkenham</surname><given-names>M.</given-names></name><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>Kelley</surname><given-names>K.W.</given-names></name></person-group><article-title>Induction of IDO by bacille Calmette-Gu&#233;rin is responsible for development of murine depressive-like behavior.</article-title><source>J. Immunol.</source><year>2009</year><volume>182</volume><issue>5</issue><fpage>3202</fpage><lpage>3212</lpage><comment>[http://dx.doi.org/10.4049/jimmunol. 0802722]. [PMID: 19234218].</comment><pub-id pub-id-type="pmid">19234218</pub-id></element-citation></ref><ref id="r339"><label>339</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connor</surname><given-names>J.C.</given-names></name></person-group><article-title>Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.</article-title><source>Mol. Psychiatry</source><year>2008</year><comment>[PMID: 18195714].</comment></element-citation></ref><ref id="r340"><label>340</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masilamoni</surname><given-names>G.J.</given-names></name><name><surname>Bogenpohl</surname><given-names>J.W.</given-names></name><name><surname>Alagille</surname><given-names>D.</given-names></name><name><surname>Delevich</surname><given-names>K.</given-names></name><name><surname>Tamagnan</surname><given-names>G.</given-names></name><name><surname>Votaw</surname><given-names>J.R.</given-names></name><name><surname>Wichmann</surname><given-names>T.</given-names></name><name><surname>Smith</surname><given-names>Y.</given-names></name></person-group><article-title>Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.</article-title><source>Brain</source><year>2011</year><volume>134</volume><issue>Pt 7</issue><fpage>2057</fpage><lpage>2073</lpage><comment>[http://dx.doi.org/ 10.1093/brain/awr137]. [PMID: 21705423].</comment><pub-id pub-id-type="pmid">21705423</pub-id></element-citation></ref><ref id="r341"><label>341</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisner</surname><given-names>F.</given-names></name><name><surname>Scheller</surname><given-names>C.</given-names></name><name><surname>Kneitz</surname><given-names>S.</given-names></name><name><surname>Sopper</surname><given-names>S.</given-names></name><name><surname>Neuen-Jacob</surname><given-names>E.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Koutsilieri</surname><given-names>E.</given-names></name></person-group><article-title>Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.</article-title><source>Neuropsychopharmacology</source><year>2008</year><volume>33</volume><issue>9</issue><fpage>2228</fpage><lpage>2236</lpage><comment>[http://dx.doi.org/10.1038/sj.npp. 1301615]. [PMID: 17971830].</comment><pub-id pub-id-type="pmid">17971830</pub-id></element-citation></ref><ref id="r342"><label>342</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheller</surname><given-names>C.</given-names></name><name><surname>Sopper</surname><given-names>S.</given-names></name><name><surname>Jenuwein</surname><given-names>M.</given-names></name><name><surname>Neuen-Jacob</surname><given-names>E.</given-names></name><name><surname>Tatschner</surname><given-names>T.</given-names></name><name><surname>Gr&#252;nblatt</surname><given-names>E.</given-names></name><name><surname>ter Meulen</surname><given-names>V.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><name><surname>Koutsilieri</surname><given-names>E.</given-names></name></person-group><article-title>Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation.</article-title><source>J. Neurochem.</source><year>2005</year><volume>95</volume><issue>2</issue><fpage>377</fpage><lpage>387</lpage><comment>[http://dx.doi.org/10.1111/j.1471-4159.2005.03373.x]. [PMID: 16190867].</comment><pub-id pub-id-type="pmid">16190867</pub-id></element-citation></ref><ref id="r343"><label>343</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.M.</given-names></name><name><surname>Ownby</surname><given-names>R.L.</given-names></name><name><surname>Waldrop-Valverde</surname><given-names>D.</given-names></name><name><surname>Fernandez</surname><given-names>B.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name></person-group><article-title>Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance.</article-title><source>J. Neurovirol.</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>26</fpage><lpage>40</lpage><comment>[http://dx.doi.org/10.1007/s13365-010-0003-4]. [PMID: 21165787].</comment><pub-id pub-id-type="pmid">21165787</pub-id></element-citation></ref><ref id="r344"><label>344</label><element-citation publication-type="journal"><article-title>aan het Rot, M. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.</article-title><source>Biol. Psychiatry</source><year>2010</year><volume>67</volume><issue>2</issue><fpage>139</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19897179</pub-id></element-citation></ref><ref id="r345"><label>345</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>R.B.</given-names></name><name><surname>Nock</surname><given-names>M.K.</given-names></name><name><surname>Charney</surname><given-names>D.S.</given-names></name><name><surname>Mathew</surname><given-names>S.J.</given-names></name></person-group><article-title>Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.</article-title><source>Biol. Psychiatry</source><year>2009</year><volume>66</volume><issue>5</issue><fpage>522</fpage><lpage>526</lpage><comment>[http://dx.doi.org/10.1016/j.biopsych.2009.04.029]. [PMID: 19545857].</comment><pub-id pub-id-type="pmid">19545857</pub-id></element-citation></ref><ref id="r346"><label>346</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.J.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>J.Y.</given-names></name><name><surname>Yu</surname><given-names>H.Y.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Serum interleukin-6 is a predictive biomarker for ketamine&#8217;s antidepressant effect in treatment-resistant patients with major depression.</article-title><source>Biol. Psychiatry</source><year>2015</year><volume>77</volume><issue>3</issue><fpage>e19</fpage><lpage>e20</lpage><comment>[http://dx.doi.org/10. 1016/j.biopsych.2014.06.021]. [PMID: 25104172].</comment><pub-id pub-id-type="pmid">25104172</pub-id></element-citation></ref><ref id="r347"><label>347</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uher</surname><given-names>R.</given-names></name><name><surname>Tansey</surname><given-names>K.E.</given-names></name><name><surname>Dew</surname><given-names>T.</given-names></name><name><surname>Maier</surname><given-names>W.</given-names></name><name><surname>Mors</surname><given-names>O.</given-names></name><name><surname>Hauser</surname><given-names>J.</given-names></name><name><surname>Dernovsek</surname><given-names>M.Z.</given-names></name><name><surname>Henigsberg</surname><given-names>N.</given-names></name><name><surname>Souery</surname><given-names>D.</given-names></name><name><surname>Farmer</surname><given-names>A.</given-names></name><name><surname>McGuffin</surname><given-names>P.</given-names></name></person-group><article-title>An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.</article-title><source>Am. J. Psychiatry</source><year>2014</year><volume>171</volume><issue>12</issue><fpage>1278</fpage><lpage>1286</lpage><comment>[http://dx.doi. org/10.1176/appi.ajp.2014.14010094]. [PMID: 25017001].</comment><pub-id pub-id-type="pmid">25017001</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. (1)</label><caption><p>Inflammation is increased in patients with mood and anxiety-related disorders due to environmental challenges such as diet and lifestyle factors, medical illness and psychosocial stress. Immune activation involves intracellular signal transduction pathways and the inflammasome, which can respond to a variety of environmental stressors beyond pathogens including psychosocial stress, to produce release of inflammatory cytokines. Increased inflammatory cytokines are in turn associated with increased oxidative stress and generation of reactive oxygen and reactive nitrogen species (ROS and RNS). Increased ROS and RNS contribute to oxidation of tetrahydrobiopterin (BH4), a cofactor required for the enzymatic synthesis of monoamines <italic>via</italic> phenylalanine hydroxylase (PAH), tryptophan hydroxylase (TPH) and tyrosine hydroxylase (TH), thus disrupting the synthesis of serotonin (5-HT), dopamine (DA) and norepinephrine (NE) through effects on the availability of monoamine precursors such as tryptophan and tyrosine. Inflammation and the release of cytokines also stimulate enzyme pathways such as indoleamine 2,3 dioxygenase (IDO), which can then lead to the release of neurotoxic metabolites of kynurenine that affect glutamate (Glu) including quinolinic acid. In the brain, inflammation causes release of Glu from microglia and reduced uptake by astrocytes. These actions of inflammatory cytokines ultimately contribute to alterations in neurocircuits in the brain including those related to basal ganglia to prefrontal reward and motor circuits, as well as fear and anxiety-related amygdala, prefrontal and insular circuitry, which may contribute to symptoms of depression and anxiety. 5-HT - serotonin; ACC - anterior cingulate cortex; BH4 - tetrahydrobiopterin; DA - dopamine; Glu - glutamate; NLRP3 - NACHT domain- leucine-rich repeat- and pyrin domain-containing protein 3; I - imaging; IDO - indoleamine 2,3 dioxygenase; MR &#8211; magnetic resonance; NE - norepinephrine; NO-nitric oxide; NOS-nitric oxide synthase; NSAIDS-non-steroidal anti-inflammatory drugs; PFC - prefrontal cortex; PHA - phenylalanine hydroxylase; ROS - reactive oxygen species; TH - tyrosine hydroxylase; Trp &#8211; tryptophan. (<italic>The color version of the figure is available in the electronic copy of the article</italic>).</p></caption><graphic xlink:href="CN-16-533_F1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of neuroimaging findings of changes in neural activity, glucose metabolism, qMT, or the dopamine or glutamate systems in reward-related circuitry following administration of peripheral inflammatory stimuli or cytokines.</p></caption><table-wrap-foot><p>
<bold>&#8593;</bold> increased; <bold>&#8595;</bold> deceased; ACC - anterior cingulate cortex; AI - anterior insula; AMPH - amphetamine; D2R - dopamine 2 receptor; DS - dorsal striatum; FDG - fludeoxyglucose; FDOPA - fluorodopa; fMRI - functional magnet resonance imaging; HCV - hepatitis C virus; IFN - interferon; k<sub>f</sub> - rate magnetization transfer from free (water) to molecular-bound protons; MIDT - monetary incentive delay task; MM - malignant melanoma; MRS - magnetic resonance spectroscopy; OFC - orbitofrontal cortex; PET - positron emission tomography; PFC - prefrontal cortex; PPE - punishment prediction error; qMT - quantitative magnetization transfer; RPE - reward prediction error; SN - substantia nigra; T<sub>2f</sub> - free water spin-spin relaxation time; vmPFC - ventromedial prefrontal cortex; VS - ventral striatum.</p></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Summary of neuroimaging findings of changes in neural activation and functional connectivity, and glucose and glutamate metabolism, in circuitry related to fear, anxiety and emotional regulation after administration of peripheral inflammatory stimuli or cytokines.</p></caption><table-wrap-foot><p>
<bold>&#8593;</bold> increased; <bold>&#8595;</bold> deceased; ACC - anterior cingulate cortex; AI - anterior insula; AMPH - amphetamine; d - dorsal; CC - cingulate cortex; DMI - dorsal middle/posterior insula; DPI - dorsal posterior insula; FDG - fludeoxyglucose; fMRI - functional magnet resonance imaging; HCV - hepatitis C virus; IFN - interferon; PET - positron emission tomography; sg - subgenual; vmPFC - ventromedial prefrontal cortex; VS - ventral striatum.</p></table-wrap-foot></table-wrap></floats-group></article>